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Thesis Summary 
Many viruses initiate infection through a multistep process involving host cell 
membrane proteins. Hepatitis C virus (HCV) is an important human pathogen that 
infects more than 185 million people worldwide and results in progressive liver disease. 
Recent advances have identified an essential role for tetraspanin CD81 and tight 
junction protein Claudin-1 in HCV entry into hepatocytes in the liver. CD81 associates 
with Claudin-1 and this complex is necessary for virus internalisation; defining the full 
length interface of this membrane protein interaction is therefore important for the 
design of future anti-viral therapies. Structural information is lacking for CD81: indeed, 
there is no high resolution structure for any full-length tetraspanin. This thesis describes 
an analysis of the protein-protein interaction interface between CD81 and Claudin-1 
full-length proteins using a split-ubiquitin yeast assay. Also, using recombinant protein 
production of CD81, this thesis describes work towards successful crystallisation trials 
of a full length tetraspanin.  
 
CD81 homotypic and heterotypic interactions with Claudin-1 were analysed in a high-
throughput format in yeast, showing that this interaction is specific and does not require 
other mammalian cell factors. This work demonstrates that the CD81 large extracellular 
loop and its first transmembrane domain are involved in the CD81-Claudin-1 
interaction: a novel full length molecular model predicted interacting amino acid 
residues that were confirmed in vivo using yeast assays. Thermal stability assays used to 
investigate recombinant membrane protein found that both detergent and buffer 
components are vital for the stability of recombinant CD81, which shows increased 
thermostability in the presence of cholesteryl hemisuccinate. Using the improved 
protein solution environment found here, and the increased understanding of the 
tetraspanin interaction interface; this work paves the way for CD81 structural 
characterisation alone or in combination with Claudin-1.  
 
Keywords: Tetraspanin, tight junction protein, site-directed mutagenesis, P. pastoris, 
recombinant protein production. 
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Amino acids 
Table 1: Standard amino acid abbreviations. Standard amino acid abbreviations used 
interchangeably throughout text. 
Amino acid 3-letter 1-letter Amino acid 3-letter 1-letter 
Alanine Ala A Leucine Leu L 
Arginine  Arg R Lysine Lys K 
Asparagine  Asn N Methionine Met M 
Aspartic acid Asp D Phenylalanine Phe F 
Cysteine Cys C Proline Pro P 
Glutamic acid Glu E Serine  Ser S 
Glutamine Gln Q Threonine Thr T 
Glycine Gly G Tryptophan Trp W 
Histidine His H Tyrosine Tyr Y 
Isoleucine Ile I Valine Val V 
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1. Introduction 
 
1.1 Hepatitis C virus (HCV) 
 
Viruses can be defined as “obligatory intracellular parasites, whose replication 
depends on pathways and functions of the host cell” (Krausslich & Bartenschlager, 
2009). 
Viruses rely on a host eukaryotic or prokaryotic cell to replicate its genome, outside of 
the host cell, viruses are inert. Viruses contain either a RNA or DNA genome that is 
surrounded by a virus encoded protein coat. Classification of viruses depends on their 
size, shape, the structure of the genome and how they undergo replication (Gelderblom, 
1996). For example, there are around 21 different families of viruses that can infect 
humans.  
The hepatitis C virus (HCV) currently infects more than 185 million people worldwide 
(Hill and Cooke, 2014). HCV is transmitted through intravenous drug use or via blood 
transfusion, although post-transfusion acquired infection is now less common in 
developed parts of the world owing to donor screening for markers of HCV (Donahue 
et al., 1992).  Typically, around 20% of those infected with HCV have acute hepatitis 
and clear infection. In contrast, approximately 80% of HCV infected individuals suffer 
chronic hepatitis. This involves progressive liver injury and an increased risk of 
developing fibrosis or hepatocellular carcinoma (Timpe and McKeating, 2008). Chronic 
hepatitis can arise due to the virus’ ability of escaping the host immune response. Much 
of the biology and virology of HCV infection is understood (Timpe and McKeating, 
2008), but the process by which the virus enters human liver cells is still incompletely 
described. 
Throughout the 1970’s, the responsible agent(s) for post-transfusion hepatitis was 
unknown.  The disease, during this period, was referred to as non-A, non-B hepatitis 
(NANB). This name occurred as diagnostic tests for hepatitis A and B viruses were 
used to eliminate them as the cause for hepatitis (Zuckerman et al., 2001). It was not 
until 1985 when Bradley and others found that the causative agent of NANB was a 
small, enveloped virus (Bradley et al., 1985). Later, with the use of molecular 
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techniques, Choo et al (1990) characterised the genome of this virus, which was then 
referred to as HCV (Choo et al., 1990).  
Chronic hepatitis caused by HCV is usually treated with a combination therapy of 
pegylated interferon (peginterferon) plus ribavirin. A clinical study suggested that out 
of the two commercially available forms of peginterferon (alfa-2a and alfa-2b); the 
combination of peginterferon alfa-2a with ribavirin demonstrated the most success in 
treating chronic HCV infection (Ascione et al., 2010). Unfortunately there is, at present, 
no successful vaccine against HCV and combination therapy has its disadvantages such 
as its high cost, severe side effects and limited efficacy (McHutchison et al., 2006). 
Hepatitis C is typically diagnosed at a late stage when signs of liver damage are 
apparent, therefore reducing the success rate of recovery. Clearly, new therapies against 
HCV are required that act early on, potentially targeting HCV entry into host cells 
(Timpe and McKeating, 2008).  
 
1.1.1 Viral features important for host infectivity 
 
HCV is a member of the Hepacivirus genus in the Flaviviridae family. The HCV 
genome is a positive sense, single-stranded RNA comprised of around 10,000 
nucleotides (Choo et al. 1990). The genomic material is contained within an icosahedral 
nucleocapsid shell, which is enclosed within a host-derived membrane envelope (see 
figure 1.1). The envelope holds two virus-encoded glycoproteins E1 and E2 (Timpe and 
McKeating, 2008). The HCV genome encodes a single polyprotein, which produces ten 
viral proteins once cleaved by both host and viral proteases. Three of the proteins that 
are produced are structural proteins, including core, E1 and E2. The remaining seven 
proteins consist of a small ion channel protein (p7) and six non-structural proteins 
(Dubuisson, 2007).  
HCV encoded glycoproteins, E1 and E2, which sit within the virus envelope play a 
critical role in viral entry (Timpe and McKeating, 2008) (figure 1.1). E1 and E2 bind 
specific host cell surface receptors, which allow the virus to enter the cell via clathrin 
mediated endocytosis. Following entry, the viral and endosomal membranes fuse in a 
pH dependent fashion, this leads to the release of the capsid and genome into the 
18 
 
cytoplasm. This viral genome is replicated and expressed within the host cell in order 
for virions to be produced.  Subsequently virions are released from the cell to infect 
others, leading to the repetition of the HCV life cycle. 
 
 
 
 
 
 
 
 
Figure 1.1: Hepatitis C virus structure. The core contains viral genetic material (RNA) 
surrounded by a protective protein shell. A host-derived lipid envelope surrounds the protein 
capsid and holds two viral glycoproteins E1 and E2 that are crucial for viral entry into a host 
cell. Picture taken from Sciencephoto.com.  
 
Great progress has been made in understanding the virus interaction with the host cell 
surface, in order to gain entry.  Following the characterisation of the HCV genome in 
1989, studies that looked into HCV entry were complicated for over 15 years due to the 
deficiency of in vitro culture systems, that were not able to demonstrate efficient virus 
replication (Timpe and McKeating, 2008). This made research difficult as levels of 
infectious virus found in serum or liver tissue were insufficient for study (Fournier et 
al., 1998). Even so, few studies using primary cultures of human hepatocytes 
demonstrated in vitro HCV infection and HCV replication after being incubated with 
human serum samples from HCV carriers (Fournier et al., 1998), (Castet et al., 2002). 
Since then, the development of suitable in vitro models, have enabled major 
advancements into the study of HCV entry and its life cycle.  
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1.1.2 HCV entry and life cycle in vitro models 
 
The first advance for an in vitro model of HCV entry used a recombinant soluble 
glycoprotein E2 (sE2). Virus-host cell surface interactions have been studied using sE2 
as a model to discover host cell surface receptors responsible for viral entry (Flint et al., 
1999). sE2 production, first shown by Selby & colleagues (1994) was achieved by 
removal of the C-terminus of E2, rendering it soluble (Selby et al., 1994). The 
tetraspanin CD81 was initially discovered as a HCV host receptor when sE2 was used 
as a probe (Pileri et al., 1998). Furthermore, neutralising antibody against HCV E2 is 
associated with the prevention of HCV infection (Rosa et al., 1996). Even though sE2 is 
a worthy model, in reality E2 does not exist alone on the HCV surface but in complex 
with E1, therefore it may not exhibit true interactions with the host cell surface. 
Later research, in 2003, developed a further working model so that the E1E2 
heterodimer was studied in vitro. This involved using retroviral pseudoparticles that 
carried HCV glycoproteins E1E2 at its surface, which were referred to as HCV 
pseudoparticles (HCVpp) (Bartosch et al., 2003), (Drummer et al., 2003), (Hsu et al., 
2003). HCVpp were designed to carry a reporter gene such as green fluorescent protein 
(GFP) or luciferase so that entry was possible to measure. Using HCVpp, primary 
hepatocytes were shown to be a key target for infection and that both E1 and E2 were 
required (Bartosch et al. 2003). HCVpp is a valuable tool to study the initial events of 
HCV entry and infectivity, although limitations come into play once the particle is 
internalised. Retroviral proteins subsequently control and dictate remaining replication 
events and so do not model HCV in vitro replication (Timpe and McKeating, 2008). 
In 2005, the revolution for HCV research came about when an exceptional HCV strain 
was discovered that had the ability to replicate and release infectious virions in culture 
conditions using a human hepatoma cell line (Huh7) (Wakita et al., 2005), (Zhong et 
al., 2005). This was an isolated strain from a Japanese patient with fulminant hepatitis 
C, so called JFH-1. The in vitro generated infectious virions were shown to be 
infectious to chimpanzees (Wakita et al. 2005). Consequently, a model, referred to as 
HCV cell culture (HCVcc), was now available to study the complete life cycle of HCV. 
Consequently, this model generated evidence to prove the involvement of multiple host 
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cell surface receptors and factors in HCV entry and provided a tool to focus on the 
generation of antiviral therapies.  
 
1.2 Host proteins involved in the HCV entry process 
 
HCV enters cells via a coordinated series of events that involves viral and host cell 
factors (Zeisel et al., 2011) (see figure 1.2).  It is biologically crucial for the virus to 
gain entrance to its host cell, so mechanisms have evolved that allow passage through 
the host’s plasma membrane that are highly specific and characterise the type of host 
and cell that is targeted by the virus. HCV circulates in the blood and directly makes 
contact with the basolateral membrane of hepatocytes, the cell type that it can enter and 
replicate inside. Agnello et al (1999) provided evidence to confirm that the low density 
lipoprotein receptor (LDLR) is an important factor in viral entry (Agnello et al., 1999). 
The group suggested HCV can indirectly interact with lipoprotein receptors due to its 
attachment to very low density lipoprotein (VLDL) or low density lipoprotein (LDL) 
prior to endocytosis. After initial attachment of HCV to the host hepatocyte cell, other 
cell surface molecules are required for efficient viral entry.  
Significant cell surface receptors involved in HCV entry include CD81 human 
tetraspanin (Pileri et al., 1998) and scavenger receptor class B type I (SR-BI) (Scarselli 
et al., 2002), both proving to bind HCV envelope glycoprotein E2. Evans et al (2007) 
later discovered another membrane protein essential for HCV entry (see figure 1.2). 
This was Claudin-1, a tight junction protein, suggesting it is involved in a late stage of 
HCV entry (Evans et al., 2007). Another tight junction protein important in viral entry 
is Occludin, which like Claudin-1 acts at a post-attachment step. Further evidence is 
required to determine if Occludin directly binds HCV particles and its exact role in the 
entry process (Lindenbach and Rice, 2013). Cell signalling events, which are initiated 
by E2 binding with CD81, result in the lateral movement of CD81-HCV complexes to 
sites of cell-cell contact. CD81 interacts with Claudin-1 and these co-receptor 
complexes are required for HCV internalisation via clathrin-mediated endocytosis 
(Lindenbach and Rice, 2013) (figure 1.2).  
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Figure 1.2: The HCV entry process. Multiple cells surface molecules are involved in HCV 
attachment to the cell surface and subsequent HCV entry. The interaction of HCV with 
lipoprotein particles initiates the initial attachment of HCV to the low density lipoprotein 
receptor (LDLR) and SR-B1. The virus glycoprotein E2 then directly binds to CD81 and this 
activates signal transduction through the epidermal growth factor receptor (EGFR) and Ras. 
This promotes lateral movement of CD81 in the hepatocyte plasma membrane to cell-cell 
contacts, where CD81 bind Claudin-1. CD81-Claudin-1 complexes result in HCV 
internalisation via clathrin-mediated endocytosis. Schematic taken from Lindenbach and Rice, 
2013. 
 
1.2.1 The tetraspanin family 
 
Tetraspanins are a family of membrane proteins found in organisms such as C. elegans, 
Drosophila and mammals (Levy et al., 1998). They are relatively small membrane 
proteins, typically around 200-300 amino acids in size. In humans, 33 tetraspanins are 
known to exist with some such as CD9, CD81 and CD151 being expressed in many 
different cell types, although not ubiquitous, whilst others are mostly found in one 
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particular cell type. Tetraspanins are involved in a variety of biological processes that 
include immune responses, sperm-egg fusion, host-parasite interactions and cell 
migration and metastasis (Rubinstein, 2011).  
A unique feature, common to all tetraspanins, is the lateral associations they form in the 
plasma membrane with each other, as well as with non-tetraspanin proteins. Tetraspanin 
function correlates with their ability to interact with one another as well as with other 
proteins.  This interacting network constitutes a so-called ‘tetraspanin web’ or a 
tetraspanin enriched microdomain (TEM), (Hemler, 2003), (Levy and Shoham, 2005). 
The tetraspanin web acts as a signalling platform that coordinates such cellular 
processes and it has been suggested that tetraspanin homodimers are the smallest unit 
that make up the tetraspanin web (Charrin et al., 2009). Imaging techniques have shown 
that interactions do not only occur within tetraspanin webs but also outside of these 
microdomains, with tetraspanins able to exchange between the two environments.  
There is accumulating evidence that cholesterol plays a significant role in the 
organisation and functioning of the tetraspanin web. A physical interaction between 
tetraspanins and cholesterol is likely to exist. In one study, CD9, CD81 and CD82 were 
labelled with a cholesterol analogue, [
3
H]photocholesterol, suggesting the tetraspanin 
and lipid exist in close proximity (Charrin et al., 2003). Furthermore, digitonin, a 
cholesterol precipitating reagent, was found to disrupt tetraspanin-tetraspanin 
interactions, suggesting tetraspanins were precipitated by digitonin due to their close 
association with cholesterol. Since cholesterol has an effect on tetraspanin protein 
interactions it therefore can modulate processes that rely on such protein-protein 
interactions. For example, Harris et al (2010) reported that removal of cholesterol from 
the plasma membrane using MβCD treatment reduced Claudin-1 expression at the 
membrane and its interaction with partner protein, tetraspanin CD81. Since CD81-
Claudin-1 interactions form a HCV entry receptor, the depletion of cholesterol caused a 
reduction in HCV entry into liver hepatocytes (Harris et al., 2010).  
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Figure 1.3: Tetraspanin structure. a) Schematic of the tetraspanin topology showing four 
transmembrane domains, intracellular N- and C- terminus and two extracellular loops (SEL and 
LEL). The LEL has a structurally variable region and a constant region throughout the 
tetraspanin family. b) The CD81 LEL crystal structure (Kitadokoro et al., 2001) shows a soluble 
homodimer, each monomer composed of 5 α-helices (A-E). The LEL variable region is made 
up of C and D helices and the constant region A, B and E helices.  
 
Tetraspanins can be distinguished from other four transmembrane domain proteins by 
their unique structural characteristics. Tetraspanins are composed of four 
transmembrane helices and two extracellular loops (the first is a small extracellular loop 
(SEL) and the second is a large extracellular loop (LEL)) and intracellular N- and C- 
terminal tails (see figure 1.3). A major milestone in structural tetraspanin research was 
in 2001: Kitadokoro and others successfully solved the crystal structure of a homodimer 
of human CD81 LEL (Kitadokoro et al., 2001), (Kitadokoro et al., 2002) confirming by 
sequence analysis that the key structural features of the LEL are conserved throughout 
the tetraspanin family. The X-ray crystallography data illustrated an antiparallel 
homodimer with each monomer being made up of five α-helices (A-E) stabilised by two 
disulphide bridges (Kitadokoro et al., 2001) (as shown in figure 1.3). The LEL has two 
important regions defined as a variable region (also known as the head domain)  
comprised of C and D helices that has shown involvement in tetraspanin interactions 
with partner proteins and ligands such as CD81 binding HCV glycoprotein E2 and a 
highly conserved region (known as the stalk domain) comprising A, B and E helices 
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that was suggested to be responsible for tetraspanin homodimerisation (Stipp et al., 
2003).   
Common throughout the tetraspanin superfamily is the conserved cysteine-cysteine-
glycine (CCG) motif that exists within the large extracellular loop (LEL) along with 2-4 
disulphide bridges. Tetraspanins also have conserved cysteine residues in the 
cytoplasmic domain of the protein, acting as palmitoylation sites (Seigneuret et al. 
2001).  
Tetraspanin conserved transmembrane domains are involved in tetraspanin intra- and 
intermolecular interactions, with TM1 and TM2 suggested to be involved in tetraspanin 
dimeric interactions (Kovalenko et al., 2005). The SEL has been shown to influence 
tetraspanin cell surface expression, in particular for tetraspanin CD81 (Masciopinto et 
al., 2001).  
Other tetraspanin family members, uroplakins Ia and Ib have their three-dimensional 
structure solved to 6 Å resolution. They were shown to form a hexameric structure of 
heterodimers and primary interactions with other membrane proteins form through tight 
interactions via their transmembrane and extracellular domains (Min et al. 2006), an 
aspect that may be common throughout the tetraspanin family.  
 
1.2.1.1 CD81 
 
CD81 was first discovered in the late 1980s, when it was initially named target of anti-
proliferative antibody 1 (TAPA-1) and later renamed as CD81 (cluster of differentiation 
81) (Levy et al., 1998) . CD81 is a 26kDa membrane protein consisting of four 
transmembrane domains, a short intracellular loop, and two extracellular loops referred 
to as small extracellular loop (SEL) and large extracellular loop (LEL) that support two 
disulphide bridges (see figure 1.4). CD81 is widely expressed in mammals including 
cells such as hepatocytes, epithelial cells, B lymphocytes, but is not expressed in 
erythrocytes or neutrophils. Multiple biological functions of CD81 exist in humans 
including cell adhesion, tissue differentiation, immune cell maturation and host-parasite 
interactions (Hemler 2003).  
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Tetraspanin functions are dependent on their association with tetraspanins or other 
partner proteins. CD81 interacts with many different host partner proteins such as 
integrin α4β1, immunoglobulin family members EWI-F and EWI-2. CD81 is also well 
documented to be involved in pathogen infection by viruses, bacteria and parasites 
(Zona et al., 2014). The work in this thesis focuses on CD81 as a HCV entry receptor, 
into its target host cell, the hepatocyte.  
Pileri and colleagues in 1998 discovered the initial HCV cell surface receptor as 
tetraspanin CD81, using sE2 in their investigation. Interestingly, sE2 was observed to 
competitively inhibit the binding of anti-CD81 to EBV-B cell lines (Pileri et al. 1998). 
HCV entry into hepatocytes is dependent on CD81. This was shown experimentally 
using a HepG2 cell line, which does not normally express CD81, but becomes 
permissive to HCVpp infection when transfected to express CD81 (Flint et al., 2006). 
The opposite scheme was true, when small interfering RNAs were used to silence CD81 
expression in Huh-7.5 cells: HCVpp infectivity was hampered (Zhang et al., 2004). 
 
 
 
 
 
 
 
 
 
Figure 1.4: CD81 structure. CD81 is composed of four transmembrane domains; two 
extracellular loops referred to as the SEL and the LEL and intracellular N- and C- terminal 
domains. The LEL shows four cysteines and the CCG motif that is characteristic of tetraspanin 
family members.  
 
The HCV entry process into hepatocytes is dependent on CD81 LEL (figure 1.2). A 
soluble recombinant form of human CD81 LEL binds HCV glycoprotein E2 as shown 
by protein immunoblot (Pileri et al. 1998). Also, full-length recombinant CD81 
expressed in Pichia pastoris bound HCV E2 (Jamshad et al. 2008). Further studies 
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provide evidence for the necessity of CD81 LEL for viral entry, showing that in vitro 
HCVpp and HCVcc infection were inhibited by recombinant CD81 LEL and by 
monoclonal antibodies against E2 and CD81 (Zhong et al. 2005), (Zhang et al., 2004), 
(Lavillette et al., 2005).  
 
Mutagenesis studies have revealed particular residues that are key for sE2 binding to 
CD81 LEL. Drummer and co-workers (2002) suggested that residues L162, I182, N184 
and F186 in CD81 LEL are important for binding sE2 (Drummer et al., 2002). 
Furthermore, Bertaux & Dragic (2006) compared sequences of human and mouse CD81 
to find that residues K171, I181, I182 and F186 were important for sE2 interactions 
with CD81 in addition to HCVpp entry.  
 
The CD81 LEL was structurally solved as a soluble homodimer, which is the only 
solved structure available for any member of the tetraspanin family (Kitadokoro et al., 
2001) (figure 1.3b). There is also a full length CD81 molecular model available, 
generated using information from the structure of soluble LEL and using homology 
modelling for the other regions in the full-length protein (Seigneuret et al., 2001). There 
is some debate as to how functionally relevant the LEL crystal structure is when used to 
predict the full length CD81 structure for a few reasons. Firstly, dimeric forms of CD81 
are believed to be a significant basic unit as shown in the LEL crystal structure and the 
form involved in HCV E2 binding (Kitadokoro et al., 2002), (Drummer et al., 2005) 
although, more recent studies using recombinant full length CD81 show evidence that 
the CD81 monomer can bind E2 (Jamshad et al., 2008). Furthermore, when residues on 
the dimeric interface observed in the CD81 LEL crystal structure were mutated, soluble 
LEL dimerisation was disrupted but the same effect was not observed when tested on 
full-length CD81 oligomers in mammalian cells (Drummer et al., 2005). Therefore, 
Drummer & colleagues (2005) hypothesised that the LEL has a more robust structure in 
the full length tetraspanin compared to the soluble LEL counterpart. Regions other than 
in the LEL are likely to be vital for CD81 dimerisation and stability, such as in the 
transmembrane domains, since the CD9 dimeric interface was found in TM1 and TM2 
(Kovalenko et al., 2005). Also, when viewing the crystal structure LEL dimer, the two 
loops are facing away from each other; incorporating the transmembrane domains into 
this orientation is impossible (Rajesh et al., 2012) (figure 1.3b). This leads to 
differences between what was found in the LEL soluble structure and what was later 
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modelled in the full length CD81 molecule (Seigneuret et al., 2001). Further research is 
still required to extend our knowledge on tetraspanins, and more specifically, CD81 full 
length structure and also the dimerisation interface.  
 
Although an extensive collection of data is published to show that CD81 is a critical 
receptor for HCV entry, it was previously apparent to researchers that other molecules 
were required for this process. Human CD81 renders human hepatoma cells permissive 
to HCV infection, although CD81 from a range of other species that do not get infected 
by HCV also had a similar ability. Therefore, it was clear that other human specific 
factors / receptors must be involved for HCV to specifically infect humans and even 
more specifically, hepatocytes (Flint et al., 2006). Additionally, CD81 is ubiquitously 
expressed in humans and so other molecules, along with CD81, must define HCV 
tropism for the liver.  
 
1.2.2 Claudin superfamily 
 
Claudins were first described in the literature in 1998 (Tsukita and Furuse, 1998). There 
are approximately 27 family members found in mammals that are important 
components of tight junctions. Claudins have four transmembrane domains, separated 
by a first extracellular loop (ECL1) and a second smaller extracellular loop (ECL2) and 
small intracellular domains (see figure 1.5a).  
 
 
 
 
 
 
 
 
 
 
a) ECL1 
ECL2 
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Figure 1.5: Claudin-1 structure and function. a) A schematic of the topology of Claudin-1 
showing four transmembrane domains, intracellular N- and C- terminal domains and two 
extracellular loops (ECL1 and ECL2). b) Tight junction proteins Claudin and Occludin 
involved in the formation of junctional strands found at tight junctions. Tight junction strands 
from a seal to prevent uncontrolled leakage of water or solutes in epithelial or endothelial 
tissues. Claudins interact with other Claudins laterally and on neighbouring cells via their 
extracellular loops.  
 
 
Claudin, from the Latin word claudere, means to close. Claudins constitute the 
paracellular seal in epithelial and endothelial tissues to allow for controlled movement 
of solutes and water between cells, as well as acting as a fence-like structure to separate 
the apical and basolateral sides of a membrane (Gunzel and Fromm, 2012) (see figure 
1.5b). Claudin proteins can form oligomers laterally with themselves, via their 
extracellular loops, or with partner proteins in opposing cells to form a tight junction 
seal. It is possible to find Claudin homo- and hetero-oligomers in the epithelial 
membrane since multiple Claudins have been found in one tight junction strand. It is 
this combination that defines the sealing properties of a given tight junction (Van Itallie 
and Anderson, 2013).  
 
Up until recently, a high resolution structure for Claudin family members did not exist. 
Suzuki and colleagues (2014) successfully solved the full length structure of mouse 
Claudin-15 at high resolution (2.4Å) (see figure 1.6). High level expression of Claudin-
15 was achieved using Sf9 insect cells and the membrane protein was purified using 
maltose neopentyl glycol (MNG) detergent (see later for description) before 
crystallising in lipidic cubic phase (Suzuki et al., 2014). The structure shows that the 
TM domains form a typical left-handed four helix bundle and the extracellular loop 
b) 
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regions form β-sheet structure comprised of five β strands; four contributed by the first 
extracellular loop and one by the second extracellular loop. Interestingly, the crystal 
lattice demonstrates how Claudin-15 monomers form a linear homo-oligomer, with 
interactions between adjacent molecules dependent on extracellular domains involving 
the extracellular loop 1 of one monomer (residue Met68) and the transmembrane 
domain 3 and extracellular loop 2 (residues Phe146, Phe147 and Leu158) of the 
adjacent monomer since transmembrane domain 3 extends above the membrane surface 
(unlike the other three transmembrane domains). This may be physiologically relevant 
and represent the linear monomer interactions that form in tight junction strands 
(Suzuki et al., 2014).  
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Claudin-15 full length crystal structure. A ribbon representation of the crystal 
structure of monomeric mouse Claudin-15 solved at a resolution of 2.4 angstroms (PDB 
number: 4P79). Image taken from Suzuki et al., 2014.  
 
 
1.2.2.1 Claudin-1 
 
Claudin-1 is a 23 kDa membrane protein known to be highly expressed in the liver 
(Evans et al. 2007). Claudin-1 is functionally responsible for constituting tight junction 
strands and can associate via homotypic or heterotypic interactions in the cell 
membrane of a single cell and with proteins of an opposing cell through interactions 
between extracellular loops. In 2007, Evans and co-workers discovered Claudin-1 was 
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an entry receptor for HCV as a result of a repetitive expression cloning approach.  This 
used the complementary DNA library of a cell line that is highly infected by HCV 
(Huh-7.5 cell line) to find specific genes that cause a cell line (CD81
+
 SR-BI
+
 293 T 
cells) that is not typically infected by HCV to one that is susceptible to infection by 
HCVpp (Evans et al. 2007). Interestingly, Claudin-7 is one of the closest family 
members to Claudin-1, with only five residues differing between them in the LEL but is 
not a HCV entry receptor. Using a mutagenesis approach, it was found that residues I32 
and E48 in the LEL of Claudin-1 are critical for HCV infection (Evans et al. 2007). 
Furthermore, other members of the Claudin family, Claudin-6 and Claudin-9 were also 
shown to support HCV entry (Zheng et al., 2007), (Meertens et al., 2008). Even so, 
Claudin-6 and -9 are not recognised to be critical factors defining HCV entry into 
hepatocytes as they are not known to be highly expressed in the liver (Timpe and 
McKeating, 2008).  
Claudin-1 can locate in non-junctional areas of the basolateral surface of hepatocytes, 
co-localising with tetraspanin CD81 (Reynolds et al., 2008). Claudin-1 associates with 
CD81 and this receptor complex has been shown to be essential for HCV entry (Harris 
et al., 2010).  
 
1.2.3 CD81-Claudin-1 as a HCV entry co-receptor complex 
 
To date, there has not been any direct evidence for Claudin-1 to interact with HCV 
glycoproteins E1/E2, unlike HCV receptors CD81 and SR-BI. This may indicate the 
requirement of HCV to bind its cell surface receptors in a defined chain of events or 
potentially due to the low sensitivity of cell-based methods (Harris et al., 2008). Studies 
have provided evidence for Claudin-1 association with CD81 and the co-localisation of 
both proteins in the plasma membrane. Harris and co-workers (2008) demonstrated this 
using fluorescently tagged CD81 and Claudin-1 and used fluorescence resonance 
energy transfer (FRET) analysis to show that homotypic (CD81-CD81) (Claudin-1-
Claudin-1) and heterotypic (CD81-Claudin-1) interactions occur in non-junctional areas 
of the plasma membrane (Harris et al. 2008). Claudin homotypic interactions are 
supported by previous work by Blasig and co-workers, reporting FRET between tagged 
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Claudin-5 molecules, indicating that homodimers exist in the plasma membrane of the 
same cell (Blasig et al., 2006).  
The CD81-Claudin-1 complex has also been demonstrated using recombinant full 
length proteins, produced in Pichia pastoris, in which Claudin-1 oligomers associate 
with CD81 at a 1:2 molar ratio using dynamic light scattering (DLS) (Bonander et al., 
2013). The complex was stabilised in the presence of cholesteryl hemisuccinate (CHS), 
suggesting that the complex is specific and does not require other cellular proteins or 
factors that might contribute to CD81-Claudin-1 complex formation.  
Further evidence to demonstrate CD81-Claudin-1 is an essential complex in HCV entry 
was shown when residues I32 and E48 in Claudin-1 LEL disrupted association with 
CD81 and also disturbed HCV receptor function (Harris et al., 2010). In contrast, 
substituting the same residues on Claudin-7 (a non-HCV entry receptor) enabled the 
protein to interact with CD81 and allow HCV entry into 293T cells (Harris et al. 2010). 
The location of CD81-Claudin-1 complexes is important for HCV entry. CD81-
Claudin-1 complexes located at basolateral areas of polarised hepatoma cells (Harris et 
al. 2010). This possibly explains the initial location of HCV infection, as the virus 
enters the liver via the sinusoidal blood; this would permit interactions between the 
virus and basal located forms of the co-receptor complex.  
Other studies have focused on other Claudin-1 regions for its association with CD81, 
including the C-terminal tail and putative palmitoylation sites. Using FRET analysis, it 
was shown that Claudin-1 without its C-terminal tail associates with CD81 as does the 
wild-type full length Claudin-1 (Harris et al. 2008). This was also the case for 
intracellular palmitoylation sites, which did not prove a significant region for HCVpp 
entry (Evans et al., 2007).   
More recently, residues in CD81 LEL T149, E152 and T153 were shown to lie on the 
interaction interface with Claudin-1 ECL1 motif between residues 62-66 (Davis et al., 
2012). In order to find the interaction interface in the extracellular loops, the study used 
a molecular modelling approach to predict the residues followed by site-directed 
mutagenesis and FRET to assess the interacting mutant proteins. It was found that the 
residues in the loop regions of both proteins are important for CD81-Claudin-1 complex 
formation and HCV entry. Importantly, mutant CD81 proteins (T149A, E152A and 
T153A) bound HCV E2 to a similar degree as WT CD81 (Davis et al., 2012) supporting 
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a previous study that showed the HCV E2 binding site is in a separate region (Drummer 
et al., 2002). This evidence may suggest the occurrence of a HCV-CD81-Claudin-1 
complex prior to particle internalisation and infection.  
It is clear in the literature that CD81-Claudin-1 loop regions are crucial for the protein 
interaction and consequently HCV entry. Little attention has focused on the 
transmembrane domains in this heterodimer but it is recognised that TM domains are 
important to drive tetraspanin dimerisation, more specifically TM1 and TM2 are 
reported to be on the dimerisation interface of CD9 (Kovalenko et al., 2005). Also, 
regarding HCV entry, Bertaux & Dragic (2006) found that mutating residues in CD81 
TM1 (N18), TM2 (C80) and TM4 (E219), reduced HCVpp entry by approximately 
40%. Since the mutants’ ability to bind HCV E2 was not affected it seems apparent that 
another mechanism(s) is involved, such as a mutant knock down of a protein-protein 
interaction that is necessary for HCV infection to occur. Therefore, further investigation 
into transmembrane residues in their role in HCV entry and four TM protein 
interactions is required.  
 
1.3 Recombinant protein production of membrane proteins 
 
Integral membrane proteins are pharmaceutically important proteins as they are key 
drug targets. More than 50% of all drugs target them due to their many vital biological 
functions such as their involvement in cellular signal transduction processes. To a great 
extent, progress in the field of research concerning membrane proteins has been 
possible over the past few years due to developments in expression using a 
heterologous host and subsequent purification and crystallisation (Freigassner et al., 
2009). High resolution structures are useful for drug development and to understand the 
function of a membrane protein but initial reliance is placed on the ability to produce 
high yields of functional and stable protein, since the majority are expressed in low 
levels naturally and their hydrophobic qualities means that they can be a challenge to 
produce and maintain in a functionally folded state (see Bill et al., 2011). There are a 
small number of membrane proteins that occur in large quantities in their native 
membrane such as rhodopsins and aquaporins, which were among the first membrane 
proteins to have their structures solved (Bill et al., 2011).  
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Hosts used to produce challenging proteins such as integral membrane proteins in the 
past include prokaryotes such as Escherichia coli, mammalian cells, insect cells and 
yeast such as P. pastoris (Fernandez and Vega, 2013). Even though prokaryotes have 
been hugely successful in the structural determination of many prokaryotic and 
eukaryotic membrane proteins, the production of a eukaryotic membrane protein may 
be favourable using a more evolutionary related recombinant host, such as the 
eukaryote yeast. The target membrane protein may benefit from eukaryotic features 
yeast can offer such as post-translational modifications and the eukaryotic secretory 
pathway for correct protein processing and functional expression (Ahmad et al., 2014).  
 
1.3.1 Pichia pastoris as a recombinant protein production host 
 
P. pastoris is a methanol-utilising yeast (methylotrophic) that can be readily grown to 
high volumes and cell densities (Daly and Hearn, 2005). The ability of yeast to use 
methanol as a sole carbon source was discovered over 40 years ago. In 1985 the alcohol 
oxidase I gene (AOX1), which is regulated by methanol, was isolated from P. pastoris 
(Ellis et al., 1985). The promoter of the AOX1 gene is now known to be one of the most 
tightly regulated and effective promoters, which provides P. pastoris with an attractive 
feature to molecular biologists with an aim to control the expression of heterologous 
proteins (Cregg et al. 2000). Researchers are currently able to purchase a Pichia 
expression kit available from Invitrogen.  
P. pastoris is widely used as a host to produce recombinant membrane proteins, in order 
to yield large quantities for structural and functional studies. Typically, it is the high 
cell densities and culture volumes that allow high yields of protein to be achieved, since 
even if a target protein is expressed at a low level on a cell basis, the volumetric yield is 
sufficient (Ahmad et al., 2014). Membrane protein production in P. pastoris has 
previously been successful in expression through to crystallisation. Shiroishi and co-
workers had success using P. pastoris for the first time to determine the structure of a G 
protein-coupled receptor (GPCR). The human histamine H1 receptor was structurally 
determined at 3.1 Å resolution (Shiroishi et al., 2011). Solving the structures of GPCRs 
is a particular challenge in the membrane protein field because it is difficult to first of 
all express sufficient amounts of recombinant protein, then success must continue to 
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purification of stable proteins that are functional and properly folded and can pack 
together to form crystals (see Bill et al., 2011). Each stage of this process will likely 
need optimisation for a particular target protein, in order to reach the final goal of a 
solved structure.  
P. pastoris was previously used at Aston University to generate milligram quantities of 
full length, correctly folded, functional CD81, for which all the palmitoylation sites 
were removed therefore referred to as CD81 p-null (Jamshad et al., 2008). The 
structural integrity of the full length CD81 p-null was determined through binding of 
specific monoclonal antibodies that were raised against native CD81. Further, the 
function of CD81 p-null was confirmed due to the specific binding with HCV E2 
glycoprotein. Using the same recombinant host system, human Claudin-1 was also 
expressed to similar quantities and quality (Bonander et al., 2013). In both cases, the 
vector pPICZB was used to independently clone PCR products of the respective genes 
into P. pastoris wild-type X33 strains (Jamshad et al., 2008).  
Recombinant Claudin-1 was previously characterised alone and in complex with CD81 
p-null (Bonander et al., 2013). Yeast membrane bound and detergent solubilised 
Claudin-1 were shown to be antigenic using specific monoclonal antibodies, confirming 
the correct protein confirmation. Furthermore, Claudin-1 did not bind HCV sE2, which 
is consistent with current literature understanding. DLS analysis of the CD81-Claudin-1 
complex found that Claudin-1 oligomers interacted with CD81 at a molar ratio of 1:2 
(Bonander et al., 2013), also this complex was stabilised with the addition of CHS. This 
is consistent with findings that tetraspanins interact with membrane cholesterol (Charrin 
et al., 2003) and that cholesterol is important for the stability of tetraspanin protein 
interactions, such as in the CD81-Claudin-1 interaction for efficient HCV entry (Harris 
et al., 2010).  
Tetraspanins have been produced recombinantly elsewhere in hosts other than yeast; 
these include CD81 in mammalian cells (Takayama et al., 2008) and CD151 and 
Uroplakin 1b in E. coli (Tarry et al., 2012). CD81 produced in a tetracycline-inducible 
stable mammalian cell line and purified using a single step immunoaffinity method 
(>95% purity) was shown to be folded and functional by binding HCV E2 (Takayama 
et al., 2008). Tarry and colleagues (2012) produced tetraspanins in E.coli and out of 
approximately 18 constructs screened for expression, only three were taken forward for 
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optimisation of expression and purification; CD81 was not taken forward. The study 
found cymal-5 as an optimal detergent for solubilisation. Although sufficient levels of 
recombinant full length tetraspanins were achieved, the protein was not homogeneous 
as seen by size exclusion chromatography, so unsuitable for structural studies, therefore 
purification optimisation using other detergents and conditions are still required in this 
area (Tarry et al., 2012). This would then enable further structural studies, such as 
protein X-ray crystallography or NMR spectroscopy, after obtaining sufficient 
concentrations of stable, functional and monodispersed CD81. To date, there has not 
been any high resolution full length structure for any member of the tetraspanin family. 
 
1.3.2 Membrane protein solubilisation 
 
Once a membrane protein of interest has been expressed to sufficient levels, the next 
step is to extract it from the host membrane. The most common approach is to solubilise 
the target protein using detergent (Prive, 2007). Detergents are used to mimic the lipid 
bilayer from where the membrane protein will be extracted due to their similarities in 
amphipathic properties. Detergent monomers are composed of a hydrophilic head group 
and a hydrophobic alkyl chain. Monomers in solution naturally form globular micelles 
at or above the critical micelle concentration (CMC) of a given detergent; so that the 
head group is solvent exposed and the hydrophobic alkyl chains are concealed from 
water molecules, forming a micelle core (Oliver et al., 2013). At detergent 
concentrations below the CMC, detergent exists as monomers, though at concentrations 
above the CMC, an equilibrium forms between monomers and micelles (Moraes et al., 
2014). Figure 1.7 shows the complexity and various stages of membrane solubilisation 
by detergent, which is dependent on the detergent concentration. At low detergent 
concentration, monomers bind to the membrane although it is not disrupted. Membrane 
disruption occurs when the detergent concentration is increased (see figure 1.7) and a 
further concentration increase results in a heterogeneous mixture of micelles containing 
protein in complex with either detergent or detergent and lipid (Kalipatnapu and 
Chattopadhyay, 2005).  
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Figure 1.7: Detergent solubilisation of membrane proteins in a lipid bilayer. A) the lipid 
bilayer, B) Low detergent (grey tails) concentration bound to the membrane, C) Higher 
concentration of detergent causes disruption of the lipid bilayer and D) shows at higher 
detergent concentrations a heterogeneous solution exists of lipid-protein-detergent mixed 
micelles. Image taken from Kalipatnapu and Chattopadhyay (2005).  
 
 
The main objective when extracting membrane proteins from the membrane is to 
achieve a soluble, functional and properly folded protein sample that can then be 
purified. Although, only too often, membrane proteins will denature and aggregate 
throughout this process since their environment is too distinct from the lipidic 
environment from which they have come from. Therefore, the addition of lipids to the 
protein detergent complex can sometimes benefit the stability of certain membrane  
proteins (Prive, 2007). Other innovative approaches to improve membrane protein 
detergent stability are now being used to obtain X-ray crystal structures, which include  
screening protein mutants, ligand addition and the use of novel detergents (Kang et al., 
2013).  
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Table 1.1: Detergents used for membrane protein solubilisation and purification. 
Commonly used detergents to solubilise and maintain the folded structure and function of 
membrane proteins include β-OG, DM and DDM, also used in this thesis. MNG represent a 
more recently developed amphiphile used to solubilise membrane proteins. In contrast to 
conventional detergents, MNG compounds have two hydrophilic and two hydrophobic subunits. 
 
The most common detergents used previously to obtain crystals have included the 
following three nonionic detergents: n-octyl-β-D-gluocopyranoside (β-OG), n-decyl-β-
D-maltopyranoside (DM) and n-dodecyl-β-D-maltopyranoside (DDM) (Oliver et al., 
2013). These detergents are regarded as ‘mild’ since they are known to break lipid-lipid 
and protein-lipid interactions rather than protein-protein interactions (Moraes et al., 
2014). This is in contrast to ‘harsh’ detergents such as ionic detergents (for example, 
sodium dodecyl sulfate (SDS)) which are likely to denature the protein of interest. 
Table 1.1 shows how head group and tail length properties can differ between three 
Detergent Formula 
Weight  
CMC (%) Structure 
n-octyl-β-D-
gluocopyranoside 
(β-OG) 
292.4 0.53  
n-decyl-β-D-
maltopyranoside 
(DM) 
482.6 0.087  
n-dodecyl-β-D-
maltopyranoside 
(DDM) 
510.6 0.0087  
maltose neopentyl 
glycol (MNG) 
- 0.0010 
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detergents. It has been found that the detergent head group is involved in the detergent- 
protein interaction, whereas the alkyl chain has an effect on the CMC value (Prive, 
2007). Shorter chains such as in β-OG (8 carbons) have a much higher CMC than 
longer chains in DM and DDM (10 and 12 carbons, respectively) and so large amounts 
of β-OG are used to solubilise membrane proteins as compared to that used for DM and 
DDM. The detergent used to solubilise is typically optimised for each individual target 
protein by assessing the stability and monodispersity of the protein-detergent complex. 
Also, the detergent used for extraction may be different to the detergent used for later 
stages of purification and crystallisation, after performing a detergent buffer exchange 
(Moraes et al., 2014).   
Since detergents may replace annular lipids surrounding the protein, which can result in 
the loss of protein structure and function, alternative solubilisation approaches have 
now been developed in order to improve membrane protein stability. One example 
includes the use of a novel set of amphiphiles composed of a quaternary carbon derived 
from neopentyl glycol and hydrophilic head groups derived from maltose, therefore the 
compounds are called maltose neopentyl glycol (MNG) (Chae et al., 2010). In contrast 
to current detergents (table 1.1), MNG compounds have two hydrophilic and two 
hydrophobic subunits. It was found that MNG could extract and maintain proper 
folding and function of various membrane proteins, with the ability to assist crystal 
formation for structural characterisation. Such findings established MNG amphiphiles 
as being more beneficial for protein stability (for those proteins that were tested) than 
standard detergents used such as DM (Chae et al., 2010). Recently, MNG was used for 
the crystallisation of membrane protein Claudin-15 (Suzuki et al., 2014).  
Given that membrane lipids surrounding target membrane proteins are crucial for 
stability, other approaches have made successful efforts to purify the protein with the 
annular lipid environment intact (Jamshad et al., 2011). For example, the poly(styrene-
co-maleic acid) (SMA) is a amphipathic polymer that is composed of alternating 
hydrophilic (maleic acid) and hydrophobic (styrene) units so that at neutral and basic 
pH the SMA forms a disc-like structure surrounding the protein plus membrane. 
Adding the SMA directly to lipid bilayers containing the protein of interest is sufficient 
to form the nano-discs and therefore detergent is not required. This enables purification 
of the target protein in particles with diameters between 9-11nm (Knowles et al., 2009), 
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which maintains the protein structure and function in order to study further using 
biophysical techniques such as analytical ultracentrifugation. 
1.3.3 Membrane protein stability studies 
It is well established that achieving stable recombinant eukaryotic membrane protein 
preparations can be a difficult challenge, but the optimisation of stability as well as 
solubility and homogeneity have been shown to be essential for a successful 
crystallisation trial (Alexandrov et al., 2008). Therefore, methods used to assess and 
optimise the stability of purified samples are imperative prior to solving a high 
resolution protein structure. One relatively recent approach exploits a thiol-specific 
fluorochrome N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM) 
used to assess the thermal stability of membrane proteins in a high throughput format, 
therefore requiring small amounts of purified material (Alexandrov et al., 2008) (see 
figure 1.8).  
 
 
 
 
 
 
Figure 1.8: CPM structure. Thiol reactive CPM is non-fluorescent until reacted with thiols 
and becomes highly fluorescent. This can be used to measure temperature-induced membrane 
protein unfolding since most cysteine residues are typically buried in transmembrane domains 
(Alexandrov et al., 2008).  
 
 
Thermal stability is assessed in this assay using a fluorescence read-out when a 
membrane protein (in a particular buffer) is incubated at a certain temperature for 
unfolding to occur. Cysteine residues that are buried within the hydrophobic interior of 
the target protein, typically within transmembrane domains, are exposed after 
temperature-induced protein unfolding. This causes the thiol-specific CPM to 
covalently bind to exposed cysteines and the fluorescence readout can be recorded over 
time using an appropriate spectrofluoremeter (Alexandrov et al., 2008). Various studies 
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have used this method to improve the stability of the target membrane protein(s). 
Sonoda et al., (2011) used the CPM assay to optimise detergent stability of 24 
eukaryotic and prokaryotic membrane proteins and found a correlation between protein 
stability and the likeliness of obtaining well-ordered crystals for high resolution 
structure determination (Sonoda et al., 2011). 
An alternative approach to improve protein stability in a different study used alanine 
scanning mutagenesis. For example, the GPCR β1-adrenergic receptor with 6 point 
mutations and bound antagonist shown an increase in thermal stability as compared to 
the WT receptor. Thermal stability was assessed by heating detergent-solubilised 
receptors to 32°C and then performing radioligand binding experiments to measure the 
remaining number of functional receptors (Serrano-Vega et al., 2008). 
 
1.4 Determination of protein-protein interactions 
 
As described in earlier sections, membrane proteins are typically organised in molecular 
complexes at the plasma membrane in order to perform their role in biological 
processes. Therefore, it is fundamental for biologists to unpick these complexes and 
determine specific protein-protein interactions that occur and for what reason. 
Typically, if a biological function is dependent on a membrane protein binding to its 
partner protein, it is also likely to be linked to disease and seen as a potential drug 
target. This is true for the CD81-Claudin-1 complex. Although it is not understood why 
tetraspanins interact with tight junction proteins normally outside of the tight junction, 
it is clear that this complex is required for HCV entry into hepatocytes (Harris et al., 
2010).  
Biochemical means to study protein-protein interactions exist such as 
coimmunoprecipitation and cross-linking, which require cell lysis using harsh 
detergents that may interfere with weak protein-protein interactions (Thaminy et al., 
2003). Consequently, alternative techniques employed to map protein-protein 
interactions at the plasma membrane (in vivo) are extremely useful to determine novel 
interaction partners and also to define the binding interface between proteins. The 
hydrophobic nature of membrane proteins adds on an extra level of complexity, since 
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the lipid bilayer is the optimal environment for membrane proteins to maintain structure 
and function. Therefore, techniques that can measure protein-protein interactions in situ 
may be advantageous over those where membrane proteins need to be extracted prior to 
measurement with partner proteins.  
 
1.4.1 The yeast split-ubiquitin Dualmembrane system 
 
A technique used in this thesis to investigate protein-protein interactions is the yeast 
split-ubiquitin Dualmembrane system (Dualsystems Biotech Ltd). The method allows 
detection of interactions between integral membrane proteins or soluble proteins in situ 
in the yeast, Saccharomyces cerevisiae. It has been developed over time from the 
original yeast-two-hybrid system (Fields and Song, 1989), which was primarily suited 
to soluble proteins and was problematic for membrane proteins since the proteins of 
interest would be required to enter the nucleus for transcriptional activation of reporter 
genes.  
Modifications of the original yeast-two-hybrid have meant that a wider range of protein 
targets can now be studied. One example uses the split-ubiquitin idea first described by 
Johnsson and Varshavsky (1994). The genetic assay uses ubiquitin, a protein that 
usually tags other proteins for degradation with chains of ubiquitin; this process flags a 
signal on the protein so that it is transported to the proteasome for degradation. 
Ubiquitin specific proteases (UBPs) recycle ubiquitin monomers by cleaving a site after 
the last residues of ubiquitin. In S. cerevisiae when ubiquitin is split into two halves and 
expressed independently, the two halves have strong affinity for each other and so re-
assemble within the cell. UBPs can then recognise and cleave the reconstituted 
ubiquitin (Johnsson and Varshavsky, 1994). In order to make these phenomena useful 
when being applied to a protein interaction assay, the N-terminal half of ubiquitin was 
mutated at residue 3 from an isoleucine to a glycine, which results in the two halves of 
ubiquitin having negligible affinity for each other and so UBPs do not recognise either 
half within the cell. Therefore, reconstitution of ubiquitin and cleavage by UBPs can 
only occur as a result of two interacting proteins that are fused to either half of ubiquitin 
(Johnsson and Varshavsky, 1994) (see figure 1.9).  
42 
 
The yeast split-ubiquitin Dualmembrane system allows heterologously expressed 
membrane proteins to reside in the membrane, in vivo, where they can undergo protein-
protein interactions, which can be measured using a reporter gene system (Stagljar et 
al., 1998). After selecting two proteins of interest, one is assigned as bait and is fused to 
the C-terminal half of ubiquitin (Cub) plus a transcription factor LexA-VP16 and the 
other is prey, which is fused to the N-terminal half of mutated ubiquitin (NubG) (see 
figure1.9). When co-expressed within the same cell, if the two proteins of interest have 
natural affinity for each other, they will interact, which forces NubG and Cub into close 
proximity. This results in re-assembly of the two halves of ubiquitin and so UBPs now 
recognise functional ubiquitin and cleave the polypeptide chain between Cub and 
LexA-VP16.  
LexA-VP16 is composed of two domains; LexA is a DNA binding domain and VP16 is 
a transcriptional activating domain. When it is released upon cleavage by UBPs it 
translocates to the nucleus and activates transcription of reporter genes (Stagljar et al., 
1998). The reporter genes used in this assay are two autotrophic growth markers; HIS3 
and ADE2. When a protein-protein interaction occurs between the proteins of interest, 
the yeast co-expressing them can grow on minimal media that lacks addition of 
histidine or adenine. The other reporter gene that can be used for measurements of 
protein-protein interactions is lacZ, which when activated, causes expression of β-
galactosidase that can be measured using colorimetric and fluorometric assays. 
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Figure 1.9: Yeast two hybrid split-ubiquitin Dualmembrane system. Bait and prey proteins 
of interest are fused to half of ubiquitin (Cub-LexA-VP16 and NubG, respectively). Upon a 
protein-protein interaction of the bait and prey proteins, Cub-LexA-VP16 and NubG are forced 
into close proximity and reconstitute ‘whole’ ubiquitin, which is recognised by UBPs that 
cleave LexA-VP16. The artificial transcription factor can then translocate to the nucleus where 
it initiates the expression of reporter genes HIS3, ADE2 and lacZ. Therefore, growth on 
histidine and adenine deficient plates or activity in a β-galactosidase assay is an indirect 
measurement of a protein-protein interaction (Johnsson and Varshavsky, 1994). 
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1.5 Aims and Objectives 
 
This thesis describes an investigation designed to increase current understanding of the 
structural and functional features of CD81 and Claudin-1. This was done using two 
yeast strains, S. cerevisiae and P. pastoris in order to determine the interaction interface 
of CD81-Claudin-1 and the structural stability of recombinant proteins, respectively, 
with the following objectives: 
 To optimise a yeast split-ubiquitin Dualmembrane system assay in order to 
detect CD81 homodimers and CD81-Claudin-1 heterodimers in the yeast 
membrane; 
 
 To determine the full length interaction interface of the CD81-Claudin-1 
complex, specifically focusing on the role of transmembrane domains and to 
learn if there are any similarities between the binding interface of homo- and 
hetero-interactions; 
 
 To select residues to test in a protein-protein interaction yeast assay guided by 
molecular modelling; 
 
 To structurally characterise full length recombinant CD81 by means of 
improvements to solubilisation, purification and stabilisation procedures. 
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2. Materials and methods 
2.1 Vector generation and Dualmembrane split ubiquitin yeast assay 
 
The DUALmembrane pairwise interaction kit was purchased from Dualsystems Biotech 
Ltd and contained the following items that were used in this thesis: 
 
Table 2.1: DUALmembrane pairwise interaction kit contents. Taken from the user manual 
(Dualsystems Biotech Ltd). 
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2.1.1 Yeast strain NMY51 
 
S. cerevisiae strain NMY51 (see table 2.1) was grown on YPAD agar plates by 
incubating at 30C for three days. Single colonies were picked into 10ml overnight 
YPAD cultures (shaking at 30C, 220rpm). The following day, glycerol stocks were 
prepared using 1:1 YPAD NMY51 saturated culture and 50% sterile glycerol and 
vortexed. Using a cryovial, glycerol stocks were stored at -80C until needed. 
NMY51 on agar plates were kept at 4C wrapped in parafilm and re-streaked every 2 
weeks from the glycerol stock. Yeast plates older than 2 weeks were not used for 
transformation.  
2.1.2 Yeast media and plates 
 
YPAD 
Liquid media was made using the Dualsystems Biotech Ltd media starter package. Each 
pouch required 1L water and YPAD was stirred until completely dissolved. Liquid 
YPAD was autoclaved. If making YPAD agar plates, 500ml dissolved YPAD was 
added to 10g agar and autoclaved. Subsequently, YPAD agar was poured into sterile 
petri dishes and allowed to solidify overnight. Agar plates were stored at 4C, wrapped 
in parafilm, until use.  
Synthetic Defined (SD) media 
Liquid or agar plates were made using Dualsystems Biotech Media Package 1 (for 
DUALmembrane), following manual guidelines. Liquid media and agar plates were 
made excluding; SD-Leu, SD-Trp, SD-Trp-Leu, SD-Trp-Leu-His and SD-Trp-Leu-His-
Ade. Amino acids (purchased from Dualsystems Biotech) were added at the following 
final concentration: 
 Adenine (A) - 10 mg/L 
 Histidine (H) - 20mg/L 
 Tryptophan (W) - 20mg/L 
 Leucine (L) - 100mg/L 
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Yeast SD plates were made using 2% agar, left to solidify overnight and stored at 4C, 
wrapped in parafilm, until use.  
 
2.1.3 E.coli competent cells 
 
XL-1 Blue supercompetent cells and XL-10 Gold Ultracompetent cells were purchased 
from Stratagene (Agilent technologies) and stored at -80C until use.  
 
2.1.4 Bacterial media 
 
Luria-Bertani (LB) broth- For liquid broth 20g/L LB was dissolved completely into 
water and autoclaved. For LB-agar, 20g/L LB and 15g/L agar was autoclaved and 
allowed to cool before pouring into sterile petri dishes. If an antibiotic was to be added, 
such as Ampicillin (LB-AMP) or Kanamycin (LB-KAN) the LB (+/- agar) was allowed 
to cool to around 40C before antibiotic addition and mixing with a magnetic stirrer.  
 
2.1.4.1 Antibiotics 
 
Kanamycin 
Stored at -20C at 50mg/ml and used at a working concentration of 40µg/ml). 
Ampicillin  
Stored at -20C at 100mg/ml and used at a working concentration of 100µg/ml). 
 
2.1.5 E. coli transformation 
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In order to obtain further vector DNA to use for yeast transformation, E.coli was 
transformed and minipreps performed for isolation of the given vector. 
For E.coli transformation, 100µl XL-1 Blue supercompetent cells were treated with 
1.7µl β-mercaptoethanol (1.42 M) prior to transformation, mixing on ice every 2 min 
for 10 min in total. 20µl of cells were taken and mixed with 2µl vector DNA 
(~500ng/µl) and incubated on ice for 30 min. A heat block was set to 42C and tubes 
containing bacteria and DNA were exposed to a heat shock for 45 seconds and then put 
immediately back on to ice for 2 min. 1ml LB was added to each tube of bacteria and 
DNA and incubated at 37C, 200rpm for 1h. After, bacterial samples (30µl and 60µl of 
mix) were added to LB-agar plates containing an appropriate antibiotic (AMP or KAN) 
in order to select for cells that harbour the selected DNA vector. Plates were then 
incubated at 37C for no more than ~18h and subsequently stored at 4C until single 
bacterial colonies were required to be picked. Using 3ml LB-AMP or LB-KAN 
(depending upon vector being used), a single bacterial colony was added into media and 
incubated overnight at 37C, 200rpm. The following morning, cultures were taken, 
centrifuged and vectors were isolated using a GenElute Plasmid miniprep kit (using the 
spin method) according to the manufacturers manual. Vector concentration would be 
determined using a NanoDrop and the quality determined using agarose gel 
electrophoresis. Successful DNA isolations were then sent for DNA sequencing 
(Eurofins).   
 
2.1.6 Vector generation 
 
Upon arrival, 50µl MilliQ water was added to lyophilized plasmids and incubated at 
50°C for 5 min, vortexed then stored at -20C until further use.  
The Oligonucleotide primers to sub-clone CLDN1 and CD81 from pTrip vectors 
(kindly provided by Professor Jane McKeating, Birmingham University) were 
generated using Dualsystems Biotech guidelines. The primers synthesised (Invitrogen) 
are shown in table. The polymerase chain reaction (PCR) used to amplify the insert is 
outlined in table.  
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Table 2.2: CD81 and Claudin-1 oligonucleotide primers. The Oligonucleotide primers were 
designed using the manufacturer’s guidelines containing Sfi I sites (DUALsystems Biotech 
Ltd). The oligonucleotide primers were synthesised by Invitrogen and on arrival diluted with 
MilliQ water so that the stock concentration was 100pmol/µl and stored at -20°C. 
 
Vector  Primer sequence  
pBT3-N- CD81  Forward primer:  
 
5'ATTAACAAGGCCATTACGGCCATGGGAGTGGAGGGCTGCACC '3  
 
Reverse primer:  
 
5'AACTGATTGGCCGAGGCGGCCTCAGTACACGGAGCTGTTCCG'3  
pPR3-N-CD81  Forward primer:  
 
5'ATTAACAAGGCCATTACGGCCATGGGAGTGGAGGGCTGCACC '3  
 
Reverse primer:  
 
5'AACTGATTGGCCGAGGCGGCCTCAGTACACGGAGCTGTTCCG'3  
pBT3-C- CD81  Forward primer:  
 
5'ATTAACAAGGCCATTACGGCCAAAAATGGGAGTGGAGGGCTGC '3  
 
Reverse primer:  
 
5'AACTGATTGGCCGAGGCGGCCCCGTACACGGAGCTGTTCCGGATGCC'3  
pPR3-C- CD81  Forward primer:  
 
5'ATTAACAAGGCCATTACGGCCAAAAATGGGAGTGGAGGGCTGC '3  
 
Reverse primer:  
 
5'AACTGATTGGCCGAGGCGGCCCCGTACACGGAGCTGTTCCGGATGCC'3  
pBT3-STE- CD81  Forward primer:  
 
5'ATTAACAAGGCCATTACGGCCGGAGTGGAGGGCTGCACCAAG'3  
 
Reverse primer:  
 
5'AACTGATTGGCCGAGGCGGCCCCGTACACGGAGCTGTTCCGGATGCC'3  
pPR3- STE-CD81  Forward primer:  
 
5'ATTAACAAGGCCATTACGGCCTTGGAGTGGAGGGCTGCACCAAG'3  
 
Reverse primer:  
 
5'AACTGATTGGCCGAGGCGGCCCCGTACACGGAGCTGTTCCGGATGCC'3  
pBT3-N- CLDN1  Forward primer:  
 
5' ATTAACAAGGCCATTACGGCCATGGCCAACGCGGGGCTGCAG'3  
 
Reverse primer:  
 
5' AACTGATTGCCGAGGCGGCCCTACACGTAGTCTTTCCCGCTGGA'3  
pPR3-N- CLDN1 Forward primer:  
 
5' ATTAACAAGGCCATTACGGCCATGGCCAACGCGGGGCTGCAG'3  
 
Reverse primer:  
 
5' AACTGATTGCCGAGGCGGCCCTACACGTAGTCTTTCCCGCTGGA'3  
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pBT3-C- CLDN1 Forward primer:  
 
5' ATTAACAAGGCCATTACGGCCAAAAATGGCCAACGCGGGGCTGCAG'3 
  
Reverse primer:  
 
5'AACTGATTGGCCGAGGCGGCCCCCACGTAGTCTTTCCCGCTGGA'3  
pPR3-C- CLDN1 Forward primer:  
 
5' ATTAACAAGGCCATTACGGCCAAAAATGGCCAACGCGGGGCTGCAG'3 
  
Reverse primer:  
 
5'AACTGATTGGCCGAGGCGGCCCCCACGTAGTCTTTCCCGCTGGA'3  
pBT3-STE- CLDN1 Forward primer:  
 
5'ATTAACAAGGCCATTACGGCCGCCAACGCGGGGCTGCAGCTGTTG'3  
 
Reverse primer:  
 
5'AACTGATTGGCCGAGGCGGCCCCCACGTAGTCTTTCCCGCTGGA'3  
pPR3-STE- CLDN1 Forward primer:  
 
5'ATTAACAAGGCCATTACGGCCTTGCCAACGCGGGGCTGCAGCTGTTG'3 
  
Reverse primer:  
 
5'AACTGATTGGCCGAGGCGGCCCCCACGTAGTCTTTCCCGCTGGA'3  
 
 
Using primers in table 2.2, the PCR reaction detailed in table 2.3 was performed using a 
GeneAmp PCR system 9700 (Applied Biosystems). 
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Table 2.3: CD81 and Claudin-1 PCR protocol. All PCR reactions were conducted in the 
GeneAmp PCR system 9700 (Applied Biosystems). The reactions were conducted in 0.25ml 
domed capped PCR tubes (Fisher Scientific Ltd). 
 
 
 
 
 
 
 
 
 
 
 
 
The PCR products were then purified using a QIAquick PCR purification kit (Qiagen), 
following the manufacturers’ guidelines. Subsequently, the purified PCR product and 
vectors were digested with a Sfi I enzyme (see table 2.4 for reaction) at 50°C for 2 h. 
 
Table 2.4: Digestion reaction. The concentration of DNA was assessed using a NanoDrop 
1000. All digestion reactions were conducted in a heat block at 50C for 2h.  
 
 
 
 
 
 
 
Subsequently, Antarctic phosphatase was added to the digested vectors but not to the 
inserts. Then a further PCR purification step was carried out (QIAquick PCR 
purification kit, Qiagen) on both the insert and digest in order to remove the Sfi I 
enzyme as it is not amenable to heat inactivation. Next, the insert was ligated into the 
appropriate vector using T4 ligase by adding a 1:3 molar ratio of vector: insert (using 
100ng of vector). The reaction was conducted for 2 h at 22°C, followed by 10 min 
incubation at 65°C to heat inactivate the T4 ligase enzyme.  
PCR reagents  PCR program  
5μl pfu buffer  
1µl Forward primer (10pmol/µl) 
1µl Reverse primer (10pmol/µl) 
1 μl dNTP (100 mM)  
1µl Template plasmid (50ng) 
1 μl pfu Turbo polymerase  
40 μl ddH2O  
 
Total volume = 50μl  
1)  94˚C for 3 min  
2)  94˚C for 1 min  
3)  55˚C for 1 min  
4)  68˚C for 2 min  
5)  Repeat steps 2,3 and 4 
30 times  
6)  72˚C for 7 min  
7)  4˚C until collection  
Digestion reaction mixture  
34 μl MilliQ H2O  
5 μl NEB buffer 4  
0.5 μl BSA (x100)  
2 μg DNA (insert or vector)  
20 units Sfi I enzyme (1 μl)  
 
Total volume = 50μl  
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The ligated vector was then transformed into XL10-Gold cells (Stratagene), using a 
heat shock method (42°C for 45 seconds) then cells were incubated in LB broth at 37°C 
for approximately 1h for recovery. LB agar plates were made with the appropriate 
antibiotic (Kanomycin or Ampicillin) depending on the vector used. After incubation at 
37C, XL10-Gold cells were plated onto LB-agar plates (with the correct antibiotic 
selection) and incubated at 37°C overnight. Single colonies were subsequently selected 
and grown overnight in LB-antibiotic and then the vector of interest was extracted using 
the GenElute Plasmid Miniprep Kit (Sigma-Aldrich), following the spin method. 
Subsequently, the vector was digested using the reaction in table 2.4 and products ran 
on an agarose gel (1%) to identify if the insert and the vector appeared as separate 
bands due to Sfi I digestion. Vector DNA sequences were confirmed by the Functional 
Genomics Lab (Birmingham University). 
 
2.1.7 Site-directed mutagenesis of split-ubiquitin fusion proteins 
 
Table 2.5: Site-directed mutagenesis primers. Primers were stored at 100pmol/µl in MilliQ 
water at -20C.  
 
Split ubiquitin vector Mutagenesis primers Mutation 
Bait-STE-CD81 or 
Prey-N-CD81 
Forward primer: 
5' GCTGTGGTGAAGGCCTTCCACGAG 3' 
 
Reverse primer: 
5' CTCGTGGAAGGCCTTCACCACAGC 3' 
 
T149A 
Bait-STE-CD81 or 
Prey-N-CD81 
Forward primer: 
5' GAAGACCTTCCACGCCACGCTTGACTGCTG 3' 
 
Reverse primer: 
5' CAGCAGTCAAGCGTGGCGTGGAAGGTCTTC 3' 
 
E152A 
Bait-STE-CD81 or 
Prey-N-CD81 
Forward primer:  
5' GAAGACCTTCCACGAGGCCCTTGACTGCTGTGGC 3' 
 
Reverse primer:  
5' GCCACAGCAGTCAAGGGCCTCGTGGAAGGTCTTC 3' 
 
T153A 
Bait-STE-CD81 or 
Prey-N-CD81 
Forward primer:  
5' GTGCATCAAGTACCTGGCCTTCGTCTTCAATTTCG 3' 
 
Reverse primer:  
5' CGAAATTGAAGACGAAGGCCAGGTACTTGATGCAC 3' 
 
L14A 
Bait-STE-CD81 or 
Prey-N-CD81 
Forward primer:  
5' GTACCTGCTCTTCGTCGCCAATTTCGTCTTCTG 3' 
 
Reverse primer:  
5' CAGAAGACGAAATTGGCGACGAAGAGCAGGTAC 3' 
 
F17A 
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Mutagenesis was performed using a QuikChange II site-directed mutagenesis kit 
(Agilent Technologies) according to the manufacturers’ guidelines. Mutagenesis 
forward and reverse primers (see table 2.5) were used to mutate Bait-STE-CD81 and 
Prey-N-CD81 vectors using the reaction in table 2.6 (N.B. all work was performed on 
ice): 
 
 
 
 
Bait-STE-CD81 or 
Prey-N-CD81 
Forward primer:  
5' GTACCTGGCCTTCGTCGCCAATTTCGTCTTCTG 3' 
 
Reverse primer:  
5' CAGAAGACGAAATTGGCGACGAAGGCCAGGTAC 3' 
L14A-
F17A 
N.B. used 
L14A 
mutant 
vector to 
make the 
double 
mutant 
Bait-STE-CD81 or 
Prey-N-CD81 
 
Forward primer:  
5' CAGGAATCCCAGGCCCTGCTGGGGAC 3' 
 
Reverse primer:  
5' GTCCCCAGCAGGGCCTGGGATTCCTG 3' 
 
C89A 
 
Bait-STE-CD81 or 
Prey-N-CD81 
 
Forward primer:  
5' CTTCAATTTCGTCGCCTGGCTGGCTGGAG 3' 
 
Reverse primer:  
5' CTCCAGCCAGCCAGGCGACGAAATTGAAG 3' 
 
F21A 
Bait-STE-CD81 or 
Prey-N-CD81 
 
Forward primer:  
5' CTGGCTGGCTGCCGGCGTGATCCTG 3' 
 
Reverse primer:  
5' CAGGATCACGCCGGCAGCCAGCCAG 3' 
 
G25A 
Bait-STE-CD81 or 
Prey-N-CD81 
 
Forward primer:  
5' CTGGAGGCGTGGCCCTGGGTGTGG 3' 
 
Reverse primer:  
5' CCACACCCAGGGCCACGCCTCCAG 3' 
 
I28A 
Bait-STE-CD81 or 
Prey-N-CD81 
 
Forward primer:  
5' GGAGGCGTGATCGCCGGTGTGGCCCTG 3' 
 
Reverse primer:  
5' CAGGGCCACACCGGCGATCACGCCTCC 3' 
 
L29A 
Bait-STE-CD81 or 
Prey-N-CD81 
 
Forward primer:  
5' GGCCCTGTGGGCCCGCCATGACC 3' 
 
Reverse primer:  
5' GGTCATGGCGGGCCCACAGGGCC 3' 
 
L35A 
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Table 2.6: Site-directed mutagenesis reaction.  
 
 
 
After the mutagenesis reaction was complete (as shown in table 2.6) 1µl Dpn1 was 
added to each reaction and incubated at 37C for 4h. This is to remove template DNA 
and leave DNA that has undergone mutagenesis. Subsequently, mutated vectors were 
transformed into XL-10 Gold Ultracompetent cells, which were selected on either LB-
AMP or LB-KAN agar plates. Single colonies were then selected and grown in LB-
antibiotic media overnight and minipreps performed the following day. Isolated vectors 
were then sent off to be sequenced (Eurofins) and results would verify the presence of a 
mutation and if the DNA sequence was in-frame.  
 
2.1.8 Split-ubiquitin NMY51 yeast transformation 
 
2.1.8.1 Yeast transformation buffers 
 
Deoxyribonucleic acid sodium salt from salmon testes (salmon sperm DNA)  
 
Salmon sperm DNA was dissolved in 10mM Tris, 1mM EDTA, pH 8.0, before 
autoclaving and aliquoted at 10mg/ml and stored at -20C. 
 
 
Mutagenesis reaction  PCR program 
 
40µl water (MilliQ) 
5µl 10 Buffer 
1µl Template plasmid (50ng) 
1µl Forward primer (10pmol/µl) 
1µl Reverse primer (10pmol/µl) 
1µl DNTp 
1µl PFU ULTRA 
 
Total volume= 50µl 
 
 
1) 95C for 2min 
2) 95C for 50 sec 
3) 55C for 50 sec 
4) 68C for 15 min 
5) repeat steps 2,3 and 4, 18 times 
6) 68C for 7 min 
7) 4C until collection 
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40% PEG solution  
PEG (40% w/v) was dissolved using 10mM Tris pH 7.4, 1% Lithium acetate, 1mM 
EDTA pH 8. 
Lithium acetate Tris EDTA (LiAc/TE) buffer  
10mM Tris pH 7.4, 1% Lithium acetate, 1mM EDTA pH 8. 
 
2.1.8.2 Yeast transformation method 
 
Yeast 2% SD agar plates were prepared and allowed to solidify overnight. 4 single 
NMY51 colonies were picked into 10ml YPAD media and grown overnight at 30C, 
shaking at 220rpm. The following day, yeast NMY51 pre-cultures (4) were diluted to 
an OD546 0.2 and grown until the OD546 reached between OD546 0.6-0.8. Cells were 
centrifuged for 5 min at 2,000rpm to obtain pellets and subsequently washed in 5ml 
LiAc/TE buffer. Cells were pelleted again then resuspended in 1ml LiAc/Te buffer into 
a homogenised solution. In the meantime, salmon sperm DNA was heated to 95C for 5 
min using a heat block and subsequently put straight on to ice before use.  
For each yeast transformation, 2µg vector DNA was added, if performing a single (one 
vector) transformation the total amount of DNA used was 2µg, if performing a double 
transformation (i.e. bait and prey vectors) 4µg DNA was used per reaction. Each 
transformation used 120µg salmon sperm DNA, 100µl homogenised yeast culture and 
1ml 40% PEG solution. Tubes were inverted and mixed before incubating at 30C for 
30 min and transferred to a heat block for 20 min at 42C for heat shock. Subsequently, 
tubes were centrifuged at 3,000rpm for 5min and PEG was carefully removed from the 
yeast pellet. For single (one vector) transformations, 100µl MilliQ water was used to 
resuspend yeast pellets and added to an appropriate SD agar plate and cells were spread 
using a glass spreader. For double (two vector) transformations, 150µl MilliQ water 
was added to resuspend yeast pellets and 50µl yeast solution was added to three SD 
agar plates (SD-W-L, SD-W-L-H and SD-W-L-H-A). All plates were incubated at 30C 
for approximately 4-5 days before counting and recording colony counts for subsequent 
data analysis.  
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2.1.8.3 Split ubiquitin protein interactions measured using yeast growth 
curves 
 
After counting NMY51 colonies selected on SD-Trp-Leu plates for specific protein-
protein interaction conditions, colonies were then pooled into 5ml SD-W-L-H-A media. 
Samples were then vortexed for 5min and then OD546 measured using a 
spectrophometer. Initially cultures were diluted to an OD546 1 in 1ml SD-W-L-H-A and 
then diluted further to an OD546 0.02 in both SD-W-L and SD-W-L-H-A media. Cells 
were then added to sterile 96-well plates (Greiner) in four replicate wells each 
containing 200µl culture. The plate was subsequently covered using a sterile Breathe-
Easy seal (Sigma) and put into a Multiskan GO (Thermo Scientific). The OD546 of all 
wells was measured every 1h and cells were incubated at 30C whilst shaking, between 
readings. Measurements were taken for at least 19h and raw data was exported to excel. 
Using GraphPad prism (San Diego), growth curves were generated by plotting the 
OD546 against time (h) using a point-to-point connecting line. Representative growth 
curves are shown. In order to compare the growth of WT CD81 with mutant CD81 (in a 
particular protein interaction) the internal positive control (Claudin-1 + NubI) was 
included in all experiments. Using GraphPad prism, when the OD546 of the NubI control 
reached an OD546 0.2, at that given time point, the OD546 of WT and mutant protein 
conditions were taken and used to plot the mean OD546 value of at least 3 repeat 
experiments (see figure 2.1). This approach took into account differences in lag time of 
yeast growth between independent experiments.  
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Figure 2.1: Growth curves in SD-W-L-H-A. S. cerevisiae strain NMY51 was co-transformed 
with two vectors (either encoding bait Claudin-1 and prey NubI or bait Claudin-1 with prey WT 
CD81) and allowed to grow for 5 days selected on SD-W-L plates. Colonies were pooled from 
each plate and diluted to an OD546 0.02 before measuring the OD546 over time using a 96 well 
format in SD-W-L-H-A for 35 h at 30°C. Representative growth curves are shown as the mean 
and ±SEM of four growth curves measured in parallel. Both bait + NubI and bait + WT CD81 
were included in all subsequent experiments for data analysis as the NubI reaction was used as 
an internal control to compare WT and mutant CD81 growth at a certain point of the curve 
(when NubI reaches OD546 0.2, the WT and mutant reaction OD546 is taken and plotted as the 
mean of at least three experiments in a separate graph). The black dashed line represents the 
time when the NubI control has reached OD546 0.2, the red dashed line shows how this time 
point is used to determine the OD546 of the WT reaction in GraphPad prism (San Diego).  
 
2.1.8.4 Split ubiquitin protein interactions measured using the lacZ 
reporter gene 
 
Two different approaches were used to quantify lacZ reporter gene expression using β-
galactosidase activity. 
The first method used the HTX β-galactosidase assay kit (Dualsystems Biotech Ltd). 
NMY51 cells transformed with bait and prey vectors were selected for on SD-W-L 
plates. Multiple colonies were selected and grown overnight in SD-W-L media, and 
diluted the next morning to OD546 0.2 and grown until they reached log phase around 
0.5-0.8. An OD546 1 in 1ml was taken for each reaction and centrifuged (2,000g, 5 
min). The supernatant was removed and 100µl lysis solution was added and incubated 
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for 30 min. Samples were centrifuged to remove unlysed cells (2,000g, 1 min) and 
100µl supernatant was added to a 96 well plate and the colour development was 
monitored using a Multiskan GO (Thermo Scientific) for 10h. Measurements were 
taken every 30 min using absorbance at 615nm. The time (min) against absorbance 
(615nm) was plotted using GraphPad prism for each reaction.  
The second method used Fluorescein-di-β-D-galactopyranoside (FDG, Invitrogen) as 
substrate for β-galactosidase. Stocks of 20 mM FDG in 100% DMSO were stored at -
20C. Similar to the first method cells transformed with two vectors were grown and 
diluted so as to reach log phase before analysis. 2µl FDG was added to 4 mLmedia 
(SD-W-L and SD-W-L-H-A) and cells were diluted to an OD546 0.02 in FDG-medium. 
100µl of culture was added in a 96-well plate (Black, clear bottom, Greiner) and a 
fluorescence plate reader (SpectraMAX Gemini EM, Molecular Devices) was used at 
30C over a 24 h period with measurement taken every 5 min (Excitation 485nm, 
Emission 535nm and cut-off 530nm). Cells were mixed for 20 sec between each 
reading. Using GraphPad prism the relative fluorescence units (RFUs) were plotted 
against time (min).  
 
2.1.8.5 Split-ubiquitin fusion protein expression 
 
NMY51 cells were transformed with a single vector, bait or prey vector, and selected on 
plates SD-Leu and SD-Trp, respectively. Single colonies were picked into 10ml SD-
Leu or SD-Trp media and grown overnight at 30C, 220rpm. The following day, the 
10ml pre-cultures were added to 40ml media and grown in a baffled shake flask 
overnight. Cells were subsequently centrifuged and yeast pellets were either subjected 
to lysis to obtain the yeast membrane fraction or alternatively used for confocal 
microscopy analysis.  
 
2.2 Culturing P. pastoris 
 
2.2.1 Stock solutions, media and yeast strains: 
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10X YNB (13.4% Yeast Nitrogen Base with Ammonium Sulphate without amino 
acids) 
 
134 g of yeast nitrogen base (YNB) with ammonium sulphate and without amino acids 
was dissolved in 1 litre of water. The solution was heated to dissolve YNB completely 
in water. Alternatively, 34 g of YNB without ammonium sulphate and amino acids and 
100 g of ammonium sulphate was used. The solution was filter sterilised and stored at 
4°C.  
 
0.02% Biotin 
 
20 mg Biotin was dissolved in 100ml of water, filter sterilised and subsequently stored 
at 4°C. 
 
20% Dextrose 
 
200 g of D-glucose was dissolved in 1 litre of water, autoclaved on a liquid cycle and 
stored at room temperature.  
 
5% Methanol 
 
5 mL of methanol mixed with 95ml of water. The solution was filter sterilised and 
stored at 4°C.  
 
10% Glycerol 
 
100ml of glycerol mixed with 900ml of water. The solution was sterilised either by 
filtering or autoclaving, then stored at room temperature  
 
1 M potassium phosphate buffer, pH 6.0 
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132ml of 1 M K2HPO4 and 868ml of 1 M KH2PO4 were mixed together before 
confirming the  pH as 6.0 ± 0.1•(if the pH was adjusted, phosphoric acid or KOH were 
used). The solution was sterilised by autoclaving then stored at room temperature.  
 
 
P. pastoris media  
Yeast Extract Peptone Dextrose Medium (YPD) (+/- Zeocin) 
 
1% yeast extract, 2% peptone, 2% dextrose, 2% agar (optional 100 mg/ml Zeocin) 
 
For 1 litre solution, 10 g yeast extract, 20 g of peptone were dissolved in 900ml water 
and 20 g of agar was added when making YPD plates. The solution was autoclaved for 
20 minutes on a liquid cycle. The solution was then cooled to ~60°C before adding 100 
mL of a 20% Dextrose stock solution and 1ml of a 100 mg/ml stock of Zeocin (if 
required). 
 
 
Buffered Glycerol-complex Medium (BMGY) and Buffered Methanol-complex 
Medium (BMMY) 
 
1% yeast extract, 2% peptone, 100 mM potassium phosphate, pH 6.0, 1.34% YNB, 4  
10
-5
% biotin, 1% glycerol or 0.5% methanol 
 
To make a 1 L solution, 10 g yeast extract and 20 g peptone were dissolved in 700ml 
water. The solution was autoclaved for 20 minutes on a liquid cycle and then cooled to 
room temperature. The following was then added and subsequently mixed well; 100ml 
1 M potassium phosphate buffer (pH 6.0), 100ml 10 YNB, 2ml of a 0.02% Biotin 
stock and 100ml 10% glycerol (for BMGY) or 100ml 5% methanol (for BMMY). The 
media was stored at +4°C and kept for no longer than two months. 
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P. pastoris strains 
This project employs P. pastoris strains that were designed and developed by M. 
Jamshad (Jamshad et al., 2008) and N. Bonander (Bonander et al., 2011, Bonander et 
al., 2013), shown in table 2.7. 
 
Table 2.7: P. pastoris yeast strains used to produce recombinant proteins. 
 
 
 
 
 
 
2.2.1.1 Storage of P. pastoris 
 
Short term working stocks of P. pastoris were prepared by streaking one colony of each 
strain on to YPD-Zeocin (100µg/ml) plates, then incubated at 30°C for three days or 
until single colonies were visible. Plates were subsequently stored at 4°C until required 
for further use. Fresh plates were renewed by re-streaking yeast glycerol freeze stocks 
every two weeks.  
Long term glycerol stocks of P.pastoris were prepared by adding one colony of each 
strain from a YPD-Zeocin plate to YPD (2-5 ml) and grown overnight at 30°C, 220rpm. 
After the incubation, 1ml of the saturated sample was added to 1ml of a 50% sterile 
glycerol stock and vortexed. All glycerol stocks were stored at -80°C until further use.  
 
 
 
P. pastoris recombinant strain Additional details 
X33 CD81 palmitoylation- null (p-null) Zeocin resistant 
X33 Claudin-1 Wild-type (WT) Zeocin resistant 
X33 Claudin-1 p-null Zeocin resistant 
X33 CD82 p-null Zeocin resistant 
X33 WT N/A 
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2.2.2 Expression of recombinant membrane proteins 
 
2.2.2.1 Shake flask culture 
 
For small scale expression of CD81 or Claudin-1 from P. pastoris, single colonies were 
picked into 10ml BMGY and grown overnight at 30C, 220rpm. The pre-culture (10ml) 
was then added to 40ml BMGY and grown overnight (30C, 220rpm) in small baffled 
shake flasks (250ml total volume) so that a 1:5 working volume was achieved. The 
following day, cells were centrifuged and resuspended into 50ml BMMY to begin 
induction from an OD600 1. Cells were supplemented with 1% total volume of 100% 
methanol after 24 h induction and again at 48h. Total induction was for a total of ~ 50h.   
For large scale recombinant protein expression, large baffled shake flasks were used. 
For each production batch, a 50ml pre-culture originating from a single colony was 
used to inoculate 8 200ml working volume (1L shake flasks), therefore 1600ml 
BMGY to build yeast biomass. Once grown to an OD600 ~7-10, cell pellets were 
obtained by centrifugation and BMGY was removed. Cells were resuspended in 
BMMY for the start of induction using 8 x 500ml working volume cultures (using 2 L 
baffled shake flasks). Cells were supplemented with methanol (1% v/v) at 24h post-
induction and subsequently harvested at around 48-54 h post-induction. This approach 
typically yielded ~80g total wet cell weight. Yeast cell pellets were subsequently used 
to isolate total membranes and further analysis of recombinant proteins.  
 
2.2.2.2 Bioreactor expression of CD81 
 
The following method used a 2L Applikon bioreactor. 
Inoculum seed preparation 
Pre-cultures were set up by adding a single colony of a P. pastoris strain to a falcon 
tube containing 15ml BMGY and left to incubate overnight. The pre-culture was then 
added to a baffled flask containing 50ml BMGY. This culture was grown overnight and 
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used to inoculate the bioreactor the following day to an OD600 of 1. All cultures were 
incubated at 30°C and 220 rpm. 
Glycerol batch phase 
Media used in bioreactors:  
 
Basal salts medium (BSM)  
 
26.7ml 85% phosphoric acid, 0.93 g calcium sulphate, 18.2 g potassium sulphate, 14.9 
g magnesium sulfate heptahydrate, 4.13 g potassium hydroxide and 40.0 g glycerol 
were dissolved in water to a total of 1 L. The solution was autoclaved in the bioreactor.  
 
PTM1 trace salts  
 
Dissolved 6.0 g cupric sulfate-5H2O, 0.08 g sodium iodide, 3.0 g manganese sulfate-
H2O, 0.2 g sodium molybdate-2H2O, 0.02 g boric acid, 0.5 g cobalt chloride, 20.0 g 
zinc chloride, 65.0 g ferrous sulfate-7H2O, 0.2 g biotin and 5.0 ml sulphuric acid in 
water to a final volume of 1 L and filter sterilised. The solution was stored at room 
temperature.  
 
Yeast extract, peptone and glycerol (YPG)  
 
10 g yeast extract and 20 g peptone were dissolved in 900ml water, added to a 
bioreactor and autoclaved. Separately, 10 g or 40 g glycerol were dissolved in 90ml 
water, was autoclaved then added to an autoclaved bioreactor using a needle and 
syringe.  
 
Method: 
 
Bioreactors were either set up using BSM and PTM1 trace salts or using complex 
medium YPG. Antifoam J673A (1ml) was added to each vessel using a needle and 
syringe. If a minimal medium was used then PTM1 trace salts (4.35ml) were added in 
the same way. The dissolved oxygen (dO) probe was allowed to polarise for > 6 h. 
Next, the stirrer (700 rpm), the temperature (set to 30°C) and aeration were applied to 
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the system. The pH of the vessel (either set to pH 5 or in later experiments pH 7) was 
controlled using 50% phosphoric acid and 28% ammonium hydroxide. The bioreactor 
was then inoculated with the yeast culture previously prepared so that the final OD600 
was 1. The dO was maintained at ~30% by the automatic addition of air from a 
compressor or oxygen enriched air from a cylinder when the culture required it for 
growth. The culture was grown until the glycerol content was completely consumed; 
this was when the dO trace increased towards 100%. The culture was then starved to 
ensure all glycerol was consumed before beginning a methanol induction phase. 
 
Methanol fed batch phase 
Methanol was added to the bioreactor vessel in one of two ways. Initially 10ml 
methanol (100% sterile filtered) was added directly to the vessel using a needle and 
syringe. The culture was allowed to grow for 4-6 h prior to the addition of a further 
10ml methanol, and then the culture was left overnight. The following morning 10ml 
methanol was added to the vessel in an aseptic manner and left to grow for a further 4-6 
h prior to harvesting the yeast. Alternatively, methanol was added to the bioreactor 
using a feed rate of 4.0 ml/h. The feed rate was increased after 4 h of growth to 8 ml/h 
for the remainder of the run. The induction period lasted for ~26 h before harvesting 
yeast. 
 
2.3 Protein determination 
 
2.3.1 Yeast membrane preparations 
 
Buffers and reagents: 
 
Breaking buffer- 
 
 50mM Na2HPO4 (N.B. use Na2H2PO4 also) 
 2mM EDTA  
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 100mM NaCl 
 5% Glycerol (w/v) 
 pH 7.4 (used NaOH), autoclaved 
 
Resuspension buffer (Buffer A)- 
 
 20mM HEPES 
 50mM NaCl 
 10% glycerol 
 pH 7 (NaOH), autoclaved 
 
 
Small scale membrane preparation: 
 
Yeast cell pellets were resuspended in 1ml breaking buffer and transferred to a 2 ml 
breaking tube. Acid washed glass beads (Sigma) measured to 1ml in an eppendorf were 
added to the breaking tube and kept on ice. Protease inhibitors (1:500) were then added 
to each tube.  
 
A Quiagen Tissue lyser was used to break yeast cells. Briefly, the metal tissue lyser 
sample holder was placed into a -80°C freezer for 30 minutes prior to use. Samples 
were then balanced in the sample holder and the tissue lyser was set at 50 Hz for 10 
min. Yeast lysates were then centrifuged at 700g for 3 min to separate cell lysate from 
glass beads. The sample was subsequently resuspended and transferred to 1.5ml tubes 
and centrifuged at 700g for 20 min at 4C. The supernatant was then centrifuged at 
100,000g for 1h at 4C. The resulting pellet was the yeast total membrane and the 
supernatant the soluble/ cytoplasmic yeast fraction. To yeast pellets, 100µl buffer A 
was added and allowed to soak overnight at 4C. The following day the membrane 
fraction was resuspend in the buffer and used for total protein quantification using a 
BCA assay or stored at -20C for later use.  
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 Large scale membrane preparation: 
 
Large cell pellets (i.e. harvested from a bioreactor or from 2L shake flasks) were passed 
through an Emulsiflex-C3 cell disrupter in order to isolate yeast membranes. The cell 
pellet (20 g cells) was resuspended in ice-cold breaking buffer at a ratio of 2:1 (v/w) 
buffer to pellet. Yeast protease inhibitors were added (1:2000 dilution). Cells were 
passed through an Emulsiflex-C3 cell disrupter (Avestin) ~6 times or approximately 15 
minutes, reaching around 25,000-30,000 psi. Sample was collected from the 
Emulsiflex-C3 and remaining unbroken cells and cell debris was removed by 
centrifugation (10,000 g, for 30 min, at 4oC). The supernatant was collected and 
ultracentrifuged (100,000 g, 1h, at 4oC). The supernatant was discarded and the 
membrane pellet was re-suspended in ice-cold resuspension buffer using a glass 
homogenizer (adding 10ml resuspension buffer per g of membrane). Homogenised 
membrane fractions were either kept on ice if being used immediately or aliquoted and 
stored at -80°C for future analysis. 
 
 
2.3.2 Protein solubilisation and purification 
 
2.3.2.1 Buffers: 
 
Solubilisation buffer: 
 
1PBS (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, and 2mM KH2PO4, pH 7.4) 
150mM NaCl 
10% Glycerol 
20mM Imidazole 
Yeast membrane stock (20% aliquots) 
Detergent (either 6% OG or 1% DM for CD81 and 3% Fos-10 for Claudin-1). 
 
Purification buffers: 
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Wash 1- 1PBS,150mM NaCl, 10% Glycerol, 30mM Imidazole, detergent used at 3 
CMC 
Wash 2- 1PBS, 150mM NaCl, 10% Glycerol, 40mM Imidazole, detergent used at 3 
CMC 
Elution buffer- 1PBS, 150mM NaCl, 10% Glycerol, 250mM Imidazole, detergent 
used at 3 CMC 
 
2.3.2.2 Method 
 
 
Yeast membranes (18ml of 20% stock added to make up 70ml solubilisation buffer) of 
CD81 or Claudin-1 were solubilised using a solubilisation buffer for 2h at 4C prior to 
ultracentrifugation at 100,000 g for 1h at 4C to obtain the solubilised material in the 
supernatant and non-solubilised in the pellet. The solubilised fraction was then 
incubated with Ni-NTA agarose (Qiagen) for 1h at 4C. The resin was added to a Bio-
Rad Econo-column Chromatography column and at 4C the flow through was collected 
followed by wash 1 (5 column volumes) and wash 2 (5 column volumes) of the resin. 
The His-tagged protein was then eluted from the resin using 2 column volumes of 
elution buffer. Samples from each stage were collected so that the protein could be 
detected on an SDS-gel. The protein concentration was determined using a NanoDrop, 
using the elution buffer as a blank). Protein was subsequently concentrated using an 
ultrafiltration unit Vivaspin 20 (50,000 Da molecular weight cut off) (Sartorius) by 
centrifugation at 3,900g at 4C. Every 5 min centrifugation, the protein samples was 
mixed by pipetting up and down to ensure the PES membrane did not get saturated and 
also to prevent protein aggregation. NanoDrop readings confirmed the protein 
concentration and typically concentration of ~10mg/ml CD81 was reached.  
Protein was analysed by various instruments at the Membrane Protein Laboratory 
(Diamond Light source). The size exclusion chromatography coupled with a multi angle 
light scattering (SEC-MALS) detector was performed using a SEC-MALS system 
(Malvern) by Matthew Jennions (MPL).  
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Crystallisation trials were performed in collaboration with James Birch (MPL) using a 
Mosquito lipidic cubic phase (TTP Labtech). The crystallisation screen used two 96 
well plates, MemGold and MemGold 2 (Molecular Dimensions) which encompass a 
range of 96 conditions each with varying pH, PEGs and salt additives based on 
crystallisation conditions taken from the Protein Data Bank. The Mosquito lipidic cubic 
phase (TTP Labtech) was used to automate the delivery of 100nl of CD81 protein 
sample to 100nl of each buffer in both 96 well plates (either MemGold or MemGold2). 
The 2 plates were then incubated at 20°C for 2-3 weeks for crystal formation. 
 
2.3.3 CPM (7-Diethylamino-3-(4'-Maleimidylphenyl)-4-Methylcoumarin) 
thermostability assay 
 
CPM (Invitrogen) was dissolved in DMSO at 4mg/ml and aliquots were stored at -
80C. Before use, CPM dye was diluted 1:100 in buffer (20mM tris, pH7.5, 150mM 
NaCl and 3 CMC detergent). Protein (CD81 or Claudin-1) was previously semi-
purified using a Ni-NTA approach and typically 6-8µg CD81 and 4µg Claudin-1 was 
used for each condition tested. Using a black, clear bottom 96 well plate (Greiner) 
150µl buffer (standard conditions- 20mM Tris, pH 7.5, 150mM NaCl and 3 CMC 
detergent) was added in duplicate. The standard buffer changed depending on what 
component was being investigated. Protein was then added to wells and incubated for 
10 min at room temperature prior to adding the CPM dye, in order to equilibrate buffer 
conditions. 3µl diluted CPM dye was then added to wells (kept in the dark as much as 
possible). Using a SpectraMAX Gemini EM (Molecular devices) the plate was 
incubated at 40C for 3h. Fluorescence was measured from the bottom of the plate 
every 5 min (Excitation 387nm, Emission 463nm, Cut-off 455nm). The plate was 
mixed prior to each measurement. In excel, at each time point raw data was converted 
to the fraction of folded protein by division of the highest fluorescence value reached 
for that condition as ‘maximal unfolded protein’. A single one-phase decay curve was 
subsequently plotted using GraphPad Prism software (San Diego, CA) and the mean 
unfolding half life (min) was obtained for each condition tested. Experiments were 
repeated with at least two different protein preparations.  
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2.3.4 Bicinchoninic acid (BCA) protein assay 
 
Protein concentration was determined using 1mg/ml Bovine serum albumin (BSA) as 
standard in a sterile 96-well flat bottom plate. A standard curve was generated by 
plating BSA standard in triplicate wells at concentrations of 0, 0.2, 0.4, 0.6, 0.8, 1.0 
mg/ml, making up a total 10µl volume with PBS. Samples were plated in triplicate to a 
total volume of 10µl (a range of dilutions can be attempted to fall within the standard 
range). 200µl BCA reagent (a 50:1 ratio (v/v) between BCA solution and 4% (w/v) 
copper II sulphate solution) was added to all triplicate wells of standards and samples. 
The plate was incubated at 37ºC for 30 min. Absorbance values were then measured on 
a Biotek EL800 microplate reader using a 570nm filter. A standard curve was generated 
to calculate the protein content of samples, expressed as mg/ml. 
 
 
2.3.5 SDS page and Western blot 
 
2.3.5.1 Buffers and reagents 
 
Laemmli sample buffer- 
 
A 4x Laemmli buffer was made using 2.4ml 1M Tris pH 6.8, 0.8 g SDS stock, 4ml 
100% glycerol,  0.01% bromophenol blue, 1ml β-mercaptoethanol and 2.8ml H2O.  The 
solution was stored in aliquots at -20C (N.B. β-mercaptoethanol was added after 
thawing and before use).  
 
Running buffer (Tris/ Glycine/ SDS buffer)- 
 
100mL ultra pure 10 SDS Tris buffer (0.25M tris, 1.92M glycine and 1% SDS) 
(National Diagnostics) was diluted in 900 mL water. 
 
 
Transfer buffer (Tris/ Glycine buffer)- 
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100ml ultra pure 10 Tris/ Glycine buffer (0.25M tris and 1.92M glycine) (National 
Diagnostics) was diluted in 200ml methanol and 700ml of water. 
 
 
Phosphate buffered saline (PBS)- 
 
10 PBS tablets (Fisher) were added to 1L water 
 
Blocking buffer- 
 
5% milk (Marvel dried milk) was added to PBS buffer (5 g milk in 100 ml PBS) 
 
Wash buffer- 
 
Tween-20 (0.2%) was added to PBS 
 
Antibodies- 
 
 Antibodies shown in table 2.8 were used for western blot analysis. 
 
Table 2.8. Primary and secondary antibodies. Primary antibodies were used to detect CD81, 
Claudin-1, Pma1p and a His6 tag with an appropriate secondary antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary Antibody Dilution 
Anti-CD81 (2.131) (mouse) (provided 
by Jane McKeating, Birmingham 
University) 
1:100 
Anti-Claudin-1 (rabbit) (Invitrogen) 2µg/ml 
Anti-Pma1p (mouse) (Abcam) 1:200 
Anti-His (mouse)  (Clontech) 1:5000 
  
Secondary Antibody  
Goat anti-mouse (HRP conjugated) 
(Sigma) 
1:2000 
Goat-anti-rabbit (HRP conjugated) 
(Abcam) 
 
1:2000 
71 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis gel preparation- 
 
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE) gels were 
prepared as detailed in table 2.9 and 2.10. Note that the separating gel and the stacking 
gel contained 12% and 4% polyacrylamide respectively. 
 
Table 2.9: SDS-PAGE 12% separating gel components. 
 
12 % separating gel Volume to prepare 
gels (2) 
(In order of addition) 
Polyacrylamide (30%)  
Water  
Tris-HCl 1.5M, pH 8.8  
SDS (10%) 
Tetramethylethylnediamine (TEMED)  
Ammonium persulphate (APS) 20%  
 
4.5 ml 
3.6 ml 
3 ml 
120 μl 
9μl 
40 μl 
 
 
Table 2.10: SDS-PAGE 4% stacking gel components. 
 
 
 
 
 
 
 
 
 
 
 
 
 
APS was added last to each gel solution. Propan-2-ol was added to the top of the 
separating gel resulting in a gel that set straight at the top. Propan-2-ol was removed 
from the gel after leaving to set, by rinsing with water and subsequently drying using 
Whatman filter paper. The stacking gel was then added to the top of the separating gel 
and a comb was inserted and removed when the gel solidified.  
 
 
4% stacking gel Volume to prepare 
gels (2) 
(In order of addition) 
Polyacrylamide (30%)  
Water  
Tris-HCl 0.5M, pH 6.8  
SDS (10%) 
TEMED  
APS 20%  
 
0.7 ml 
3.1 ml 
1.3 ml 
50 μl 
5 μl 
20 μl 
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2.3.5.2 SDS PAGE 
 
5μl of a 4x Laemmli sample buffer was added to a given amount of total protein sample 
(e.g. yeast membrane preparations) as determined by a BCA assay. Samples were made 
up to 25µl total volume with buffer A (20mM HEPES, 50mM NaCl, 10% glycerol, pH 
7). The samples were vortexed and loaded on to an SDS PAGE gel in the presence of a 
Tris/ Glycine/ SDS running buffer. A Protometrics national diagnostics ladder (Fisher) 
was added to each gel (5μl) along with a transfer ladder (PageRulerTM Plus prestained 
protein ladder from Fermentas). Using the Bio-Rad PROTEAN 3 cell the SDS PAGE 
was run at 150 volts for ~1 h or until the dye front reached the bottom of the gel. 
 
2.3.5.3 Western Blotting 
 
Following SDS PAGE, the separating gel was removed from the stacking gel. Fibre 
pads, filter paper (Whatman 3mm chromatography paper) and nitrocellulose (Whatman 
PROTRAN nitrocellulose transfer membrane) were soaked in transfer buffer to allow 
for equilibration. After, using a Bio-Rad colour coded easy lock cassette a transfer 
insert was arranged in the following order with the cassette placed black side-down. 
 
 1 fibre pad 
 3 filter papers 
 Separating gel 
 Nitrocellulose membrane 
 3 filter papers 
 1 fibre pad 
 
The cassette, after being locked, was then placed into a colour-coded electrophoretic 
blotting cell. The blotting cell and a Bio-ice cooling unit were added to a Bio-Rad 
PROTEAN 3 cell. Using transfer buffer, the cell was then filled to the top and the 
transfer was carried out at 100V for 1h. 
 
The nitrocellulose membrane was then removed and transferred to a container with 
blocking buffer (50 ml blocking buffer per membrane). The membrane was then 
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blocked overnight, covered at 4°C. The following day, the primary antibody was added 
directly to the blocking buffer (dilution dependent on antibody used, see table 2.8). The 
membrane was placed on to a rocker and incubated for 1 h (30 rpm). Then the 
membrane was washed three times in PBS-Tween (0.2%) for ~5-10 mins. The 
secondary antibody (see table 2.8) was then added to each membrane in blocking buffer 
and incubated for 1 h (30 rpm). A further 3 washes were performed on each membrane 
with PBS-Tween (0.2%). An EZ-ECL chemiluminescence detection kit (Geneflow) was 
used to detect protein bands, as suggested by the manufacturers’ instruction guidelines.  
 
2.3.6 Confocal Microscopy 
 
Split-ubiquitin vectors were transformed into NMY51 cells and selected on either SD-
W or SD-L plates, for example Prey CD81 expression was selected using SD-W. Single 
colonies were picked into 10ml SD media and grown overnight at 30C, 220rpm. 500µl 
formaldehyde (3.7% in PBS) was added to the culture and incubated for ~15 min at 
30C, 220rpm. An OD600 1 of cells were taken and washed twice in 1 ml PBS/0.5% 
Tween-20. Cells were then resuspended in 0.5ml 50µg/mL Zymolyase diluted in PBS 
and incubated for 20 min at 30C. Washes were performed three times in 1ml PBS 
using centrifugation at 4,000rpm for 3min.  
 
To stain cells with appropriate antibodies, cells were resuspended in 100µl primary 
antibody (anti-CD81 1:100 dilution in PBS/1% BSA) and incubated for 1h at room 
temperature, 30rpm. Cells were subsequently washed twice in 500µl PBS/BSA. 
Following washes, cells were resuspended in secondary antibody, Alexa Fluor-488 goat 
anti-mouse IgG (H+L) (Life Technologies) using 40µg/mL in PBS/1% BSA. Samples 
were incubated for 1h at room temperature in the dark and two washes performed after 
in PBS/BSA before centrifugation and resuspension of cells in 20µl PBS. Microscope 
slides were prepared by adding 10µl sample on to slide with 3µl of mounting solution. 
Cover slips were then attached and slides viewed under a confocal microscope by 
Charlotte Bland (Aston University).    
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2.3.7 Anti-CD81 ELISA 
 
NMY51 cells expressing either a bait or prey protein fusion were grown and the cell 
pellet lysed for total membrane preparation. A BCA assay was performed on crude 
membrane preparations to determine the total protein concentration. 50µl total yeast 
membranes were added to a 96-well plate (Immulon II ELISA plates Nunc) in duplicate 
at 0.2µg/µl and left overnight to coat the plate overnight at 4C. Unbound protein was 
removed by washing three times with PBS. Plates were blocked with 2% BSA/PBS 
adding 100µl per well at RT for 20min. After three washes, primary antibodies (anti-
CD81 2.131 and 2.66, kindly provided by Professor Jane McKeating) diluted 1:2 in 
0.05% Tween20/PBS were added to wells (50µl per well) and left to bind at RT for 1h. 
After three PBS washes, secondary antibody (ECL anti-mouse IgG, HRP linked whole 
antibody (from sheep), Amersham) was added at a dilution of 1:1000 in 0.05% 
Tween20/PBS (50µl per well) and incubated at RT for 1h covered in foil. Three washes 
were subsequently performed before adding TMB supersensitive one component HRP 
microwell substrate (50µl/well) and incubated at RT for 20min. Then, 450nm stop 
reagent for TMB microwell substrate was used and the absorbance measured on a 
Fusion plate reader (Perkin-Elmer) using a 450nm wavelength.  
 
2.4 Molecular modelling 
 
Molecular models were produced by Dr Jonathan Mullins (Swansea University) and 
were used in this thesis to guide amino acid mutagenesis targets. 
 
2.4.1 Claudin-1 structural modelling by protein threading 
 
Claudin-1 was modelled by protein threading using the I-Tasser program (Roy et al., 
2010). Overall percentage sequence identity of the whole template chains with the 
query sequence ranged from 11-22%, which are typical values obtained for modelling 
with low and remote homologues. The top PDB hit in the list of templates used by I-
Tasser is 3A0O (chain A), which is alginate lyase from Agrobacterium tumefaciens 
C58 (Ochiai et al., 2010).  
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2.4.2 Structural modelling by homology modelling 
 
The CD81 and Claudin-1 structures were modelled using a homology pipeline 
assembled in the Biskit structural bioinformatics platform (Grunberg et al., 2007), 
which scans the entire PDB database for candidate homologs (Mullins, 2012). The 
pipeline incorporates elements of the NCBI tools platform (Wheeler et al., 2008) 
including BLAST for similarity searching of sequences (Altschul et al., 1990). T-
COFFEE was used to align candidate sequences with the template (Notredame et al., 
2000) and the MODELLER program was used for model assembly, iterated to final 
structure (Eswar et al., 2003). This software pipeline has been widely employed in the 
structural modelling of several membrane protein families (Mullins et al., 2011), (Davis 
et al., 2012).  
CD81 was modelled using PDB: 2AVZ (Seigneuret, 2006) and includes the known 
coordinates derived from the CD81 crystal structure (PDB: 1G8Q) (Kitadokoro et al., 
2001). Claudin-1 was ultimately modelled by 34% homology with the recently 
determined structure for mouse Claudin-15 (PDB: 4P79) (Suzuki et al., 2014). 
Interactions between these in silico models of Claudin-1 and CD81 were simulated 
using Hex 8.0 (Ritchie and Venkatraman, 2010), fitting for shape and electrostatic 
interactions.  
 
2.4.3 In silico mutagenesis using FoldX analysis 
 
Using the structural model of CD81-Claudin-1 produced by Dr Jonathan Mullins as 
template (as described in section 2.4.2), the computer program FoldX was used in a 
graphical user interface plugin for the YASARA molecular graphics suite (Van Durme 
et al., 2011) to calculate the free energy (ΔΔG) difference for CD81 mutants. CD81 TM 
residues investigated in this thesis were substituted to alanine and the protein stability 
and the stability of the CD81-Claudin-1 complex were determined. A positive ΔΔG 
suggested the disruption of protein/complex stability and negative values implied 
increased stability. The default FoldX settings were used; temperature 298K, pH 7.0, 
Ionic strength 50mM, van der Waals design 2 and number of runs 3.  
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3. Optimisation of a DUALmembrane split ubiquitin yeast assay to explore CD81-
Claudin-1 interactions 
 
3.1 Chapter 3 objectives 
 
A yeast hybrid based system designed for membrane proteins referred to as the 
DUALmembrane system (Dualsystems Biotech Ltd) was used to identify and explore 
protein- protein interactions using CD81 and Claudin-1. Chapter 4 describes site-
directed mutagenesis studies on the interaction interface between CD81 homodimers, 
Claudin-1 homodimers and CD81-Claudin-1 heterodimers. Since these proteins had not 
been previously characterised in this experimental system, this chapter describes the 
optimisation steps taken to establish a suitably robust assay, such as:  
 Optimisation of vector selection; 
 Characterisation of protein specificity in assay; 
 Reporter gene selection and in what format it is used; 
 Protein localisation and expression analysis. 
 
3.2 Overview of the split-ubiquitin method 
 
The assay uses the split-ubiquitin system as devised by Nils Johnsson and Alexander 
Varshavsky (1994). Yeast ubiquitin can be split into two halves which are referred to as 
Nub (amino- terminal ubiquitin) and Cub (carboxy- terminal ubiquitin). When in close 
proximity the two halves bind to each other and adopt the native folded conformation. 
Ubiquitin proteases (UBPs) are able to recognise and cleave the ‘whole’ ubiquitin. Wild 
type Nub has an isoleucine at position 3 which is required for high affinity binding with 
Cub. When isoleucine is mutated to a glycine, the two halves do not associate readily 
and therefore UBPs do not cleave the protein. This feature is exploited in the 
DUALmembrane system because the two halves must be brought into close proximity 
by a protein-protein interaction as shown in figure 3.1. 
The first protein of interest (Bait) can be fused to Cub (which is also fused to the 
synthetic transcription factor LexA-VP16) and the second protein of interest (Prey) can 
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be fused to mutant Nub (NubG) (see figure 3.1a). If the bait and prey protein have 
natural affinity for each other it will in turn force NubG and Cub to re-assemble. 
Therefore, the ‘whole’ ubiquitin will be recognised and cleaved by UBPs. Furthermore, 
the UBPs cleave the polypeptide chain between Cub and LexA-VP16. The artificial 
transcription factor, LexA-VP16, which is a fusion of the LexA DNA binding domain 
and the transcriptional activator VP16 (from the Herpes simplex virus) translocates to 
the nucleus after UBP cleavage. In the nucleus it binds LexA operators positioned 
upstream of a reporter gene. Transcriptional activation of the reporter gene takes place 
after VP16 recruitment of RNA polymerase II. The reporter genes used in the yeast 
hybrid system are two growth markers (HIS3 and ADE2), when activated, allow the 
yeast to grow on minimal medium lacking histidine or adenine. Also lacZ is used as a 
reporter gene, which encodes the enzyme β-galactosidase, therefore when two 
membrane proteins interact this can be measured in a quantitative β-galactosidase assay 
(figure 3.1b) 
 
 
 
 
Figure 3.1: Bait and Prey reconstitution of split ubiquitin. a) Protein of interest chosen as 
Bait is fused to Cub (carboxy- terminal ubiquitin) and artificial transcription factor LexA-VP16. 
The second protein of interest is fused to mutant NubG (amino- terminal ubiquitin). If bait and 
prey proteins have a natural affinity and can bind to each other, this causes reconstitution of 
split ubiquitin. Ubiquitin proteases (UBPs) recognise reconstituted ubiquitin and therefore 
cleave a site between Cub and LexA-VP16. b) In the nucleus transcription is switched on as a 
result of LexA-VP16 translocating to the nucleus and activating reporter genes ADE2, HIS3 and 
lacZ since there are LexA binding sites in the promoter region. Schematic taken from the 
DUALmembrane pairwise interaction kit manual (Dualsystems Biotech Ltd).  
 
The initial aim was to clone CD81 and Claudin-1 into vectors that are compatible with 
the DUALmembrane system (which are provided by Dualsystems Biotech Ltd). The 
  
a) 
b) 
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choice of vector is dependent on the topology of the protein of interest. The cloning 
strategy employed here intended to increase the likelihood of success of this assay. 
The S. cerevisiae yeast reporter strain used here, NMY51, is an auxotroph for 
tryptophan, leucine, adenine and histidine. The ADE2 phenotype results in 
characteristic pink/red yeast colonies due to a red coloured intermediate that builds up 
in the adenine metabolic pathway. If the ADE2 gene is activated here due to the 
presence of a protein-protein interaction then the cells display a white or pink colour 
depending on the interaction strength (white colonies representing the strongest 
interactions).  
 
3.3 Generation of split-ubiquitin expression vectors 
 
The human genes, CD81 and CLDN1, were cloned from mammalian pTrip vectors 
(kindly provided by Professor Jane McKeating, Birmingham University) into various 
vectors that were compatible with the DUALmembrane system. The choice of vector 
was dependent on the topology of the protein of interest; in this case both membrane 
proteins contain their C- and N- terminus within the cytosol. In order for the system to 
work, Nub and Cub are required to be present on the cytosolic side of the membrane, 
therefore Nub and Cub could be fused to either the C- or N- terminus of both CD81 and 
Claudin-1 (see figure 3.2). According to the DUALmembrane user manual, three 
different vectors could have been suitable for each protein of interest (the reasoning is 
explained in figure 3.2). Therefore the genes encoding CD81 and CLDN1 were sub-
cloned into six different vectors (three bait vectors and three prey vectors). 
Consequently, twelve novel vectors were produced and later tested in the 
DUALmembrane split ubiquitin assay. 
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Figure 3.2: Rationale for generating different vectors encoding bait and prey with four 
transmembrane domains. a) Vectors that encode both prey and bait proteins. Carboxyl- and 
amino-terminal NubG and Cub LexA-VP16 proteins were generated to assess the potential 
effect of the relative orientations of each half of ubiquitin. Vectors that encode the STE2 
sequence were selected based on the manufacturer’s guidelines as it has been found in certain 
targets to enhance translation. b) Schematic showing one combination of protein fusion pairing 
that were tested, C-terminal CD81 Cub fusion and N-terminal NubG fusion on Claudin-1, 
whilst c) shows N- and C- fusions, respectively.  
 
 
Both CD81 and CLDN1 cDNA were cloned into bait and prey vectors (see materials 
and methods) in order to optimise the orientation of the Cub- NubG interaction. All 
a) 
a) 
c) b) 
a) 
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vectors were sequenced verified (example shown in figure 3.3) and used for subsequent 
interaction studies. A summary of vectors made, correctly sequenced and in frame can 
be found in table 3.1. 
 
Figure 3.3: Sequence confirmation of pBT3-C-CLDN1. a) pBT3-C-CLDN1 was sequenced 
with the pBT3-C forward primer. CLDN1 gene sequence begins with start codon (ATG) which 
is preceded by ‘AAAA’ to ensure efficient initiation of translation. The ‘AAAA’ sequence is 
underlined and the start codon (ATG) can be found immediately after. b) pBT3-C-CLDN1 was 
sequenced with the pBT3-C reverse primer. The blue triangle represents the end of 
CLDN1coding sequence. Note, that the stop codon of CLDN1 gene has been removed. c) 
Represents the multiple cloning site of the pBT3-C vector and the correct reading frame of Cub 
coding sequence. CLDN1 gene was sub-cloned using the two differing Sfi I sites. The figure 
represents that the CLDN1 gene has been successfully sub-cloned into the pBT3-C vector in the 
correct reading frame. All sequencing primers can be found in DUALmembrane system manual 
(Dualsystems Biotech Ltd). 
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Table 3.1: Summary of final vectors generated. Bait and prey vector names show which gene 
was sub-cloned (CD81 or CLDN1 and if a STE2 leader sequence (referred to as STE) is present 
at the 5´ end of the gene. Information is also given as to what protein is synthesised from a 
given vector and specifically whether the Cub (bait) or NubG (prey) fusion is on its C- or N- 
terminus.  
 
 
3.4 Selection of optimal vectors for use in CD81-Claudin-1 interaction assay 
 
To establish a robust read-out for CD81 homodimer interactions or CD81 heterodimer 
interactions with Claudin-1, a screen encompassing five bait vectors and five prey 
vectors was performed (see table 3.1). Since this was a screen intended to be executed 
quickly, there were no controls incorporated into these initial experiments. Any 
conditions that appeared interesting from the screen were repeated with all necessary 
controls.  
Theoretically, each bait fusion protein has the potential to interact with each prey fusion 
protein, which equated to 25 conditions to be included in a screen. The NMY51 yeast 
strain was transformed with paired vectors (all shown in table 3.1), in different 
combinations, and then grown on three different plates lacking various components SD-
W-L, SD-W-L-H and SD-W-L-H-A. The first plate selects for vector transformation as 
bait vectors include a LEU2 marker and prey vectors a TRP1 marker, therefore if both 
vectors are transformed yeast will grow in the absence of leucine (L) and tryptophan 
(W), respectively. The further two plates lacking histidine (H) and adenine (A) are 
selecting for yeast with activated reporter genes (HIS3 and ADE2, which are activated 
due to a protein-protein interaction). All plates were left to incubate at 30°C and 
colonies were counted on day five of incubation as was suggested in the manufacturers’ 
Bait vector name Protein expressed Prey vector name Protein expressed 
pBT3- N- CD81 VP16-LexA- Cub-CD81 pPR3- C- CD81 CD81-NubG 
pBT3-STE-CD81 CD81-Cub-LexA-VP16 pPR3- N- CD81 NubG-CD81 
pBT3- C- CD81 CD81-Cub-LexA-VP16 pPR3- STE- CD81 CD81-NubG 
pBT3- STE- CLDN1 Claudin-1-Cub-LexA-VP16 pPR3- C- CLDN1 Claudin-1-NubG 
pBT3- C- CLDN1 Claudin-1-Cub-LexA-VP16 pPR3- STE- CLDN1 Claudin-1-NubG 
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manual. The numbers of red and white colonies on SD-W-L plates were recorded since 
in all conditions colonies will grow on this plate if both vectors are transformed, but 
they will turn red if cells express a non-interacting protein pair and white if they express 
a protein-interacting pair. The red phenotype is due to a block in the adenine synthesis 
pathway, therefore this colour accumulates over time if yeast cannot synthesise adenine 
due to not expressing a pair of interacting proteins (see table 3.2). 
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Table 3.2: Yeast colony counts from initial protein interaction screen. Each bait vector was co-transformed in NMY51 with each prey vector. After 
yeast transformation (see materials and methods) cells were incubated on selective plates for 4-5 days at 30°C before counting and recording the 
number and colour of individual colonies on each plate. The growth on SD-W-L-H and SD-W-L-H-A plates is the % of the total counted on the SD-W-
L control plate for each reaction. Reactions in bold show where successful protein interactions were found.  
 
 
Reaction Bait and prey vectors involved in 
reaction 
SD- W-L SD-W-L-H Growth 
on 
SD-W-L-H  
(%) 
SD-W-L-H-A Growth on 
SD-W-L-H-A 
(%) Colony colour Colony colour Colony colour 
  RED WHITE RED WHITE  RED WHITE  
1 pBT3-STE-CD81 + pPR3-C-CD81 360 0 0 0 0 0 0 0 
2 pBT3-STE-CD81 + pPR3-C-CLDN1 432 0 0 0 0 0 0 0 
3 pBT3-STE-CD81 + pPR3-N-CD81 11 329 2 44 13.5 0 22 6.5 
4 pBT3-STE-CD81 + pPR3-STE-CD81 412 1 0 0 0 0 2 0.5 
5 pBT3-STE-CD81 + pPR3-STE-CLDN1 407 1 0 0 0 0 0 0 
6 pBT3-STE-CLDN1 +  pPR3-C-CD81 314 9 0 5 1.5 0 2 0.6 
7 pBT3-STE-CLDN1 +  pPR3-C-CLDN1 500 0 0 10 2 0 6 1.2 
8 pBT3-STE- CLDN1 + pPR3-N-CD81 10 308 0 16 5 0 14 4.4 
9 pBT3-STE-CLDN1 + pPR3-STE-CD81 338 8 0 3 0.8 0 3 0.8 
10 pBT3-STE-CLDN1 + pPR3-STE-CLDN1 304 12 0 9 2.8 0 6 1.9 
11 pBT3-C-CLDN1 + pPR3-C-CD81 221 13 0 2 0.9 0 1 0.4 
12 pBT3-C-CLDN1 + pPR3-C-CLDN1 136 5 0 0 0 0 0 0 
13 pBT3-C-CLDN1 + pPR3-N-CD81 266 21 0 3 1.0 0 1 0.3 
14 pBT3-C-CLDN1 + pPR3-STE-CD81 259 6 0 0 0 0 0 0 
15 pBT3-C- CLDN1+ pPR3-STE-CLDN1 234 6 0 0 0 0 0 0 
84 
 
 
 
 
 
 
 
 
Reaction Bait and prey vectors involved in 
reaction 
SD- W-L SD-W-L-H Growth on 
SD-W-L-H  
(%) 
SD-W-L-H-A Growth on 
SD-W-L-H-A 
(%) Colony colour Colony colour Colony colour 
  RED WHITE RED WHITE  RED WHITE  
16 pBT3-N-CD81  + pPR3-C-CD81 201 7 0 0 0 0 0 0 
17 pBT3-N-CD81 + pPR3-C- CLDN1 251 11 0 0 0 0 0 0 
18 pBT3-N-CD81 + pPR3-N-CD81  129 6 0 0 0 0 0 0 
19 pBT3-N-CD81 + pPR3-STE-CD81  155 4 0 0 0 0 0 0 
20 pBT3-N-CD81 + pPR3-STE-CLDN1 206 15 0 0 0 0 0 0 
21 pBT3-C-CD81 + pPR3-C-CD81  246 0 0 0 0 0 0 0 
22 pBT3-C-CD81 + pPR3-C-CLDN1 252 0 0 0 0 0 0 0 
23 pBT3-C-CD81 + pPR3-N-CD81  136 4 0 3 2.1 0 3 2.1 
24 pBT3-C-CD81 + pPR3-STE-CD81  150 0 0 0 0 0 0 0 
25 pBT3-C-CD81 + pPR3-STE-CLDN1 212 3 0 0 0 0 0 0 
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Table 3.3: Overview of screen results. 5 bait vectors were used in combination with 5 
different prey vectors to co-transform yeast strain NMY51, the expressed protein fusions are 
shown in the table in bold. After an initial screen of 25 vector combinations, colonies were 
counted on various selective plates. Symbols represent (-) no protein-protein interaction found, 
(?) low colony numbers but no protein-protein interaction and (y) shows positive protein-
protein interactions. 
 
 
 
Results from the protein interaction screen indicated which reactions provided the 
optimal orientation for NubG and Cub fusions to detect membrane protein-protein 
interactions. Firstly, the colour of colonies on SD-W-L plates indicated if protein 
interactions had occurred (white) and if they had not (red). Reaction 3 (pBT3-STE-
CD81 + pPR3-N-CD81) and 8 (pBT3-STE-CLDN1 + pPR3-N-CD81) gave the highest 
numbers of white colonies overall, being 329 and 308 respectively (see table 3.2). In 
contrast a negative result such as reaction 1 (pBT3-STE-CD81 + pPR3-C-CD81) 
resulted in 360 red colonies and 0 white colonies on a SD-W-L plate.  
Furthermore, a positive protein-protein interaction should result in the activation of two 
growth reporter genes HIS3 and ADE2. Table 3.2 shows Reaction 3 resulted in 13.5% 
growth on SD-W-L-H and 6.5% growth on SD-W-L-H-A, whilst reaction 8 showed 5% 
growth on SD-W-L-H and 4.4% growth on SD-W-L-H-A. Both reactions demonstrated 
a result positive for protein-protein interactions compared to other reactions in the 
screen which did not show >1% growth on SD-W-L-H-A; therefore were considered 
negative because protein interaction signals were not detected. 
                         
PREYS 
 
 
BAITS 
pPR3-C-
CD81 
CD81-
NubG 
pPR3-C-
CLDN1 
Claudin-1-
NubG 
 
pPR3-N-
CD81 
NubG-
CD81 
pPR3-STE-
CD81 
CD81-NubG 
pPR3-STE- 
CLDN1 
Claudin-1-NubG 
pBT3-STE-CD81 
CD81-Cub-LexA-
VP16 
- - y - - 
pBT3-STE- CLDN1 
Claudin-1-Cub-
LexA-VP16 
? ? y ? ? 
pBT3-C- CLDN1 
Claudin-1-Cub-
LexA-VP16 
? - ? - - 
pBT3-N-CD81 
VP16-LexA- Cub-
CD81 
- - - - - 
pBT3-C-CD81 
CD81-Cub-LexA-
VP16 
- - ? - - 
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3.5 Characterisation of Bait proteins CD81 and Claudin-1 
 
Once having selected bait proteins, Bait-CD81 and Bait-Claudin-1, expressed from 
vectors pBT3-STE-CD81 and pBT3-STE-CLDN1, respectively. It was then necessary 
to functionally characterise them by initial genetic experiments using control prey 
vectors (see figure 3.4). The positive prey control vector is pOst1-NubI that expresses a 
fusion of the yeast resident ER protein Ost1 to wild-type (WT) Nub portion of yeast 
ubiquitin (referred to as NubI). This should readily associate with the Cub fusion of the 
bait protein of interest if the bait protein is correctly expressed and the Cub-LexA-VP16 
fusion is accessible to the NubI fusion. The negative control vector construct pPR3N 
expresses NubG (mutated Nub) fused to a nonsense peptide fusion. Since NubG has no 
affinity for Cub there should not be activation of reporter genes as a result of the 
expression with the bait (protein of interest) with NubG. Using NubG expression with 
the bait protein would determine if the bait protein causes any ‘leakiness’ of reporter 
genes.  
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Figure 3.4: Schematic of prey NubI and NubG controls. a) Prey control vector pOst1-NubI 
expresses a fusion of the yeast resident ER protein Ost1 to WT Nub (referred to as NubI). NubI 
should associate with the Cub-LexA-VP16 fusion if the bait protein (this could be CD81 or 
Claudin-1) is properly expressed. Activation of reporter genes results as a consequence of 
ubiquitin proteases cleaving LexA-VP16 from the re-assembled ubiquitin molecule. b) Prey 
control vector pPR3N expresses NubG (mutated Nub) fused to a nonsense peptide and has no 
natural affinity for Cub fused to the bait protein of interest. When co-expressed in yeast this 
should not lead to the activation of reporter genes. 
+ 
+ 
NubI = Activation of reporter genes 
HIS3, ADE2 and LacZ 
NubG = No activation of reporter 
genes HIS3, ADE2 and LacZ 
a) 
b) 
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Bait proteins, Bait-CD81 and Bait-Claudin-1 were tested for their expression and 
potential to activate growth reporter genes when co-expressed with one of the two 
control prey proteins, NubI or NubG (positive and negative control, respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Bait CD81 and Bait Claudin-1 genetic experiment to determine expression and 
function using the split-ubiquitin system. Bait vectors pBT3-STE-CD81 and pBT3-STE-
CLDN1 (expressing bait CD81 (a) or bait Claudin-1 (b) respectively) were co-expressed with 
either pOst1-NubI or pPR3N control prey vectors, expressing NubI or NubG portions of 
ubiquitin, respectively. After yeast (NMY51) co-transformations (see materials and methods) 
yeast were incubated for 5 days at 30°C before counting the number of colonies on three plates; 
SD-W-L, SD-W-L-H and SD-W-L-H-A. The percentage growth on SD-W-L-H and SD-W-L-
H-A plates was calculated by using the number of colonies on SD-W-L as 100% growth. 
Experiments were repeated (n=3). 
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Figure 3.5 shows that the Bait-CD81 Cub fusion demonstrates high binding with NubI 
since 57.3% and 65.5% growth was observed on SD-W-L-H and SD-W-L-H-A plates 
respectively. This suggests successful CD81 expression and insertion into the 
membrane so that Cub and NubI can bind to each other and subsequently activate 
growth reporter genes. The same trend was seen for Bait-Claudin-1 with NubI (see 
figure 3.5) giving higher 83.2% and 105.3% growth on SD-W-L-H and SD-W-L-H-A 
plates respectively.  
In contrast, minimal growth was observed for Bait-CD81 with NubG, 0.11% and 0.39% 
on SD-W-L-H and SD-W-L-H-A plates respectively (figure 3.5). This demonstrates 
CD81 has negligible levels of self auto-activation of reporter genes. Slightly higher 
signals of auto-activation were shown for Bait-Claudin-1 with NubG, 6.7% and 4.19% 
on SD-W-L-H and SD-W-L-H-A plates respectively, but this was lower than the signal 
observed for specific protein interaction signals later. (See figure 3.6).  
 
3.5.2 Specificity of CD81 and Claudin-1 interactions 
 
To demonstrate that the split-ubiquitin system in yeast can detect specific protein 
interactions, a positive control protein pair was used. APP (amyloid A4 precursor 
protein) APP, a type I integral membrane protein, was used as bait along with the 
cytosolic protein Fe65 (amyloid beta A4 precursor protein-binding family B member 1) 
as prey. Figure 3.6 demonstrates that APP and Fe65 interact in this assay as shown by 
56.2% growth on SD-W-L-H and 58.3% on SD-W-L-H-A plates. The APP bait protein 
does not show any signal of auto-activation as shown using prey protein NubG as a 
negative control.  
Since CD81 is used as a prey protein in this assay it was expressed with APP to assess 
its non-specific binding. Figure 3.6 show that APP + CD81 produce a negligible signal. 
Therefore, Prey-CD81 was then co-expressed with either Bait-CD81 or Bait-Claudin-1. 
The homodimer CD81-CD81 condition showed a positive interaction and gave 27.8% 
growth on SD-W-L-H and 24.8% growth on SD-W-L-H-A. A reaction demonstrating 
heterotypic interactions by Claudin-1 and CD81 also showed a positive interaction by 
resulting in 24.9% growth on SD-W-L-H and 17.2% on SD-W-L-H-A.  
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Figure 3.6: WT CD81 homo- and heterotypic interactions with Claudin-1 using the 
DUALmembrane split-ubiquitin assay. a) APP and Fe65 were used as a positive control 
protein interaction pair in the yeast split-ubiquitin assay. Prey negative control protein NubG 
was used to show bait auto-activation of reporter genes. b) Prey-CD81 was co-transformed with 
Bait-CD81 or Bait-Claudin-1. Following co-transformations (see materials and methods) yeast 
were incubated for 5 days at 30°C before counting the number of colonies on the three 
following plates; SD-W-L, SD-W-L-H and SD-W-L-H-A. The percentage growth on SD-W-L-
H and SD-W-L-H-A plates was calculated by using the number of colonies on SD-W-L as 
100% growth. Experiments were repeated (n=3). 
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3.5.3 Frequency of CD81 and Claudin-1 interaction 
 
The frequency of a protein-protein interaction can be measured using a yeast split-
ubiquitin assay as an indirect measurement of the rate of reporter gene expression, 
which results in the growth of yeast on selective agar plates. To demonstrate the 
frequency of WT interactions of CD81-CD81 and CD81-Claudin-1, a yeast spot assay 
was used on selective agar plates. Colonies selected to co-express two transformed 
plasmids were grown on SD-W-L media and then diluted to an OD546 0.2. Diluted 
cultures were used to perform 10-fold serial dilutions on to selective agar plates (see 
figure 3.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Yeast spotting assay to demonstrate the frequency of membrane protein 
interactions. NMY51 cells were selected in SD-W-L media to maintain the transformation of 
two plasmids (bait and prey vectors). Cultures were subsequently diluted to an OD546 0.2 and 
used to perform 10-fold serial dilutions on to agar plates; SD-W-L, SD-W-L-H-A and SD-W-L-
H-A + 5 mM 3AT. Serial dilutions were carried out from left to right (high to low cell 
concentrations, respectively) for co-expression of Bait-CD81 with a) positive prey control b) 
negative prey control c) CD81 homodimerisation and d) CD81-Claudin-1 heterodimerisation. 
 
 
a) Bait-CD81: NubI 
b) Bait-CD81: NubG 
c) Bait-CD81: Prey-CD81 
d) Bait-CD81: Prey-Claudin-1 
1) SD-W-L 2) SD-W-L-H-A 
3) SD-W-L-H-A + 5 mM 3-AT 
a) Bait-CD81: NubI 
b) Bait-CD81: NubG 
c) Bait-CD81: Prey-CD81 
d) Bait-CD81: Prey-Claudin-1 
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Figure 3.7 shows yeast growth spots on three different plates for four different protein 
reactions. The first plate, SD-W-L, is a control to show cells are transformed with two 
plasmids (bait and prey) that are selected for by their ability to grow. All four reactions 
labelled a-d can grow over the four dilutions, except the positive control, which may be 
due to reduced levels of yeast transformation using the vector that expresses NubI. 
Since growth on plates 2) and 3) is relative to growth on 1), this result does not suggest 
NubI is not a good positive control.  
The second plate, SD-W-L-H-A, shows the level of activation of growth reporter genes 
ADE2 and HIS3 as a result of bait and prey protein interaction. Figure 3.7 demonstrates 
that the positive (a) and CD81 homodimerisation (c) reaction can grow successfully 
over four dilutions on SD-W-L-H-A whereas the negative control (b) does not grow at 
all. Finally the CD81-Claudin-1 reaction (d) can grow over three dilutions in contrast to 
four dilutions for CD81-CD81, suggesting that the CD81 homotypic interaction is more 
frequent than the heterotypic interaction as a result of increased levels of reporter gene 
activation. This observation is also shown in the third plate, SD-W-L-H-A + 5mM 3AT. 
Since 3-AT is a competitive inhibitor of the product of the HIS3 gene, colonies cannot 
grow to the same extent as what they did on SD-W-L-H-A. Presence of 3-AT 
emphasises that CD81 homodimerisation (colonies shown over three dilutions) is more 
frequent than the CD81-Claudin-1 heterodimerisation interaction (colonies only shown 
in first dilution).  
 
3.5.4 Localisation of bait proteins 
 
After finding that WT CD81 and Claudin-1 interactions could be monitored/ detected in 
the yeast strain NMY51, it was imperative to investigate the expression of these WT 
fusion proteins and if they were present in the yeast membrane.  
 
3.5.4.1 Immunoblot analysis 
 
A few methods were used to assess expression of CD81 and Claudin-1. The first 
approach used western blot analysis which allowed independent analysis of protein 
93 
 
Bait CD81 Prey CD81 Bait  
Claudin-1 
Prey  
Claudin-1 
100 kDa Pma1p 
expression either in yeast membranes or cytosolic fractions. A method used by Gisler et 
al., 2008 was modified slightly to isolate the yeast total membrane fraction from the 
cytosolic fraction using a glass bead cell lysis method followed by an 
ultracentrifugation spin to obtain the membrane (see materials and methods, section 
2.3.1) (Gisler et al., 2008). In order to assess if the method was valid for membrane 
isolation a yeast plasma membrane ATPase, PMA-1p, was chosen as a housekeeping 
control protein that should be detected in the membrane but not in the cytosolic 
fraction.  
 
 
 
 
 
 
 
Figure 3.8: Method validation to isolate yeast membrane fractions. NMY51 cells were 
transformed with a single vector and grown for 3 days at 30°C. Single colonies were picked and 
grown overnight before harvesting. The cells were subsequently broken using a glass bead 
method followed by a high speed ultracentrifugation spin to separate yeast total membrane 
found in the pellet and the cytoplasmic fraction in the supernatant. Samples were quantified for 
total protein using a BCA assay and 40µg was loaded per sample on to an SDS gel (see 
materials and methods). The membrane (M) and cytosolic (C) fractions were run on a 12% 
separating gel and Pma1p was detected using an anti-Pma-1p antibody.  
 
Figure 3.8 shows that the plasma membrane ATPase can be detected only in yeast 
membrane fractions and not present in any of the cytosolic fractions for cells expressing 
both CD81 and Claudin-1 bait and prey plasmids. This implies that this method for 
membrane isolation is valid and that it can be used to identify the correct expression of 
CD81 and Claudin-1 in the yeast membrane. 
 
Subsequently, WT bait and prey CD81 and Claudin-1 proteins were transformed into 
the yeast strain NMY51 in order to investigate membrane protein expression using 
western blot analysis. As the previous validation method used 40µg total protein in 
order to observe Pma1p expression, the same total amount was loaded again. Results 
  M      C      M      C       M     C     M    C 
Protein expressed: 
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revealed that only Prey CD81 and Prey Claudin-1 could be observed using this amount 
of total protein (see figure 3.9); in contrast neither bait proteins were detectable. This is 
likely to be due to the difference in yeast copy number depending on which plasmid the 
protein is expressed. Prey proteins are present in a high copy yeast plasmid whereas 
Bait proteins are in low copy yeast plasmids. Therefore, for western blot analysis, prey 
proteins were subsequently loaded and observed using only 15 µg of total protein 
(figure 3.9). Bait proteins were observed using confocal microscopy since the 
sensitivity of confocal microscopy is higher than that of a western blot (see figure 3.10).  
 
 
 
 
 
 
 
 
 
Figure 3.9: Expression analysis of Prey CD81 and Claudin-1. NMY51 cells were 
transformed with a single prey (CD81 or Claudin-1) vector and grown for 3 days at 30°C. 
Single colonies were picked and grown overnight before harvesting. The cells were 
subsequently broken using a glass bead method followed by a high speed ultracentrifugation 
spin to separate yeast total membrane found in the pellet and the cytoplasmic fraction in the 
supernatant. Samples were quantified for total protein using a BCA assay and 15µg was loaded 
per sample on to an SDS gel (see materials and methods). The membrane (M) and cytosolic (C) 
fractions were run on a 12% separating gel and proteins were detected using anti-CD81 or anti-
Claudin-1 antibodies.  
 
 
Western blot analysis shown Prey CD81 and Prey Claudin-1 were both present in 
membrane fractions of yeast and absent from cytosolic fractions (see figure 3.9). Non-
transformed NMY51 cells did not show any protein bands using either antibody (data 
not shown). Prey CD81 is estimated to be 33 kDa and Claudin-1 30 kDa. Both ran 
approximately at the correct molecular weight but slightly lower which is characteristic 
of a membrane protein. Also both appeared as higher oligomeric bands which are 
expected in a non-reducing SDS-PAGE.  
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3.5.4.2 Confocal microscopy analysis 
 
To gain an insight into the localisation of WT CD81 expression in the NMY51 yeast 
strain, protoplasts were prepared (see materials and methods) followed by staining with 
a specific anti-CD81 antibody and then viewed using confocal microscopy. 
 
 
Figure 3.10: Visualisation of CD81 in S. cerevisiae NMY51 strain. NMY51 cells 
transformed with Bait-CD81 or Prey-CD81 were partially digested with Zymolyase to produce 
yeast protoplasts that were then stained with anti-CD81 2.131 followed by secondary antibody 
(Alexa Fluor-488 goat anti-mouse IgG (H+L), Life Technologies) (see materials and methods, 
section 2.3.6). Slides were prepared and viewed on a confocal microscope with the help of 
Charlotte Bland (Aston University). a) Bait CD81 expression and b) Prey CD81 expression in 
NMY51.  
 
Figure 3.10 show that anti-CD81 2.131 can probe for Bait and Prey CD81 in yeast 
protoplasts. Gisler et al., 2008 also used a similar approach to show the expression of 
fusion proteins in the yeast membrane and although this method does not provide 100% 
evidence that the membrane protein resides in the plasma membrane specifically, the 
ring structures shown in figure 3.10 suggest that this may be the case. Also, since bait 
proteins are more difficult to capture using a western blot since expression levels are 
low, confocal microscopy provided an alternative method to visualise the expression of 
Bait-CD81 using specific antibodies against the protein.  
a) 
b) 
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3.6 Analysis of reporter genes 
 
Now that the split-ubiquitin system was initially explored to look at WT protein 
interactions using the HIS3 and ADE2 growth reporter genes, it was then interesting to 
explore the third reporter gene, lacZ. The aim here was to first of all identify if the 
experiment could be performed in a timelier manner using any of the reporter genes and 
in a higher-throughput format i.e. using a 96-well plate. Secondly, if a quantitative 
assay was possible, that could support data generated, up to now, from manual counting 
of yeast colonies on agar plates. 
 
3.6.1 lacZ reporter gene 
 
Two different approaches were used to monitor lacZ reporter gene activation. The first 
used a HTX β-galactosidase assay kit (Dualsystems Biotech) and the second used 
Fluorescein-di-β-D-galactopyranoside (FDG, Invitrogen). The lacZ gene encodes β-
galactosidase and active enzyme can be detected using substrate X-gal, which is an 
analog of lactose. X-gal is hydrolysed by β-galactosidase and produces galactose and 5-
bromo-4-chloro-3-hydroxyindole (the latter product contributes to a blue product that is 
measured as the activity of the lacZ gene). The HTX β-galactosidase assay kit is an 
efficient approach for lysing yeast cells and subsequent detection of β-galactosidase 
activity using X-gal as substrate to provide a colorimetric read-out. The second 
approach uses FDG as substrate for β-galactosidase, which hydrolyses non-fluorescent 
FDG initially to fluorescein monogalactoside and then further to highly fluorescent 
fluorescein. lacZ gene activation can therefore be quantitatively measured by a highly 
sensitive fluorescent read-out. The similarities and differences between the two 
approaches are summarised in table 3.4. 
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Table 3.4: A comparison of two methods that quantitate lacZ activation. The HTX β-
galactosidase assay kit allows efficient lysis and detection of β-galactosidase activity using an 
X-gal substrate and a colorimetric read-out. FDG is a sensitive substrate for β-galactosidase and 
is hydrolysed in its presence to produce highly fluorescent fluorescein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Two quantitative assays to measure β-galactosidase activity were performed on lysed or 
unlysed yeast cells (depending on the substrate used, see table 3.4). Cells were co-
transformed with both Bait-CD81 and Prey-CD81 to detect homo-oligomers or Bait-
Claudin-1 and Prey-CD81 to detect hetero-interactions.  
 
 
 
 
 
 
 
 
 
 
Method HTX β-galactosidase 
assay kit 
(Dualsystems Biotech) 
Fluorescein di-β-D-
galactopyranoside (FDG) 
Format 96 well 96 well 
Material used Lysed yeast cells Viable yeast cells 
Type of measurement Colorimetric Fluorescence 
Data generated Quantitative Quantitative 
Substrate used X-gal (blue colour 
development) 
FDG (hydrolysed by β-
galactosidase) 
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Figure 3.11: lacZ quantification using two different substrates. NMY51 cells co-
transformed with bait and prey vectors were grown on agar plates for 4-5 days at 30°C. Pre-
cultures were set up in SD-W-L media and grown overnight. a) CD81 homodimerisation and b) 
CD81-Claudin-1 heterodimerisation show lacZ expression using a HTX β-galactosidase assay 
kit (Dualsystems Biotech) of lysed cells at an OD546 0.5-0.8. c) CD81-Claudin-1 
heterodimerisation show β-galactosidase quantification over time using Fluorescein-di-β-D-
galactopyranoside. Viable yeast cells grown from a starting OD546 0.02 were selected for in SD-
W-L, and then grown in SD-W-L-H-A during data point measurements. 
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Figure 3.11 indicates that tetraspanin interactions can be detected using this approach 
by measuring colour development of β-galactosidase over 10 hours. The positive 
control, Bait CD81 with NubI gave an increasing positive signal over time whilst the 
negative control, Bait CD81 with NubG gave a negligible signal over time. Also, figure 
3.11b shows that Claudin-1- CD81 interactions can be detected using this method. The 
positive control (Bait Claudin-1 with NubI) showed a higher response than for the WT 
Claudin-1–CD81 interaction. In contrast the negative control (Claudin-1 + NubG) is 
low, although being slightly higher than the negative control for Bait CD81 plus NubG 
in figure 3.11a, which is consistent with what was observed using growth reporter 
genes, as shown in figure 3.6.   
Dowell & Brown (2009) used yeast reporter genes to look at GPCR agonism using 
FDG (Dowell and Brown, 2009). Here, FDG has been used to quantitate lacZ reporter 
gene expression over time using viable yeast cells co-transformed with various vectors 
pairs. Figure 3.11c indicates FDG can be used to show CD81-Claudin-1 interactions 
and the results run parallel with that shown in 3.11b using a different substrate. 
Although, using this method, cells were grown in SD-W-L-H-A to provide these growth 
curves and so essentially three reporter genes; HIS3, ADE2 and lacZ were used to 
generate this data.  
Overall, both approaches allow determination of a protein-protein interaction using the 
lacZ reporter gene.  
 
3.6.2 HIS3 and ADE2 
 
Since growth reporter genes HIS3 and ADE2 worked well to observe protein-protein 
interactions using an agar plate format and colony counting (seen earlier in this 
chapter), we then investigated if HIS3 and ADE2 could be used in a 96-well plate 
growth curve format using a spectrophotometer (OD546 vs. time). More specifically, 
alongside counting colonies on agar plates, transformed cells would then be picked and 
grown in liquid culture whilst the OD546 was monitored over time.  
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3.6.3 Optimisation of a growth curve read-out in 96-well plates 
 
To begin with, when cultures were grown in 96-well plates there was an evaporation 
problem. Since yeast were grown at 30°C over 24 h, at the end of the incubation period 
there would be outer columns and rows with a major loss in culture volume, therefore 
data would be hugely variable and could not be relied upon. In order to prevent this 
issue, Breathe-Easy sealing membrane (Sigma) were used thereafter, which prevented 
excessive vapour loss throughout the course of the experiment incubation period.  
NMY51 single colonies co-transformed with WT proteins (Claudin-1 and CD81) were 
pooled into dropout media, vortexed for 5min and diluted to an OD546 0.02 in both SD-
W-L and SD-W-L-H-A media. 200µl cells were added to wells across a 96-well plate 
and then incubated at 30°C in a shaking spectrophotometer and the OD546 was read 
every 1h to generate yeast growth curves. 
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Figure 3.12: Liquid culture growth curves monitored over 18h in a 96-well plate. 
NMY51cells were co-transformed with appropriate vectors and grown on agar plates for 4-5 
days at 30°C. Colonies selected on SD-W-L plates were pooled into dropout media, vortexed 
and diluted to an OD546 0.02 in SD-W-L and SD-W-L-H-A media. 200µl of cultures were added 
to quadruplicate wells, plate covered with a Breathe Easy seal (Sigma) and then incubated at 
30°C in a spectrophotometer. The OD546 was measured every 1h between shaking. a) growth in 
SD-W-L media selecting for double vector transformation, b) growth in SD-W-L-H-A selecting 
for protein-protein interactions using HIS3 and ADE2 reporter genes. Representative curves are 
shown of a least three independent experiments.  
 
Figure 3.12 suggests that measuring OD546 over time is sufficient to monitor growth 
reporter gene activation (HIS3 and ADE2), therefore protein-protein interactions. Figure 
3.12a demonstrates growth over 18h in SD-W-L and b) growth in SD-W-L-H-A. It is 
clear that growth differs amongst the various reactions. This is apparent using SD-W-L 
for which the presence of two vectors is selected, showing the Claudin-1-CD81 
interaction reaches the highest OD546 (~0.75), whilst the positive and negative reactions 
fall much lower (~0.4).  
a) 
b) 
0 5 1 0 1 5 2 0
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
S D -W -L
T im e  (h )
O
D
 (
5
4
6
n
m
)
C la u d in -1 + N u b I
C la u d in -1 + N u b G
C la u d in -1 +  C D 8 1
0 5 1 0 1 5 2 0
0 .0
0 .2
0 .4
0 .6
0 .8
S D -W -L -H -A
T im e  (h )
O
D
 (
5
4
6
n
m
)
C la u d in -1 +  N u b I
C la u d in -1 + N u b G
C la u d in -1 + C D 8 1
102 
 
In more stringent selection media, SD-W-L-H-A, cells expressing Claudin-1-CD81 
reached a higher OD546 than the positive control over 18 h initial growth. The negative 
control does not increase in comparison, reaching an approximate OD546 0.16 at 18h 
growth (see figure 3.12b).  
 
Since reactions differed regarding growth rate in SD-W-L (figure 3.12a), it was 
interesting to investigate why this was the case, as it might dictate how data were later 
analysed. One possibility was that adenine and histidine were not in excess in SD-W-L; 
therefore this would affect the growth ability of cells expressing a positively interacting 
protein pair and cells that were not. Those that expressed a positive protein-protein 
interaction would produce more adenine and histidine and in turn show a higher growth 
rate as a consequence of HIS3 and ADE2 being activated.  
 
This idea was subsequently tested by using a negative control for a protein interaction, 
Claudin-1+ NubG. In theory a negative control should serve as a good condition to test 
as negligible levels of adenine and histidine should be produced by such transformed 
cells. The question would then be; can you increase growth by supplementing with 
higher levels of adenine or histidine than what is usually found in SD-W-L standard 
media? The experiment was set up using standard SD-W-L, as well as media 
supplemented with increasing amounts of adenine, histidine or both (see figure 3.13).  
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Figure 3.13: Growth curves to monitor supplementation with adenine or histidine and 
both. NMY51 cells co-transformed with vectors for Claudin-1 and NubG expression were 
selected on SD-W-L plates. Colonies were pooled into dropout media, vortexed and diluted to 
an OD546 0.02 in appropriate media. 200µl cultures were added to a 96 well plate in triplicate 
wells and incubated at 30°C in a spectrophotometer whilst shaking. OD546 measurements were 
taken every 1h in between shaking for 20h. Representative curves are shown for triplicate mean 
values ±SEM. Experiment was repeated at least twice.  
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Figure 3.13a shows that increasing the concentration of histidine up to 40mg/L did not 
make a substantial difference in yeast growth over 20h compared to the levels of 
histidine already in standard SD-W-L. In contrast, figure 3.11b demonstrates increasing 
the concentration of adenine results in higher OD546 values measured over 20h. OD546 
values approximately doubled from ~0.4 OD546 in standard SD-W-L to ~0.8 when 
supplementing with at least 25mg/L adenine, 30mg/L did not produce a further increase 
in OD546.  
When both adenine and histidine are supplemented together (figure 3.13c) the growth 
curve profiles are very similar to that seen with adenine alone, suggesting further that 
histidine does not provide additional yeast cell growth as compared to levels already in 
standard SD-W-L, whereas adenine levels maybe are lacking in standard SD-W-L for 
these specific cells. These data would suggest that cells expressing a positive protein-
protein interaction may grow to higher OD546 values over time in SD-W-L compared to 
cells expressing a negative protein interacting pair. This could affect the way in which 
data is interpreted using yeast growth assays since data generated using SD-W-L-H-A 
may or may not be normalised to data generated using SD-W-L (in which vectors are 
selected for), since positive interacting protein pairs would likely grow to higher cell 
densities in SD-W-L than negative interacting protein pairs. Hereafter (in chapter 4), 
data from growth curves will not be normalised to SD-W-L, but will be treated 
independently when SD-W-L-H-A is used. 
In summary, growth reporter genes can demonstrate the ability to monitor the 
occurrence of protein-protein interactions using a split-ubiquitin yeast assay. It is a 
relatively inexpensive approach since a substrate does not need to be used in contrast to 
using the lacZ reporter gene. Also, relatively little time is taken using transformed yeast 
to set up a 96-well plate prior to measuring OD546 over time. A limiting factor using this 
approach is that OD546 values appear to be accurate between 0.2-0.8. The 
spectrophotometer cannot read accurately above OD546 1 and so data will plateau even 
if cells are still growing above this in a given well.  
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4. Exploring the CD81-Claudin-1 binding interface 
 
4.1 Chapter 4 objectives 
 
Claudin-1 and CD81 oligomerise with themselves (homo-oligomers) and with other 
interaction partners (hetero-oligomers) at the plasma membrane. Claudin-1 direct 
associations with tetraspanins, such as CD9 and CD81, were observed previously by 
Kovalenko and colleagues (2007) using a covalent chemical cross-linking approach. In 
a different study, CD81-Claudin-1 interactions were detected using fluorescence 
resonance energy transfer (FRET) (Harris et al., 2010) and it was found that the 
complexes act as essential co-receptors in HCV entry. Interestingly, two residues in 
Claudin-1 extracellular loop 1 (ECL1) (see figure 4.1), I32 and E48, when mutated to 
alanine cause a knock-down in CD81-Claudin-1 association which in turn inhibits HCV 
entry, demonstrating that the receptor complex is essential in the infection process. 
 
Figure 4.1: CD81 and Claudin-1 schematic. The two membrane proteins explored in this 
study. a) CD81 as shown with four transmembrane domains, a small extracellular loop (SEL) 
and a large extracellular loop (LEL). b) Claudin-1 also crosses the plasma membrane four times 
and has a larger extracellular loop 1 (ECL1) and a smaller extracellular loop 2 (ECL2). 
Residues found important for CD81-Claudin-1 interactions in CD81 LEL (T149, E152 and 
T153) (Davis et al., 2012) and Claudin-1 ECL1 (I32 and E48) (Evans et al., 2007), (Davis et al., 
2012) are in bold.  
 
a) 
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Since HCV entry into hepatocytes is a potential target for antiviral therapy (Xiao et al., 
2014) research into the binding interface between CD81-Claudin-1 is of great 
importance. Davis et al., (2012) used a molecular modelling approach to predict that the 
CD81 large extracellular loop (LEL) residues T149, E152 and T153, are important for 
binding to Claudin-1 ECL1 (predicted motif between residues 62-66) (see figure 4.1). 
Mutagenesis and FRET were performed to test the prediction and results showed that 
CD81 LEL residues (T149, E152 and T153) are imperative in CD81-Claudin-1 
interactions and consequently in HCV infection. 
It has been described in the literature that the LEL also contributes to CD81 
dimerisation (Drummer et al., 2005), although residues throughout the full length 
molecule, including extracellular and transmembrane (TM) regions, participate in 
CD81-CD81 interactions (Kovalenko et al., 2004). Therefore, investigation into CD81 
transmembrane regions involved in the CD81-Claudin-1interaction would extend our 
knowledge of the full length protein binding interface.  
This chapter describes an investigation of both LEL and transmembrane regions of 
CD81 involved in CD81-CD81 and CD81-Claudin-1 associations, using the yeast split-
ubiquitin method (explored in Chapter 3), site-directed mutagenesis and molecular 
modelling. Specific objectives include: 
 Assess CD81 LEL residues T149, E152 and T153 in the CD81-Claudin-1 
interaction and the CD81-CD81 interaction; 
 Explore CD81 TM1 residues; L14, F17 and C89 in CD81 homo-oligomer and 
hetero-oligomer interactions; 
 Assess the expression of WT CD81 and mutant CD81 using western blot 
analysis and ELISA; 
 Test CD81 TM residues as predicted by a molecular model in the yeast split-
ubiquitin method. 
 
4.2 Assessment of protein-protein interactions 
 
Details on optimisation of the yeast split-ubiquitin method used in this chapter to 
monitor protein-protein interactions were presented in chapter 3. This chapter explores 
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specific residues in CD81 that are predicted to be involved in the CD81-Claudin-1 
interaction. Data were collected in two different ways in order to determine the most 
sensitive method for comparing WT and mutant protein interactions: 
1) The first approach used yeast colony counts as a quantitative measure of the output 
of a protein interaction. Yeast strain NMY51 was co-transformed with two vectors (one 
encoding the bait and the other encoding the prey protein) then grown on plates (SD-W-
L, SD-W-L-H-A) for 5 days prior to enumerating colonies. Data was represented in two 
ways; the number of colonies grown on SD-W-L-H-A (selecting for a protein-protein 
interaction normalised to NubG and NubI controls to account for day to day variability) 
and secondly, the percentage growth on SD-W-L-H-A relative to colonies grown on 
SD-W-L to account for vector transformation efficiency (as reported by the ability of 
cells to grow without tryptophan and leucine) (see figure 4.2).  
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e.g. 50 colonies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Yeast agar colony count data analysis. Colony count data analysis was performed 
in two different ways and both are shown in subsequent figures to analyse WT and mutant 
protein interactions. a) Data is represented as the % of colonies on SD-W-L-H-A plates. The 
colony number counted on the WT protein-protein test condition is normalised to that grown for 
the positive (NubI) and negative (NubG) internal controls (co-transformed with the same bait 
protein as the test condition). Example colony numbers and associated normalised data are 
shown. b) Data is represented by using the results from two agar plate colony counts, that on 
SD-W-L (selecting for vector transformation) and SD-W-L-H-A (selecting for a protein-protein 
interaction). The final % growth for a reaction is the number on SD-W-L-H-A as a percentage 
(%) of the number grown on the SD-W-L plate. Example colony and growth (%) is shown as an 
example. 
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2) The second approach used to quantify protein-protein interactions used an automated 
measure of cell growth over time in SD-W-L-H-A liquid media in a 96-well format. 
Comparing WT and mutant CD81 binding to Claudin-1 was achieved as an indirect 
measurement of reporter gene (histidine and adenine) activation. Growth curves were 
plotted as OD546 versus time (h). Growth curves were used to determine the OD546 of 
the WT interaction compared to a mutant interaction at a specific point when the 
internal positive control (Claudin-1 + NubI) reaches an OD546 of 0.2. This point was 
chosen to analyse data between independent experiments because OD546 0.2 is 
approximately the beginning of the exponential phase of growth for the NubI with 
Claudin-1. Note that this interaction shows a longer lag growth phase in comparison to 
WT CD81-Claudin-1 growth profiles (see figure 4.3), maybe due to a lower occurrence 
of NubI interactions with Claudin-1 than that of CD81 with Claudin-1. Therefore, as an 
internal positive control, it provides a point at which to compare the OD546 reached of 
WT and mutant CD81 interactions. The frequency of a protein-protein interaction is 
relative to the activation of reporter genes (histidine and adenine) and the ability of 
yeast to grow in SD-W-L-H-A lacking histidine and adenine demonstrates the 
occurrence of such interactions.  
 
 
 
 
 
 
 
 
 
Figure 4.3: Growth curves in SD-W-L-H-A showing differences in lag phase before 
exponential growth of two protein reactions. S. cerevisiae strain NMY51 was co-transformed 
with two vectors (either encoding bait Claudin-1 and prey NubI or bait Claudin-1 with prey WT 
CD81) and allowed to grow for 5 days selected on SD-W-L plates (see materials and methods). 
Colonies were pooled from each plate and diluted to an OD546 0.02 before measuring the OD546 
over time using a 96 well format in SD-W-L-H-A for 35 h at 30°C. Representative growth 
curves are shown as the mean and SEM of four growth curves measured in parallel. Both bait 
and NubI and bait and WT CD81 were included in all subsequent experiments for data analysis 
as the NubI reaction was used as an internal control to compare WT and mutant CD81 growth 
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at a certain point of the curve (when NubI reaches OD546 0.2, the WT and mutant reaction OD546 
is taken and plotted in a separate graph at this point). 
 
4.3 CD81 LEL residues involved in Claudin-1 interactions 
 
To investigate previously reported residues in CD81 LEL that, when mutated, disrupt 
CD81-Claudin-1 interactions, three residues T149, E152 and T153 were mutated using 
site-directed mutagenesis to alanine. S. cerevisiae strain NMY51 was then co-
transformed with bait and prey vectors (WT or mutant CD81) and grown on selective 
plates before counting colonies formed. This would allow for validation of the yeast-
based assay.  
 
 
 
 
 
 
 
 
 
 
Figure 4.4: CD81 LEL interaction with Claudin-1 ECL1. Molecular modelling of the loop 
domains, CD81 LEL and Claudin-1 ECL1 show the residues predicted and demonstrated to be 
involved in CD81-Claudin-1 interaction. Residues labelled in CD81 LEL (green) tested here 
using a split ubiquitin assay are T149, E152 and T153 (taken from Davis et al., 2012). 
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Figure 4.4 shows the position of the mutated residues in CD81 LEL along with residues 
in Claudin-1 ECL1 (between residues 62-66) that are involved in the interaction as 
described previously by Davis et al., (2012). Figure 4.5a and c show the results of 
Claudin-1 interaction with CD81 WT, T149A, E152A or T153A in the yeast split-
ubiquitin method. A colony count approach showed that there is a decrease in the 
interaction of Claudin-1 with CD81 T149A, E152A and T153A (2.48%, 4.70% and 
4.53%) as compared to WT CD81 (6.58%) when normalising to SD-W-L to account for 
transformation efficiencies (figure 4.5a). Only CD81 T149A showed a statistically 
significant decrease compared to WT CD81 (figure 4.5a and c). When the 
transformation efficiency is not considered, the same trend is observed for the number 
of colonies grown on SD-W-L-H-A alone (but normalised to internal NubI and NubG 
controls), with CD81 T149A showing further reduced binding to Claudin-1 than CD81 
E152A or T153A (figure 4.5c).  
 
Expression analysis performed on total yeast membranes showed that WT CD81 and 
mutant prey proteins (E152A and T153A) are expressed to similar levels to WT CD81, 
whilst CD81 T149A expression is slightly higher than WT (figure 4.5b). Reduced 
interactions shown between mutated CD81 and Claudin-1 (figure 4.5 a and c) are likely 
a result of the residues being important in the WT binding interface rather than due to 
the lack of expression of mutant CD81, as compared to WT CD81.  
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Figure 4.5: CD81 LEL residues involved in Claudin-1 interactions. NMY51 cells were 
transformed, using lithium acetate (see materials and methods), with appropriate bait and prey 
vector pairs (WT or mutant). Cells were incubated at 30°C and selected on plates; SD-W-L or 
SD-W-L-H-A, for 5 days before colonies were counted. a) WT Claudin-1 and CD81 
interactions (WT or mutant) represented as growth on SD-W-L-H-A relative to the SD-W-L 
control. b) Western blot analysis of yeast total membranes expressing prey WT CD81 and 
mutants (T149A, E152A and T153A).  c) Table summarising data normalised in two ways; SD-
W-L-H-A colony counts normalised to internal NubI and NubG controls and growth on SD-W-
L-H-A normalised to SD-W-L to take into account yeast transformation efficiency. Experiment 
was repeated four times to compare mean ± SEM of WT to mutant CD81 using a one-way 
ANOVA followed by a Dunnett’s multiple comparison test.  
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Colonies grown on SD-W-L for each protein-protein interaction were further used to 
assess if protein interactions can be monitored using growth in liquid culture (SD-W-L-
H-A) in a 96 well plate. Others have attempted to grow yeast in this format to generate 
useful data (Toussaint et al., 2006) but it is not typically used in this context to measure 
membrane protein-protein interactions. Figure 4.6 shows that yeast growth curves are 
useful to analyse mutants that may knock-down a protein-protein interaction, since the 
initial onset of growth (as a consequence of reporter gene activation) is delayed 
compared to a WT interaction. For mutants CD81 T149A, E152A and T153A the 
growth curve shifts to the right as compared to WT CD81 (figure 4.6 a, b and c, 
respectively) due to a decrease in protein-protein interaction frequency at the membrane 
which reduces activation in reporter gene expression and consequently yeast growth.  
 
Yeast growth curves generated were used to quantitatively compare WT CD81-
Claudin-1 interaction and CD81 mutant interactions. At the time point when the OD546 
of the internal NubI control reached 0.2 (not shown), the OD546 reached at this point by 
WT and mutant CD81 was taken and the mean of three experiments was plotted (figure 
4.6d). Again this approach showed the same trend as in figure 4.5. All three CD81 LEL 
mutants knock-down CD81-Claudin-1 interactions. Even though CD81 T149A, E152A 
and T153A resulted in similar mean OD546 values to each other (0.47, 0.45 and 0.43 
respectively) only E152A and T153A were significantly different to WT (mean OD546 
0.55). CD81 T149A was not significantly different from WT although a reduction in the 
mean value is visually apparent (figure 4.6). These data, taken together, confirm that 
T149, E152 and T153 in CD81 LEL are important for binding to Claudin-1, presumably 
to Claudin-1 ECL1. Furthermore, it is possible to assess mutant protein interactions 
using the yeast split-ubiquitin method as it was consistent with results found elsewhere 
in the literature using FRET with mammalian cells and the same CD81 mutations in the 
LEL.  
 
Both approaches used here; yeast colony counts and growth in liquid culture, provide 
useful data as they assess growth at distinct stages (after 5 days for colony counts and 0-
23h for liquid growth cultures) and should be used in conjunction with one another to 
get the most out of the split-ubiquitin method. This work started by using yeast colony 
counts alone to assess protein interactions but later progressed to use both colony 
counts and yeast growth curves.  
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Figure 4.6: Liquid growth curves show CD81 LEL residues T149, E152 and T153 regulate 
interaction with Claudin-1. S. cerevisiae strain NMY51 was transformed with bait and prey 
vector pairs and were grown on SD-W-L plates. Colonies from a single plate were pooled, 
vortexed and diluted to an OD546 0.02 before adding to a 96-well plate for growth analysis. 
OD546 measurements were taken every 1h and cells were shaken between readings and 
incubated at 30°C. a-c) OD546 was plotted against time to generate growth curves for WT and 
mutant CD81 interactions with Claudin-1. d) The mean OD546 value of the WT and mutant 
interactions was compared at the time point where the internal NubI control reached an OD546 
of 0.2. Experiments repeated 3 times, each experiment performed 4 growth curves in parallel. 
Data analysed using a one way ANOVA followed by a Fisher’s LSD test, n=3, p 0.05. 
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4.4 Exploring CD81 TM1 residues 
4.4.1 Rationale for exploring CD81 TM1 
 
A previous study (Bertaux & Dragic, 2006) explored CD81 transmembrane residues in 
the context of HCV entry. CD81 residues C80, N18 and E219 when mutated to alanine, 
reduced HCVpp entry by approximately 40% as compared to control (Bertaux & 
Dragic, 2006). Binding ability of the CD81 mutants to soluble E2 (sE2) was not 
affected, suggesting that another mechanism had caused reduced infection. One 
hypothesis that was not tested at the time was that these transmembrane residues are 
involved in CD81 binding to a partner protein such as its co-receptor Claudin-1 or 
another CD81 molecule, which in turn is important for the HCV entry process. 
When mapping residues using protein viewer software (Swiss-Pdb Viewer v 4.0.4) on 
to a CD81 full length homology model (Seigneuret, 2006), it was observed that C80, 
N18 and E219 combined with LEL residues (T149, E152 and T153) that are known to 
reduce CD81-Claudin-1 interactions (Davis et al., 2012), together pointed towards 
CD81 TM1 and TM2 as a potential binding interface for Claudin-1 or another CD81 
molecule (see figure 4.7 a-c). Looking from a bird’s-eye view, the LEL residues T149, 
E152 and T153 appear to line up on the same side face as TM2 residue C80 between 
the space of TM1 and TM2 (figure 4.7b).  
Furthermore, a computed hydrogen bond is predicted to exist between N18 (TM1) and 
E219 (TM4) (figure 4.7c) by Swiss-Pdb Viewer version 4.0.4. Consequently, the double 
mutant (N18A-E219A) used in  Bertaux & Dragic (2006) possibly caused a reduction in 
HCV entry as the residues may be involved in stabilising the TM domains, particularly 
CD81 TM1 in this hypothetical scenario. This evidence taken together highlights the 
possibility that CD81 TM1 is involved in partner protein interactions, which may have a 
functional effect for HCV entry. 
In a separate study that also focused on CD81 TM1 and TM2, Kovalenko et al., (2005) 
provided insight into the dimeric interface of tetraspanin CD9 using a disulphide 
crosslinking approach of single cysteine mutants. Results suggested TM1 and TM2 are 
involved in the dimeric interface of CD9 including residues L14, F17 and G80. 
Bringing together this information, here we performed a homology alignment between 
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CD9 and CD81 (93% similarity) and selected the corresponding residues in CD81 (L14, 
F17 and C89). Such residues were then mutated to alanine and tested in CD81 homo- 
and heterotypic interactions in comparison to WT CD81. Therefore, these residues were 
selected and tested without using a molecular model to predict the interaction interface 
of CD81-Claudin-1. 
 
 
 
Figure 4.7: CD81 predicted full length model. Full length CD81 homology model accessed 
using protein data bank (PDB) accession 2AVZ, Seigneuret (2006). a) CD81 predicted full 
length model mapped with LEL residues T149 (yellow), E152 (purple) and T153 (pink). TM2 
residue also highlighted C80 (cyan). The zoomed-in area shows residues in the large 
extracellular loop (LEL) b) Birds-eye view of residues indicated in part a. c) TM1 and TM4 
showing residues N18 (yellow) and E219 (orange), hydrogen bond shown with white dotted 
line. Pictures produced using Accelrys, Discovery studio 4.0.  
 
 
 
 
a) b) 
c) 
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4.4.2 CD81 TM1 involvement in Claudin-1-CD81 interactions 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: CD81 TM1 mutants knock-down Claudin-1 interaction. NMY51 cells were 
transformed, using lithium acetate (see materials and methods), with appropriate bait and prey 
vector pairs (WT or mutant). Cells were incubated at 30°C and selected on plates; SD-W-L or 
SD-W-L-H-A, for 5 days before colonies were counted. a) WT Claudin-1 and CD81 
interactions (WT or mutant) represented as growth on SD-W-L-H-A relative to the SD-W-L 
control. b) Table summarising data normalised in two ways; SD-W-L-H-A colony counts 
normalised to internal NubI and NubG controls and growth on SD-W-L-H-A normalised to SD-
W-L to take into account yeast transformation efficiency. Experiment was repeated three times 
to compare mean ± SEM of WT to mutant CD81 using a one-way ANOVA followed by a 
Dunnett’s multiple comparison test.  
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Figure 4.8 demonstrates residues on CD81 TM1 are important in its association with 
Claudin-1. Residues L14, F17 and C89, when mutated to alanine show a reduction in 
the level of CD81-Claudin-1 interactions as compared to WT (see figure 4.8a and b). 
Normalisation of data to the SD-W-L control plate (accounting for transformation 
efficiency) showed higher levels of significance than when normalising colony counts 
on SD-W-L-H-A to internal controls (figure 4.8b). When normalising growth on SD-
W-L-H-A to SD-W-L, residues L14A, C89A and a double mutant L14A-F17A show a 
significant reduction in the CD81-Claudin-1 interaction (3.62%, 1.82% and 2.64% 
respectively) as compared to WT (8.41%). Residue F17A on CD81 TM1 also showed a 
reduction in yeast growth (5.56%), although this was not statistically different from WT 
(figure 4.8a and b). Even so, introducing a double mutation in CD81 (L14A-F17A) 
demonstrated a further knock-down than L14A alone. Therefore, both residues are 
likely to play a part in the binding interface of CD81-Claudin-1, but L14A is shown to 
have a larger knock-down effect than F17A when mutated and involved in the 
interaction.  
These data suggest that CD81 residues at the bottom of TM1 are likely to be involved 
or on the interface of the Claudin-1 interaction binding site. This was explored further 
using a molecular model of the complex and mutating residues that continue up CD81 
TM1 from L14 and F17.  
 
4.4.3 Expression of CD81 TM1 mutants 
 
We next investigated if CD81 TM1 mutants were being expressed in order to determine 
whether the mutation had decreased the expression thereby decreasing potential CD81-
Claudin-1 interactions or whether the interaction was a direct result of the mutation. 
Western blots were performed on yeast membrane fractions to determine expression 
and furthermore membrane fractions were tested in an ELISA to detect binding of anti-
CD81 antibodies that bind specifically to the folded LEL of CD81.   
 
 
 
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: WT and mutant CD81 expression. NMY51 cells were transformed (see materials 
and methods) to express WT or mutant (L14A, F17A, C89A or L14A-F17A) Prey CD81. Cells 
grown on SD-W plates were selected and grown in SD-W liquid culture overnight. Cells were 
harvested and then lysed in order to isolate the yeast total membrane fraction using a tissue 
lyser method. Membranes were resuspended in buffer and quantified for total protein. a) 
Western blot of yeast membrane (M) and cytosolic fractions (C) expressing WT or mutant Prey 
CD81 or NubG (negative control). b) ELISA on yeast membranes expressing NubG, WT or 
mutant CD81 and Claudin-1 using anti-CD81 2.131 and c) anti-CD81 2.66. Dashed line 
indicates negative control NubG background signal. Data represents the mean ± SEM of two 
independent experiments.  
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Expression data for CD81 TM1 mutants (L14A, F17A, C89A and L14A-F17A) suggest 
that expression is similar to that found for WT CD81 (see figure 4.9). The same amount 
of total protein was loaded for western blot analysis of CD81 yeast membranes; figure 
4.9a shows that the protein band intensity is similar between WT and mutant CD81, 
suggesting comparable expression. Also, both WT and mutant CD81 show both 
monomer and dimer protein bands. The negative control, cells expressing NubG, does 
not show any equivalent banding pattern (figure 4.9a).   
To further assess the expression of CD81, equivalent levels of total protein of WT and 
mutant CD81 membranes (as determined by a protein BCA assay) were coated on to 
ELISA plates before probing with anti-CD81 antibodies 2.131 or 2.66. Both antibodies 
target the CD81 LEL and do not bind if the structure is unfolded. Negative control 
samples (NubG and Claudin-1) provided the background signal of the ELISA (the 
average background indicated with a dashed line) (figure 4.9b). Anything above the 
dashed line indicates higher than background for the ELISA and reports positive 
binding to both anti-CD81 antibodies tested. 
Figures 4.9 b and c show ELISA data for different CD81 samples and suggest both 
antibodies bind slightly increased levels of mutant CD81 (L14A, F17A and L14A-
F17A) in yeast membranes as compared to WT CD81. Furthermore, double mutant 
CD81 L14A-F17A shows the highest increase in binding antibodies 2.131 and 2.66 as 
compared to WT CD81 (figure 4.9b and c, respectively). The double mutation may 
have an effect on the accessibility of both antibodies to the site in which they bind to 
the CD81 folded loop. One theory may be that the double mutant decreases tetraspanin 
oligomerisation and therefore may reveal more antibody binding sites in the LEL.  
CD81 C89A in contrast shows a decrease as compared to WT CD81, suggesting that 
the structure of CD81 is compromised when residue C89 is mutated to alanine. The 
mutation may result in an unstructured LEL or more specifically a change in loop 
conformation in the region where anti-CD81 2.131 and 2.66 bind to WT.  
Overall, the expression data show that L14A and F17A CD81 mutants are expressed 
and can bind similar levels of antibody as WT CD81 and so their knock-down of CD81-
Claudin-1 interactions (figure 4.8) suggest that the residues are involved in the protein 
binding interface. L14A-F17A supports this idea and the increased level of ELISA 
antibody binding may suggest a decrease in CD81-CD81 interactions. Mutation of 
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residue C89 shows a decrease in CD81-Claudin-1 interactions (figure 4.8) but also a 
reduction in binding anti-CD81 antibodies as compared to WT CD81. Therefore, the 
reduction in the Claudin-1- CD81 C89A interaction (figure 4.8) may be a result of an 
unfolded CD81 LEL that cannot bind anti-CD81 antibodies to WT level (figure 4.9 b 
and c) or Claudin-1 (figure 4.8).  
Plasma membrane expression data of WT and mutant CD81 would have been useful 
evidence to further interpret mutant knock down results seen in figure 4.8. Even so, 
evidence shown in this chapter to demonstrate that the CD81-Claudin-1 interaction can 
be monitored using the DUALmembrane system shows that the Nub and Cub moieties 
are facing the cytosolic side of the plasma membrane in order to be cleaved by UBPs, in 
contrast to residing in the ER or Golgi membrane (hence Nub and Cub would not be in 
the cytoplasm) where the Cub fusion would not be cleaved by UBPs, translocate to the 
nucleus and activate reporter genes.  
 
4.5 CD81 LEL and TM1 residues involved in homo-oligomerisation 
 
Residues in CD81 LEL T149, E152 and T153 and in TM1 L14, F17 and C89 were 
tested in the CD81 homotypic interaction to determine if there was a common binding 
interface with CD81-Claudin-1 heterotypic interactions. 
Figure 4.10 shows how CD81 mutations affect homo-oligomerisation. The data 
suggests that CD81 loop residue, T153, when mutated to alanine significantly reduces 
CD81-CD81 interactions as shown by reduced yeast growth and reporter gene 
activation (figure 4.10a). This result is apparent when growth data is normalised to 
NubI and NubG internal controls (figure 4.10a) where WT CD81 shows 30.5% growth 
as compared to CD81 T153A shows 5.9% growth in comparison. CD81 T149A and 
E152A also show reduced growth compared to WT (24.2% and 18.5%, respectively) 
but are not statistically different. The same trend in the data is shown when growth is 
normalised to the SD-W-L control (figure 4.10a). This data suggests that T153A is 
involved in CD81-CD81 interaction and T149A and E152A may have less of an 
involvement. T149A and T153A are known to be involved in CD81 dimerisation 
(Martino and Guido, 2002) and so the knock-down seen with the same mutants in the 
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CD81-Claudin-1 interaction may result from indirect effects on CD81-CD81 
interactions. 
When CD81 TM1 mutants L14A, F17A, C89A and L14A-F17A were tested in CD81 
homo-oligomerisation, L14A and L14-F17A mutants exhibited significantly lower 
growth than WT CD81 when data was normalised to internal controls (15.9%, 12.6% 
and 30.6% respectively) (figure 4.10b). This may suggest that the residues are also 
involved in CD81-CD81 interactions as well as CD81-Claudin-1 interactions seen 
earlier in this chapter. Again, an indirect effect of reducing CD81-CD81 interactions 
may be the case on the frequency of CD81-Claudin-1 interactions. Mutants F17A and 
C89A do not have a significant effect on yeast growth in CD81-CD81 interactions, if 
only showing a small knock-down as compared to WT, but they did not reach statistical 
significance (figure 4.10b).  
This data suggests that CD81-Claudin-1 oligomerisation may be directly linked to the 
status of CD81-CD81 oligomerisation. When CD81-CD81 interactions are reduced this 
may cause a reduction in the occurrence of CD81-Claudin-1 interactions. Previous 
studies suggest that two CD81 molecules bind one Claudin-1 molecule (Bonander et al., 
2013) so potentially a CD81 dimer is required to interact with Claudin-1. Alternatively 
CD81 may be a monomer, dimer or higher order oligomer and binds Claudin-1 on the 
same side ‘face’ as it would another CD81 molecule, suggesting a common binding 
interface of CD81 and Claudin-1. 
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Figure 4.10: CD81-CD81 interactions. NMY51 cells were transformed with appropriate 
CD81 bait and prey vector pairs (WT or mutant). Cells were incubated at 30°C and selected on 
plates; SD-W-L or SD-W-L-H-A, for 5 days before colonies were counted. a) CD81-CD81 
interactions (WT or loop residue mutant) represented as growth on SD-W-L-H-A normalised to 
internal controls NubI and NubG and CD81-CD81 interactions normalised using SD-W-L 
control. b) CD81-CD81 interactions (WT or TM1 residue mutant) represented as growth on SD-
W-L-H-A normalised to internal controls NubI and NubG and CD81-CD81 interactions 
normalised using SD-W-L control. Experiment was repeated twice to compare mean ± SEM of 
WT to mutant CD81 using a one-way ANOVA followed by a Dunnett’s multiple comparison 
test. 
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4.6 Using a molecular modelling approach to predict further CD81 TM1 residues 
involved in the CD81-Claudin-1 binding interface 
 
In collaboration with Jonathan Mullins (Swansea University), we produced a model of 
the full length CD81-Claudin-1 complex using the Seigneuret (2006) CD81 homology 
model (shown in figure 4.11) docked with a threading based model of Claudin-1, 
generated by Dr Mullins, using Hex 8.0 (a protein docking program). We explored 
CD81 TM1 further using the model complex which allowed us to choose appropriate 
residues along the TM1 interface to perform site-directed mutagenesis and evaluate in 
the yeast split-ubiquitin system.  
 
4.6.1 Molecular model complex of CD81-Claudin-1 using a Claudin-1 
threading based model 
 
Figure 4.11 shows the CD81-Claudin-1 structural model complex, using the Claudin-1 
threading-based model, which was used as a guide to direct mutagenesis experiments. 
Residues L14 and F17 on CD81 TM1 appeared to form part of a hydrophobic ridge that 
could possibly fit into a groove present on Claudin-1 TM2 (residues G87 and G91). 
Using this information, we next selected residues on CD81 TM1 from L14 and F17 that 
faced the same direction to probe this face for its interaction with Claudin-1. Residues 
were F21, G25, I28, L29 and L35. On Claudin-1 TM2 G87 and G91 also appeared to be 
good mutagenesis targets. The initial plan was to mutate all chosen residues to alanine 
and assess the mutants in protein-protein interaction experiments using the yeast split-
ubiquitin assay.  
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Figure 4.11: CD81-Claudin-1 complex model. A CD81-Claudin-1 homology based model 
using CD81 full length homology model by Seigneuret (2006) with a Claudin-1 threading-based 
model generated and docked using Hex 8.0 by Dr Jonathan Mullins (Swansea University). 
CD81 TM1 (yellow) shows residues L14, F17, F21, G25, I28 and L35 pointing outwards as a 
possible interaction interface with Claudin-1 TM2 (residues predicted to be involved are G87 
and G91 in orange).  
 
4.6.2 Testing CD81 TM residues predicted to be involved in the Claudin-1 
interaction 
 
Residues on CD81 TM1 (F21, G25, I28, L29 and L35) predicted to interact with 
Claudin-1 using a full length model were tested in the yeast split-ubiquitin assay.  
Figure 4.12 shows data generated using yeast colony counts on plates selecting for a 
protein-protein interaction (SD-W-L-H-A). A similar data trend is shown when growth 
on SD-W-L-H-A is normalised to internal controls or to the SD-W-L control plate (see 
figure 4.12a-c). Using data that was normalised to SD-W-L, CD81 I28A and L35A 
resulted in a reduction in yeast growth (3.01% and 3.82% respectively) in comparison 
to WT CD81 (7.88%) (figure 4.12b and c), even though the apparent reduction was not 
statistically significant. This would suggest that introducing mutations at I28 and L35 
have an effect on the CD81-Claudin-1 interaction, possibly due to disrupting the protein 
binding interface on CD81 TM1. CD81 mutants F21A, G25A and L29A showed similar 
levels of growth on SD-W-L-H-A as WT CD81 (figure 4.12) suggesting that these 
CD81 mutants can bind equally well to Claudin-1 as WT CD81.  
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Figure 4.12: Predicted CD81 TM1 residue mutants in Claudin-1-CD81 interactions. 
NMY51 cells were transformed with appropriate bait and prey vector pairs (WT or mutant). 
Cells were incubated at 30°C and selected on plates; SD-W-L or SD-W-L-H-A, for 5 days 
before colonies were counted. a) WT Claudin-1 and CD81 interactions (WT or mutant) 
represented as growth on SD-W-L-H-A internal controls NubI and NubG. b) WT Claudin-1-
CD81 interactions normalised using SD-W-L control. c) Table summarising data normalised in 
two ways. Experiment was repeated five times to compare mean ± SEM of WT to mutant CD81 
using a one-way ANOVA followed by a Dunnett’s multiple comparison test. 
 
 
 
Reaction 
 
Bait Claudin-1 + 
SD-W-L-H-A 
colony count 
normalised to 
NubI and NubG 
controls 
Mean ± SEM 
(%) 
Significance Growth on SD–
W-L-H-A 
normalised to 
SD–W-L 
Mean ± SEM 
(%) 
Significance 
NubI 100 - 104.8 ± 26.17 - 
NubG 0 ** 0.53 ± 0.29 * 
 
WT CD81 8.71 ± 0.54 - 7.88 ± 2.50 - 
CD81 F21A 6.81 ± 1.50 ns 6.00 ± 2.29 ns 
CD81 G25A 8.94 ± 1.29 ns 6.80 ± 1.81 ns 
CD81 I28A 4.05 ± 1.00 ns 3.01 ± 0.35 ns 
CD81 L29A 6.49 ± 2.35 ns 4.56 ± 1.25 ns 
CD81 L35A 5.65 ± 1.63 ns 3.82 ± 1.11 ns 
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In order to determine the effects of predicted CD81 TM1 residues further in the CD81-
Claudin-1 interaction, yeast liquid growth curve analysis was performed. Colonies 
grown on SD-W-L plates selected for double vector transformations were pooled from 
each test condition. Yeast was diluted to an OD546 0.02 and incubated for approximately 
20h whilst measuring the OD546 reached by the sample every hour.  
 
Data in figure 4.13 show that the slowest growth, hence a reduction in CD81-Claudin-1 
interaction was due to L14A-F17A, I28A and L35A CD81 mutants. This was 
demonstrated in representative growth curves by a shift to the right of the mutant 
growth profiles as compared to WT (figure 4.13b-g). Other mutants tested, F21A, 
G25A and L29A did not result in different growth profiles as compared to WT CD81. 
Furthermore, figure 4.13a compares WT and mutant CD81 average OD546 at a specific 
point in the curve for the CD81-Claudin-1 interaction. CD81 L14A-F17A and L35A 
had significantly different OD546 values in comparison to WT (0.47, 0.50 and 0.62 
respectively) and I28A demonstrated a decrease (OD546 0.53) although not significantly 
different from WT CD81. F21A, G25A and L29 caused a slight growth reduction as 
compared to WT but this was not significantly different.  
 
This suggests that mutants that reduce CD81-Claudin-1 interactions as determined by 
yeast growth are L14A-F17A, I28A and L35A. Possibly due to being involved in the 
CD81-Claudin-1 binding interface. Although predicted to be facing the same direction 
and on the interaction interface, residues F21A, G25A and L29A did not have such 
pronounced effects on yeast growth, hence are likely to not disrupt the CD81-Claudin-1 
interaction when mutated to alanine. Substitution of another amino acid other than 
alanine may have shown a different result.  
 
This approach suggests that subtle differences in the interaction of CD81 TM mutants 
with Claudin-1 can be shown in liquid growth cultures, even on a small scale in a 96 
well format.  
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Figure 4.13: CD81 TM1 residues involved in the CD81-Claudin-1 interaction. NMY51 was 
transformed with bait and prey vector pairs and were grown on SD-W-L plates. Colonies from a 
single plate were pooled, vortexed and diluted to an OD546 0.02 before adding to a 96-well plate 
for growth analysis. OD546 measurements were taken every 1h and cells were shaken and 
incubated at 30°C. a) The mean OD of the WT and mutant interactions were compared at the 
time point where internal NubI control reached OD 0.2. b-g) OD546 was plotted against time(h) 
for WT and mutant CD81 interactions with Claudin-1. Experiments repeated 4 times, each 
experiment performed 4 growth curves in parallel. Data analysed using a one way ANOVA 
followed by a Fisher’s LSD test. n=4, p 0.05. 
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4.6.3 CD81 TM1 mutant expression 
 
In order to determine expression of the predicted CD81 TM1 mutants in yeast as 
compared to WT CD81, western blot analysis and ELISA were performed using 
specific anti-CD81 antibodies. Western blot analysis on CD81 WT or mutant membrane 
and cytosolic fractions (figure 4.14a) shown that mutant protein bands were of the same 
density as WT as seen by monomer and dimer molecular weight sizes. This was except 
CD81 I28A, which showed evidence of reduced protein band intensity which would 
point towards reduced expression as compared to WT CD81.  
Further experiments were performed using an ELISA with anti-CD81 antibodies. The 
negative controls (NubG and PBS) were used to determine background signal with 
anything above the dotted line showing positive binding of antibodies to CD81 samples 
(figure 4.14b and c). Anti-CD81 2.131 and 2.66 both bound relatively equal levels of 
WT CD81 as mutant CD81 in yeast membranes (figure 14b and c). This suggests that 
firstly the expression level in yeast membranes is similar between all proteins and 
secondly, the ability to bind CD81 folded LEL specific antibodies is consistent between 
WT and mutants. These data provide evidence that the reduced interaction between 
CD81-Claudin-1 by mutants I28A and L35A (figure 4.13) is possibly due to their 
involvement in the protein binding interface and not due to reduced expression or 
protein mis-folding as compared to WT CD81. Evidence shown here to suggest folded 
mutant CD81 demonstrates that the mutants are likely not mis-folded and retained in 
the ER or Golgi, hence similar plasma membrane expression as WT CD81.  
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Figure 4.14: CD81 TM1 mutant expression. NMY51 cells were transformed (see materials 
and methods) to express WT Prey CD81 or mutant (F21A, G25A, I28A, L29A or L35A). Cells 
grown on SD-Trp plates were selected and grown in SD-Trp liquid culture overnight. Cells 
were harvested and then lysed in order to isolate the yeast membrane fraction using a tissue 
lyser method. Membranes were resuspended in buffer and quantified for total protein. a) 
Western blot of yeast membrane (M) and cytosolic fractions (C) expressing WT or mutant Prey 
CD81 or pPR3N (negative control). b) ELISA on yeast membranes expressing pPR3N, WT or 
mutant CD81 using anti-CD81 2.131 and c) anti-CD81 2.66 monoclonal antibodies. Dashed 
line indicates negative control NubG background signal. Data represents the mean ± SEM of 
two independent experiments.  
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4.6.4 Molecular model complex of CD81-Claudin-1 using a Claudin-15 
based homology model 
 
A major milestone for the Claudin family, the structure of mammalian Claudin-15 
solved to 2.4 Angstroms (Suzuki et al., 2014) allowed us to improve our CD81-
Claudin-1 complex model. Since the threading based model of Claudin-1 was based on 
alginate lyase from Agrobacterium tumefaciens C58 as template, the revised model 
based on Claudin-15 (a close homologue of Claudin-1 and therefore a good template) 
would likely be more reliable. 
 
Figure 4.15: Two Claudin-1 full length models used in this study. a) Cytoplasmic view of 
full length Claudin-1 threading based model showing TM domains (TM1-4) in red going in a 
clockwise direction. b) Cytoplasmic view of full length Claudin-1 homology based model. 
TM1-TM4 (red) is shown to be going in an anti-clockwise direction. Models produced by Dr 
Jonathan Mullins. Pictures using PDB files were generated using Accelrys Discovery Studio 4.0 
Visualizer.  
 
Figure 4.15 shows how the two Claudin-1 full length models differ regarding TM 
bundle direction as viewed from the cytoplasm. The reasons for the difference depend 
on the method and the template that was used to generate each model i.e. threading 
template alginate lyase from Agrobacterium tumefaciens C58 and the homology model 
used the Claudin-15 structure as template. The latter is a much more reliable template 
a) b) 
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than the former due to increased homology with Claudin-1, but was not available until 
2014. This shows the development of molecular modelling over time. 
  
 
Figure 4.16: Claudin-15 homology based model used to generate a CD81-Claudin-1 
complex model. CD81-Claudin-1 complex docked together using Hex 8.0. The Claudin-1 
homology based model (blue) was used with CD81 full length homology model by Seigneuret 
(2006) (red). Residues on CD81 TM1 L14, F17, I28 and L35 are highlighted in green and 
predicted to have an effect on the CD81-Claudin-1 interface via Claudin-1 TM2 (V85 and V92) 
and the intracellular loop (M105). Produced by Dr Jonathan Mullins. 
 
Figure 4.16 shows the evolved CD81-Claudin-1 complex model using a homology 
approach. Using this model we were able to plot residues in CD81 TM1 that were 
mutated and tested earlier in the yeast split-ubiquitin assay and subsequently predict 
residues in Claudin-1 that may be on the interaction interface. The predictions on 
Claudin-1 included V85, V92 on Claudin-1 TM2 and M105 on Claudin-1 intracellular 
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loop (see figure 4.16). Further experiments are required to test if the Claudin-1 
predictions are correct.  
 
Using the revised CD81-Claudin-1 homology model, FoldX, which is a computer 
algorithm that can predict the effect of an amino acid mutation on the stability of 
proteins and protein complexes, was used to predict the effect of CD81 TM1 mutations 
on protein stability and on the stability of CD81-Claudin-1 interactions. Each CD81 
TM1 residue that was mutated to alanine and explored in yeast split-ubiquitin assays 
were analysed (see table 4.1). 
 
Table 4.1: FoldX analysis of CD81 TM1 mutants on protein stability and stability of 
CD81-Claudin-1 interactions. The CD81-Claudin-1 homology based model generated by Dr 
Jonathan Mullins was used in FoldX. Each CD81 TM residue was mutated to alanine and 
scored (Gibbs free energy (ΔG)) for protein stability and protein interaction stability. If a 
mutation increases protein stability, ΔG <0, if it is less stable ΔG >0. 
 
 
 
 
 
 
 
 
FoldX analysis was useful to analyse the CD81-Claudin-1 homology model (figure 
4.16) and help make a judgement of the analysis in context with experimental data of 
CD81 mutants in the split-ubiquitin yeast assay. Mutants that caused instability to the 
CD81-Claudin-1 complex as predicted using the model were L14A, F17A, F21A and 
I28A. Results from the split-ubiquitin assay are consistent with L14A, F17A and I28A, 
but not F21A, which is in the middle of CD81 TM1 and so may be involved in non-
specific hydrophobic interactions.  L35A resulted in a reduction in CD81-Claudin-1 
interactions in yeast but was not shown to in FoldX analysis (table 4.1), even though the 
molecular model does show a close association between L35 on CD81 and V85 on 
Claudin-1 (figure 4.16). Taken together, results from yeast assays and FoldX analysis 
CD81 mutant Average protein 
stability ΔΔG 
(Kcal/mol)  
Average interaction 
energy  ΔΔG 
(Kcal/mol)  
L14A 2.02 0.15 
F17A 0.79 0.69 
C89A 0.29 0.00 
F21A 2.01 0.80 
G25A 1.82 0.00 
I28A 3.22 0.99 
L29A 2.58 0.01 
L35A 1.56 -0.28 
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using a molecular model suggest that residues at the bottom (L14 and F17) and at the 
top (I28A and L35A) of CD81 may be involved in the interaction interface with 
Claudin-1 TM2 (see figure 4.16). 
 
Most of the mutations, according to FoldX analyses caused protein instability since ΔG 
scores >0 were regarded as less stable. The mutation which was suggested to cause the 
highest level of protein instability was I28A and so this may suggest that protein 
instability is the cause of any reduction seen in CD81-Claudin-1 interactions. Although, 
ELISA experimental data did not find a difference in expression of CD81 I28A 
compared to WT CD81 (figure 4.14b) but western blot analysis did find reduced protein 
expression as compared to WT. Further work is required to clarify the effect of CD81 
I28A on protein stability (figure 4.14a).  
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5. Improving the thermal stability of recombinant, full length CD81 for structural 
and functional characterisation 
5.1 Chapter 5 overview and objectives 
 
Recombinant protein production is a major route investigators take to produce protein 
samples in order to characterise the structural and functional elements of prokaryotic 
and eukaryotic membrane proteins. In contrast to naturally abundant membrane proteins 
such as the G-protein coupled receptor, rhodopsin (Stenkamp et al., 2002), the majority 
are found in relatively low quantities naturally and so prokaryotic or eukaryotic host 
systems are chosen to specifically overproduce a protein of interest for further study, 
which is likely to require high protein concentrations.  
This chapter focuses on the yeast recombinant host, P. pastoris, as it has many 
advantages for over-expression of human proteins. Firstly, P. pastoris are unicellular 
organisms able to grow to high cell densities at fast rates, they are relatively 
inexpensive to culture, and the yeast also offers its eukaryote features for protein 
production such as post-translational modifications as well as a secretory pathway 
(Mattanovich et al., 2012). Moreover, strong inducible promoters are available such as 
the alcohol oxidase I (AOX1) promoter, utilised in this chapter, which enables protein 
expression induced in the presence of methanol (see Ahmad et al., 2014 for review). 
P. pastoris has previously shown success in producing eukaryotic membrane proteins 
that were subsequently structurally solved (Carpenter et al., 2008). Once overexpressed, 
membrane proteins must be solubilised from the yeast membrane, most commonly 
using detergents but this in itself introduces problems due to the hydrophobic nature of 
membrane proteins. Detergents are often screened for their ability to yield soluble, 
stable and homogenous membrane protein from the host membrane. It has been shown 
using various approaches that optimising conditions such as buffer, detergent or the 
addition of lipids, which may render a protein more stable, can result in improved 
crystallisation efforts (Carpenter et al., 2008). 
One relatively recent approach, used to optimise and guide membrane protein 
purification conditions, measures thermal stability using the thiol-specific fluorochrome 
N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM) (Alexandrov et 
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al., 2008). The method relies on native cysteines embedded within a folded protein 
which bind CPM if exposed due to temperature-induced protein unfolding, which 
results in a measureable fluorescent signal.  
This chapter describes the expression, solubilisation, purification and optimisation of 
the thermal stability of human CD81 and Claudin-1. Our aim was to focus on CD81 in 
particular, in order to aspire towards the first full length tetraspanin solved structure. 
Specific objectives included: 
 Expression of full length human CD81 and Claudin-1 in P. pastoris; 
 Solubilisation and purification of CD81 and Claudin-1; 
 Thermal stability assessment of CD81 to optimise solution conditions such as 
buffer composition, pH, ionic strength, glycerol content and lipid addition; 
 CD81 crystallisation trials. 
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5.2 CD81 and Claudin-1 expression, solubilisation and antigenicity 
 
Recombinant, full length human CD81, mutated at palmitoylation sites (from Cys to 
Ala) was previously produced in mg quantities using P. pastoris as the eukaryotic host 
(Jamshad et al., 2008). Similar quantity and quality of human wild-type Claudin-1 was 
also produced using the same system (Bonander et al., 2013) (see figure 5.1).  
 
 
 
 
Figure 5.1: Membrane protein constructs of CD81 and Claudin-1 used in this study. 
Recombinant full length human CD81 (Jamshad et al., 2008) and Claudin-1 (Bonander et al., 
2013) were previously produced in mg quantities. P. pastoris X33 cells were used to produce 
four transmembrane proteins under tight regulation using the AOX1 promoter in the pPICZB 
vector (Invitrogen).  a) Full length human CD81 was mutated at palmitoylation sites (Cys to 
Ala) and a His6 tag was incorporated on the C-terminal tail for detection and purification 
purposes. b) Full length human Claudin-1 used was wild-type that has a His6 tag at the C-
terminal tail.   
 
P. pastoris colonies, selected on YPD-zeocin plates were initially tested for their 
expression profile for CD81 and Claudin-1 in shake flasks over time using western blot 
analysis and two different approaches. The first approach determined if the AOX1 
promoter was tightly regulated by methanol induction using CD81 expression as an 
example. Yeast cells were grown for approximately 22h in BMGY to accumulate 
biomass prior to induction. Cells were then diluted to an OD600 5 and grown for 47h in 
BMMY in order to induce CD81 expression. Samples were collected pre- and post-
induction (see figure 5.2a) and the total membrane was isolated. The same amount of 
a) b) 
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total protein (25µg) for each sample was then loaded on to an SDS-gel for western blot 
analysis and CD81 detection.  
The second approach focused on post-induction expression of both CD81 and Claudin-
1 over a time course. After cell growth in BMGY, cells were induced in BMMY and 
3ml samples were collected between 0-50 h induction. Samples were analysed for 
protein expression by isolating the total membrane, the total protein concentration was 
this time not quantified, but equal volumes of membrane preparation (20µl) was loaded 
per sample on to an SDS gel to determine the volumetric yield of membrane protein. An 
anti-His antibody was used to detect CD81 and Claudin-1 using a western blot approach 
(see figure 5.2b). 
 
 
 
 
 
 
 
 
Figure 5.2: CD81 and Claudin-1 full length expression in P. pastoris. a) CD81 expression 
pre- and post induction. Yeast were grown in BMGY for ~22 hours to an OD of 7-10 and then 
induced in BMMY for ~47h prior to harvesting the cell pellet. Samples equating to the same 
OD were collected both pre-induction (BMGY) and post-induction (BMMY) and the total 
membrane fraction isolated and total protein quantified using a BCA assay. 25µg total protein 
was loaded on to an SDS gel for each sample and then CD81 detected using an anti-His 
antibody. b) CD81 and Claudin-1 expression over time (0-50 h) during induction in BMMY. 
3ml samples collected at each time point were broken and the total membrane was isolated. 
Equal volumes (20µl) of membrane were loaded on to an SDS-gel and CD81 and Claudin-1 
were detected using an anti-His antibody. Molecular size markers are indicated in part a) using 
a ProtoMetrics ladder (national diagnostics) (also shown in part b). L=ladder, B= blank lane.  
 
   L    BMGY BMMY 
Time (h):   20   22    0    18    24     47 
Time (h):     0     4      6     13     20     27      43    50 
Time (h):   0     4    6     13       L     B     20      27       43      50 
a) b) CD81- BMMY 
Claudin-1- BMMY 
OD        :  10.1   10.5   5    9.4     9.6    12.9 
CD81 
kDa 
 
35 
25 
 
15 
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Figure 5.2a demonstrates tight regulation of the AOX1 promoter by methanol as 
induction of CD81 expression is only apparent at 18h post-induction and not before. 
This continues to at least 47 h post-induction as the cellular biomass continues to 
increase up to an OD600 of 12.9 in BMMY. Increasing biomass in BMMY over time is 
more apparent in figure 5.2b. The same volume of yeast membranes were loaded for 
each sample collected between 0-50 h induction (and therefore not corrected for total 
protein concentration). It was observed that as the time increased, the total yield of 
recombinant CD81 and Claudin-1 increased in the collected sample (figure 5.2b). This 
is likely due to an increase in cellular biomass over time as yeast use methanol as an 
alternative carbon source. In this instance, CD81 detection was apparent at 43h 
induction, whilst Claudin-1 at 13h induction. This may account for slower growth of 
CD81 expressing cells in comparison to Claudin-1 expressing cells since we know 
CD81 is expressed much earlier than this (18h post-induction) as seen in figure 5.2a. 
Based on these findings and a quote from Shi et al., (2002), ‘production is roughly 
proportional to cell density’, all subsequent expression of recombinant CD81 and 
Claudin-1 was performed for 50h induction in BMMY prior to harvesting cells. 
 
Recombinant CD81 is predicted to have a molecular weight of 26.7 kDa and Claudin-1 
23.7 kDa, since both proteins are expressed with a C-terminal His6 tag. CD81 shows the 
ability to form monomers and dimers (figure 5.2a) on a non-reducing SDS-PAGE and 
Claudin-1 monomers, dimers and trimers (figure 5.2b).  
 
After producing CD81 and Claudin-1 independently in P. pastoris membranes, it was 
then necessary to extract the proteins from the membrane, rendering them soluble. This 
was previously achieved using detergents (Jamshad et al., 2008), (Bonander et al., 
2013). CD81 was solubilised using β-OG and Claudin-1 using foscholine-10 (Fos-10); 
the detergent for each protein was previously selected in our laboratory.  
 
Figure 5.3a demonstrates detergent CD81 and Claudin-1 extractions from the yeast 
membrane after an ultracentrifugation spin of the solubilised material. The supernatant 
was run on a SDS gel in order to detect solubilised protein. Subsequently, Claudin-1, 
CD81 and a non-HCV receptor CD82 solubilised in detergent were further analysed for 
HCV sE2 functional binding in an ELISA. Figure 5.3b demonstrates that CD81, but not 
Claudin-1 or CD82 bind to sE2, which is consistent with current literature (Bonander et 
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al., 2013) where Claudin-1 has not shown sufficient evidence of binding directly to 
HCV, or more specifically sE2, in contrast to CD81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: HCV sE2 functional binding of detergent solubilised CD81 but not Claudin-1. 
a) CD81 and Claudin-1 were extracted from yeast membranes using detergents, β-octyl-
glucopyranoside (β-OG) and foscholine-10 (Fos-10), respectively and detected with an anti-His 
antibody using western blot analysis. Solubilisation also achieved with polymers (referred to as 
polymer 1 and polymer 2) produced in Professor Brian Tighe’s laboratory, Aston University, 1) 
non-solubilised protein and 2) solubilised protein. A ProtoMetrics ladder is shown for 
molecular weight markers (National Diagnostics).b) Claudin-1, CD81 and a non-HCV receptor 
CD82 were solubilised in detergent and subsequently analysed for HCV sE2 functional binding 
in an ELISA (performed by Ke Hu at Birmingham University). 
 
 
In addition to extracting CD81 and Claudin-1 from yeast membranes using detergents, a 
more recent novel approach for solubilisation was performed using polymers. 
Amphipathic polymers known as styrene maleic acid lipid particles (SMALPs) directly 
a) 
b) 
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extract membrane proteins from the native membrane and form a disc-like structure that 
surrounds both protein and maintains surrounding lipids. This approach has been 
previously shown to enhance protein stability and function (Rajesh et al., 2011), 
(Jamshad et al., 2011). Figure 5.3 shows CD81 and Claudin-1 solubilisation achieved 
with polymers (referred to as polymer 1 and polymer 2) produced in Prof Brian Tighe’s 
laboratory, Aston University. Polymer 1 was able to extract monomeric CD81, but was 
not 100% efficient as CD81 was found in the non-soluble fraction (figure 5.3a, lanes 2 
and 1, respectively). Claudin-1 was extracted using a different polymer (referred to as 
polymer 2) and was shown to exist as higher oligomeric forms in the solubilised 
fraction, although a large level of protein remained unsolubilised (figure 5.3a, lanes 2 
and 1, respectively). Future work using polymers would include optimisation of 
solubilisation conditions to improve extraction efficiency. Furthermore, protein 
functional assays would be useful to determine structural stability of CD81 and 
Claudin-1 in polymers. If structure and function were maintained, polymers may be 
useful for downstream crystallisation trials.  
 
  5.2.1 Scaling up recombinant protein production 
 
Having confirmed functional expression could be achieved in shake flasks, P. pastoris 
recombinant protein expression was scaled up from small shake-flasks to either a 2 L 
bioreactor or multiple 2L baffled shake flasks.  
Scaling up from a shake-flask to a bioreactor should increase the total yield of protein 
produced in the system because the cells grow in a more controlled environment on 
account of improved aeration. This was investigated by preparing a bioreactor 
containing basal salts medium (BSM) as a standard medium to use in a controlled 
environment, in order to grow and induce a culture of P. pastoris strain expressing 
CD81. 
Figure 5.4 is a bioreactor trace, which shows variables such as pH, temperature, 
dissolved oxygen (dO) and evolved carbon dioxide (CO2). The level of dO used by the 
bioreactor culture decreases very slowly and does not fall with a simultaneous rise in 
CO2 until ~80 h from the beginning of the run (see figure 5.4). This suggested that the 
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culture did not undergo high levels of respiration and growth early on in the run and 
therefore would result in low levels of biomass, which is not optimal prior to induction 
of recombinant protein expression. 
 
 
 
Figure 5.4: P. pastoris CD81 recombinant strain grows at a slow rate in minimal medium. 
P. pastoris expressing recombinant human CD81 was inoculated into a bioreactor consisting of 
a minimal medium, BSM. Culture conditions were set at 30°C, pH 5 and 30% dissolved oxygen 
(dO). This bioreactor run did not include an induction phase with methanol as the yeast cells did 
not grow efficiently, as shown by the lack of respiration up until ~80h by the dO and CO2 
traces. 
 
 
Since P. pastoris CD81 production had earlier been achieved in shake flasks using a 
complex medium (BMGY), we investigated the effect of P. pastoris growth in a 
bioreactor by changing the medium from a minimal (BSM) to a complex (YPG) 
medium, which had been used successfully in a laboratory protocol to produce 
recombinant CD81 and Claudin-1 (Bonander et al., 2011).  
 
dO decreased at ~80 h 
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Results indicated that the yeast strain grew successfully using a complex medium and 
we were able to assess the growth profile of the culture using online bioreactor 
measurements (see figure 5.5). The growth profile demonstrates a drop in the dO and 
rise in CO2 within 12h of bioreactor inoculation, in contrast to that seen using a minimal 
medium (see figure 5.5 and 5.4 respectively). The culture OD600 was measured 
throughout the run and reached 16.5 just prior to the start of induction. Over time, there 
was a reduced capability for the culture to respire as the dO gradually increased. This 
immediately changed at the beginning of induction, when methanol was added to the 
vessel, the dO dramatically declined and CO2 increased (see figure 5.5). This also 
occurred as a result of the third methanol supplementation to the vessel. Furthermore, 
the OD600 of the culture increased throughout the induction period and reached an 
OD600 of 31.8 at 52 h of the total bioreactor run. 
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Figure 5.5: P. pastoris CD81 expressing strain is suited for growth in a bioreactor using a 
complex medium. a) P. pastoris strain expressing CD81 was inoculated into a bioreactor 
consisting of YPG (10g/L of glycerol in YPG, 1 L working volume) and methanol was added as 
indicated on the trace. Culture conditions were set at 30°C, pH 7 and 30% dO. The level of 
dissolved oxygen (dO) in the bioreactor and the amount of CO2 evolved was recorded over 
time. The trace shows a bioprocess response. As P. pastoris demands a high level of O2 for 
growth, the system attempts to maintain a specific set-point (i.e. the dO will be maintained at 
~30%). When this is not achieved the system responds by increasing the stirrer speed; following 
this more air (40% O2; 60% N2) is pumped into the vessel in order to reach set-point. This can 
be seen here by the dO trace fluctuating around 30% and also the stirrer trace (rpm) responding 
accordingly. b) Western blot analysis confirming CD81 expression. 
 
 
 
 
Methanol addition to vessel 
CD81 26.7 kDa 
a) 
b) 
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CD81 expression was successful using a bioreactor containing complex medium such 
as YPG (figure 5.5b). Even so, in order to produce high yields of membrane protein 
easily and efficiently from P. pastoris, large baffled shake flasks were tested in 
comparison to a bioreactor and were deemed just as successful regarding cell biomass 
reached at the end of the batch run and regarding set-up time was a more efficient 
approach. For each production batch, 1600ml BMGY was used to grow the yeast strain 
using 8 200ml working volume (1L shake flasks). Once grown to an OD600 ~7-10 the 
cells were used for BMMY induction in 8 500ml working volume cultures (using 2L 
flasks). Cells were supplemented with methanol (1% v/v) at 24h post-induction and 
subsequently harvested at around 48-54 h post-induction. This approach typically 
yielded ~80g total wet cell weight. In comparison a bioreactor with 1L working volume 
would yield approximately 60-70g wet cell weight. Since there was not a great 
difference between the resulting cell weight yields of the two production approaches, 
ultimately large 2L flasks were used routinely for CD81 production hereafter due to 
ease of use and sufficient material obtained for solubilisation and purification. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: CD81 expression in large 2L baffled shake flasks. a) One batch culture would 
consist of 8 x 2L shake flasks (500ml working volume) and cells were induced in BMMY for 
~50h. b) 3 independent batches of cells were broken using a glass bead method and the total 
membrane isolated. 5µl per sample was loaded on to a gel with/without 2-mercaptoethanol 
(2ME) included in the western loading sample buffer. A western blot was performed and CD81 
-2ME +2ME -2ME +2ME 
Anti-His       L    1   2   3       1   2    3     Anti-CD81   L    1   2   3     1   2   3 
a) 
b) 
147 
 
was either detected using an anti-His (Clontech) antibody or anti-CD81 (2.131). +/- 2ME in 
sample buffer is indicated in figure. L= ProtoMetrics ladder (national diagnostics) and 1, 2 and 
3 indicates if the protein sample was from batch culture 1, 2 or 3 produced independently.  
 
 
Figure 5.6b indicates CD81 expression in three independent large scale batch cultures 
using 2L baffled shake flasks. The protein band intensity appears consistent between 
batches suggesting reproducibility in the method used. Recombinant CD81 was 
detected using both anti-His and also a specific anti-CD81 antibody, showing both 
monomers and dimers are present in the yeast membrane. The anti-His antibody bound 
both +/- 2-mercaptoethanol (2ME) treated samples in contrast to the anti-CD81 
monoclonal antibody used, which could only bind -2ME samples. The anti-CD81 
antibody is conformationally sensitive; therefore this experiment suggests CD81 is 
correctly folded in yeast membranes since the anti-CD81 antibody cannot bind to 
reduced CD81 samples. Since anti-CD81 2.131 specifically binds the folded LEL it 
seems likely that the absence of disulphide bonds in this structure, as a result of 2ME in 
the sample buffer, prevents binding of the antibody.  
 
5.3 Large scale CD81 solubilisation and purification 
 
Now that there was sufficient evidence for CD81 production, antigenicity and insertion 
into P. pastoris membranes, the next challenge was to extract high yields of CD81 from 
yeast membranes using detergent. In order to do this, time was spent at the Membrane 
Protein Laboratory (MPL) at the Diamond Light Source (Oxfordshire) in order to gain 
expert advice on dealing with membrane proteins from Isabel Moraes, James Birch and 
other group members with an aim to put CD81 through crystallisation trials. Initially, 
CD81 was solubilised and purified in DDM as this is a standard detergent used in the 
membrane protein field for crystallisation attempts (Gutmann et al., 2007) and seemed 
like a good place to begin. Standard buffer conditions tried initially were 1 PBS 
(137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, and 2mM KH2PO4, pH 7.4); 150mM 
NaCl, 10% glycerol and DDM (1% for solubilisation and 0.1% in purification buffers) 
(figure 5.7).  
After solubilisation in DDM for 2h at 4°C, the sample was spun in an ultracentrifuge to 
remove unsolubilised material in the pellet. Solubilised material in the supernatant was 
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then bound to Ni-NTA resin in order to purify CD81. Subsequently two imidazole 
washes (30mM and 40mM) and a final elution at 250mM imidazole rendered semi-pure 
CD81 observed as a monomer, dimer and possibly higher order forms (as shown in 
figure 5.7). The sample was then concentrated using a 50 kDa cut off centrifugal 
concentrator (Sartorius), although soon into the concentration procedure CD81 at 
around 0.593 mg/ml appeared to have aggregated under these conditions, therefore 
either the buffer conditions, detergent or both were not suitable to maintain CD81 
stability. 
 
 
  
 
 
Figure 5.7: Solubilisation and purification of CD81 using DDM. CD81 was solubilised 
using 1% DDM in buffer (1 PBS, 150 mM NaCl, 10% glycerol, 20mM imidazole) for 2h at 
4°C. After an ultracentrifuge spin, the solubilised material was taken as the supernatant and 
bound to nickel resin for 1h at 4°C. After performing 30mM and 40mM imidazole washes, 
CD81 was eluted from the column containing resin using 250mM imidazole. The protein was 
concentrated using a 50 kDa cut off centrifuge spin tube with PES membrane (Sartorius). 
Samples collected at each point of the solubilisation and purification procedure were loaded on 
to an SDS-gel and later developed using Instant blue (Expedeon). Arrow represents size of 
monomeric CD81. 
 
 
Sample Solubilisation/purification 
fraction 
1 Prior to ultracentrifugation spin 
2 After ultracentrifugation spin 
3 Column flow through (unbound 
material) 
4 30mM imidazole wash 
5 40mM imidazole wash 
6 250mM imidazole elution 
7 Concentrated CD81 sample 
8 Aggregated pellet 
 L     1     2      3    4      5      6     7    8   
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5.4 Optimisation of the thermal stability of CD81 for crystallisation trials using a 
CPM assay 
 
CD81 must be extracted from the host membrane in order for purification to occur; 
crucial annular lipids that maintain protein structure are lost and replaced by detergent 
molecules forming a protein-detergent complex. Naturally, detergents cannot mimic the 
lipid bilayer exactly and so membrane proteins typically undergo instability problems, 
which may lead to protein aggregation. Since ideally 10mg/ml was needed for 
crystallisation trials, conditions that yield soluble and stable CD81 were investigated 
using a CPM thermal stability assay (Alexandrov et al., 2008), since this is one factor 
that may contribute to successful crystallisation trials. Figure 5.8 shows cysteine 
residues in CD81 and Claudin-1 used in the assay that are involved in binding CPM 
during protein unfolding, which is measured by a fluorescent read-out over time at 
40°C.  
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Protein sequence for CD81 palmitoylation null mutant: 
M S G V E G A T K A I K Y L L F V F N F V F W L A G G V I L G V A L W 
L R H D P Q T T N L L Y L E L G D K P A P N T F Y V G I Y I L I A V G 
A V M M F V G F L G A Y G A I Q E S Q A L L G T F F T C L V I L F A C 
E V A A G I W G F V N K D Q I A K D V K Q F Y D Q A L Q Q A V V D D D 
A N N A K A V V K T F H E T L D C C G S S T L T A L T T S V L K N N L 
C P S G S N I I S N L F K E D C H Q K I D D L F S G K L Y L I G I A A 
I V V A V I M I F E M I L S M V L A A G I R N S S V Y G G G H H H H H 
H Stop 
 
 
Figure 5.8: Cysteines available in CD81 and Claudin-1 for CPM reactivity. Temperature 
induced protein unfolding of CD81 or Claudin-1 causes embedded cysteine residues to be 
exposed to CPM reactivity, which is measured as fluorescence emitted over time. a) Mutant 
CD81 protein sequence highlighting putative palmitoylation residues mutated from Cys to Ala 
(alanine residues are blue and bold) (Jamshad et al., 2008). Cysteines remaining for CPM 
reactivity are in TM 3 and highlighted in yellow (C97) and green (C104). Cysteines involved in 
disulphide bonds are highlighted in red and found in the LEL. b) CD81 showing TM3 cysteines 
(yellow C97) and green (C104) and those involved in the two disulphide bonds in the LEL. C) 
WT Claudin-1 showing cysteines embedded in TM4 (black stars), C175, C183 and C184.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) c) 
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5.4.1 CD81 thermal stability in detergent solutions 
 
Optimising the detergent used to maintain solubility and stability is imperative for a 
recombinant membrane protein. The CPM assay was used to assess the stability of 
CD81 in different detergents as aggregation issues were apparent for CD81 in DDM. 
All detergents were tested at 3 critical micelle concentration (CMC) in buffer; 20mM 
Tris, pH7.5, 150mM NaCl, and using 8µg total CD81 for each condition. Buffer and 
protein were allowed to equilibrate at room temperature for ten minutes before addition 
of CPM and subsequent incubation at 40°C for 180 minutes, measuring the 
fluorescence read-out every 5 minutes in a 96-well spectrofluoremeter. Using the raw 
data from each time point, the fraction of folded protein was calculated using the 
highest fluorescent score for each test detergent condition as the ‘maximal unfolded 
state’. An exponential one phase decay curve was fitted, in order to deduce the 
unfolding half life in minutes. 
The results shown that all detergents tested were more stabilising than DDM (see figure 
5.9), which correlated well with observations that CD81 aggregated in this detergent. 
CD81 shows improved stability in smaller detergents such as β-OG (292 Da) resulting 
in a half life of 19.5 min in comparison to larger detergents such as DDM (511 Da) with 
a half life of only 9.6 min (figure 5.9b). Furthermore, the addition of cholesteryl 
hemisuccinate (CHS) with β-OG results in further stability of CD81 (mean half life 25 
min). β-OG + CHS was found to be significantly more stabilising as compared to 
DDM, UDM and DM alone and also when compared to β-OG and CYMAL6 alone, but 
the latter did not reach statistical significance (figure 5.9b). Cholesterol has previously 
shown importance in its contribution to stability and function of tetraspanins in the 
mammalian plasma membrane (Harris et al., 2010) and also stability to recombinant 
CD81 when in complex with Claudin-1 (Bonander et al., 2013).  
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Figure 5.9: CD81 thermal stability in detergent solutions. 8µg of purified CD81 was 
incubated with different detergents at 3 critical micelle concentration (CMC) in buffer (20mM 
Tris, pH 7.5, 150mM NaCl) for 10 minutes at room temperature prior to adding CPM and 
incubating at 40°C for 180 minutes. Using a spectrofluoremeter, measurements were recorded 
every 5 minutes and the raw data for each condition were converted to a fraction of folded 
protein, using the highest fluorescence value reached for that condition as ‘maximal unfolded 
protein’. a) Representative exponential one phase decay curve. b) The mean unfolding half life 
in minutes for n=3. ANOVA was performed followed by a Tukey’s multiple comparison test.  
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DM was used for CD81 solubilisations since it had shown evidence of extracting higher 
yields of CD81 in comparison to β-OG (0.64 mg/ml and 0.29 mg/ml in the column 
eluate, respectively). Also, a larger pellet was observed after the β-OG solubilisation 
ultracentrifugation step in comparison to DM solubilised material suggesting that DM is 
able to extract CD81 more efficiently than β-OG. 
During the purification procedure CD81 was exchanged into β-OG with CHS or left in 
DM. Samples collected from solubilisation through to purification are shown on a gel in 
figure 5.10. It can be seen that CD81 exists predominantly in a monomer and dimer in 
both detergents (lane 7 and 11 in figure 5.10). Furthermore, in contrast to CD81 in 
DDM, the ability to concentrate CD81 in β-OG or DM was achieved without protein 
aggregation to concentrations of 9 mg/ml and 13 mg/ml, respectively. The ability to 
concentrate a membrane protein without aggregation issues suggests a more stable 
protein preparation, therefore an improvement in comparison to using DDM (seen 
earlier). Since we had CD81 at reasonably high concentrations, we next used the 
samples for crystallisation trials and analysis using size-exclusion chromatography 
coupled to a multi-angle light scattering detector system (SEC-MALS).  
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Figure 5.10: CD81 solubilisation and purification in β-OG+CHS and DM. CD81 was 
solubilised from yeast membranes using 1 PBS, 150mM NaCl, 10% glycerol, 20mM 
imidazole and 1% DM for 2h at 4°C. After binding solubilised material to nickel resin for 1h at 
4°C the column resin was washed in 30mM and 40mM imidazole followed by elution in 
250mM imidazole using either a DM buffer or β-OG+CHS buffer (3X CMC). CD81 was then 
concentrated using 50kDa cut off concentrating device (Sartorius) and reached concentrations 
of 9mg/ml in OG+CHS  (lane 7) and 13mg/ml in DM (lane 11). Samples from each stage of 
solubilisation and purification were run on an SDS-gel and developed using Instant blue 
(Expedeon).  
 
 
Sample Solubilisation/purification fraction run on 
gel 
1 Pre-ultracentrifugation spin (unsolubilised 
material) 
2 Post ultracentrifugation spin (solubilised 
material) 
3 Flow through (unbound to column resin) 
4 30mM imidazole wash (OG+CHS) 
5 40mM imidazole wash (OG+CHS) 
6 Elution (OG+CHS) 
7 Concentrated CD81 in OG+CHS  
(9 mg/ml) 
8 30mM imidazole wash (DM) 
9 40mM imidazole wash (DM) 
10 Elution (DM) 
11 Concentrated CD81 in DM (13 mg/ml) 
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5.4.1.1 Crystallisation trials for CD81 
 
Using CD81 purified in DM (13 mg/ml) and in β-OG+CHS (9 mg/ml) crystallisation 
plates were set up, guided by James Birch (MPL). CD81 samples were spun down to 
remove any particulate matter. The crystallisation screen used two 96 well plates, 
MemGold and MemGold 2 (Molecular Dimensions) which encompass a range of 96 
conditions each with varying pH, PEGs and salt additives based on crystallisation 
conditions taken from the Protein Data Bank. This aims to find a condition for 
crystallisation that is suited to the protein target. A Mosquito lipidic cubic phase (TTP 
Labtech) was used to automate the delivery of 100nl of CD81 protein sample to 100nl 
of each buffer in both 96 well plates (either MemGold or MemGold2). The 2 plates 
were then incubated at 20°C and after 2-3 weeks crystals had formed, but were later 
found not be CD81 crystals as confirmed by Isabel Moraes (MPL). Therefore, at this 
point it was concluded that further optimisation regarding preparation of purified CD81 
was required before repeating this process again. 
 
5.4.1.2 SEC-MALS analysis of CD81 
 
SEC-MALS is a useful method to analyse a protein sample regarding the size of a 
protein-detergent complex, the ratio between how much is protein and how much is 
detergent and also the level of free detergent in a sample and its molecular weight. The 
MALS part of the system is composed of a low-angled light scattering and right angled 
light scattering detectors. The system includes a refractive index (RI) detector and an 
ultraviolet light detector (information from MPL). CD81 were processed using SEC-
MALS by Matthew Jennions (MPL).  
CD81 purified in DM at 1mg/ml was taken and analysed using SEC-MALS in order to 
assess the effect of two different buffers on CD81 homogeneity, the size of protein-
detergent complexes and the level of excess detergent in the sample. Large levels of 
free detergent in comparison to the level seen in protein-detergent complexes are not 
typically optimal for crystallisation trials.  
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The first buffer was identical to that used during nickel resin purification, 1 PBS, 
150mM NaCl, 10% glycerol, 250mM imidazole and 3 CMC DM, whilst the second 
buffer was composed of 20mM Tris, pH 7.5, 150mM NaCl and 3 CMC DM.  
The SEC-MALS trace given for CD81 in the PBS buffer (see figure 5.11) shows that 
the protein-detergent complex is predominantly a dimer with a molecular weight of ~ 
140 kDa (see purple line, peak 3, figure 5.11). Potentially the glycerol and high salt 
content of the buffer may be pushing the equilibrium to a CD81 dimer. There is also a 
much larger oligomer present that is ~570 kDa (peak 2 purple trace, figure 5.11). The 
refractive index trace (red trace) represents the level of detergent present. The trace in 
figure 5.11 suggests that there is no detergent present in the oligomer complex but there 
is in the dimer protein-detergent complex. The CD81 oligomer may have formed due to 
the lack of detergent surrounding the CD81 molecules. It is also clear from the 
refractive index (red trace) that there is excess detergent present in the protein sample 
since the level of excess detergent is higher (indicated by * in figure 5.11) than that 
present in the dimeric detergent-protein complexes and so this particular sample would 
be predicted as non-optimal for crystallisation trials because of the crystallising 
propensity of detergent themselves, which is likely to have occurred in the previous 
crystallisation trial. 
The SEC-MALS trace (see figure 5.12), which used a Tris buffer shows that there are 
two CD81 species present, a dimer (~110 kDa, peak 2) and a monomer (~53 kDa, peak 
3) involved in protein-detergent complexes. Again, it is shown by the refractive index 
that the excess free detergent present is much higher than detergent involved in protein-
detergent complexes (see *, figure 5.12). Optimally, free detergent should have a lower 
level than that seen in protein-detergent complexes and may explain why crystallisation 
trials were unsuccessful in this attempt. DM was used in this sample at 3 CMC, 
therefore future work could try using CMC values lower than this, although not 
reducing lower than 1 CMC (advice from Isabel Moraes, MPL). Also, CD81 could be 
concentrated using a 100 kDa cut off device rather than 50kDa cut off in order to aim 
towards a more homogenous CD81 preparation. Since CD81 buffers used thus far had 
not been optimised for tetraspanin stability, investigations next explored all solution 
components using the CPM thermal stability assay.  
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Figure 5.11: SEC-MALS analysis of CD81 in a PBS buffer. Purified CD81 (1mg/ml) was injected into a SEC-MALS system equilibrated with 1 
PBS, 150mM NaCl, 10% glycerol, 250mM imidazole and 3 CMC DM. The purple trace represents ultra violet (UV) (280nm) detecting the absorption 
of protein present in the sample, detergent show negligible UV signal. The red trace represents the refractive index (RI) which detects both protein and 
detergent in solution. The difference between RI and UV allows estimation of the molecular weight of the protein involved in protein-detergent 
complexes. The run was executed by Matthew Jennions (MPL). UV peaks 1, 2 and 3 are shown in the figure. Excess detergent present in the sample 
(*). 
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Figure 5.12: SEC-MALS analysis of CD81 in a tris buffer. Purified CD81 (1mg/ml) was injected into a SEC-MALS system equilibrated with 20mM 
Tris, pH 7.5, 150mM NaCl and 3 CMC DM. The purple trace represents ultra violet (UV) (280nm) detecting the absorption of protein present in the 
sample, detergent show negligible UV signal. The red trace represents the refractive index (RI) which detects both protein and detergent in solution. 
The difference between RI and UV allows estimation of the molecular weight of the protein involved in protein-detergent complexes. The run was 
executed by Matthew Jennions (MPL). UV peaks 1, 2 and 3 are shown in the figure. Excess detergent present in the sample (*).
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5.4.2 Effect of buffer ionic strength on CD81 thermal stability 
 
In order to determine if ionic strength has an effect on CD81 stability, CD81 was 
purified in DM and resuspended in buffer containing 20mM Tris, pH 7.4, 0.26% DM 
and increasing concentrations of NaCl from 100mM to 1M. Buffer and 8µg total 
protein were allowed to equilibrate at room temperature for ten minutes before addition 
of CPM and subsequent incubation at 40°C for 180 min, measuring the fluorescence 
read-out every 5 min.  
As shown in figure 5.13, the NaCl concentration did not have a significant effect on 
CD81 stability. 100mM NaCl gave the highest mean unfolding half life (20.24 ± 1.80 
min). When the NaCl concentration was increased up to 1000mM, the mean unfolding 
half life for CD81 decreased (17.55 ± 2.97 min), although it was not significantly 
different to 100mM NaCl. These data suggest that the stability of CD81 does not differ 
in solutions containing increasing NaCl concentrations from 100-1000Mm.  
 
 
 
 
 
 
Figure 5.13: Effect of buffer ionic strength on CD81 thermal stability. 8µg of purified 
CD81 was incubated with increasing concentrations of NaCl, 100mM-1M in buffer (20mM 
Tris, pH 7.5, 0.26% DM) for 10 min at room temperature prior to adding CPM and incubating 
at 40°C for 180 min. Using a spectrofluoremeter, measurements were recorded every 5 minutes 
and the raw data for each condition were converted to a fraction of folded protein, using the 
highest fluorescence value reached for that condition as ‘maximal unfolded protein’. a) 
Representative exponential one phase decay curve. b) The mean unfolding half life in minutes 
for n=2 (using 2 different protein preparations). ANOVA was performed followed by a Tukey’s 
multiple comparison test.  
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5.4.3 Effect of glycerol on CD81 thermal stability 
 
Glycerol included in solubilisation and purification buffers can be used to stabilise 
protein structure (Alexandrov et al., 2008). Tetraspanin stability with or without 
glycerol has not been shown before using a thermal stability assay, therefore glycerol 
was investigated using 0, 10, 20 and 30% glycerol in buffer (20mM Tris, pH 7.5, 
150mM NaCl, 0.26% DM). 8µg total protein was added in each buffer condition and 
left to incubate for ten minutes before exposing to CPM and recording fluorescence 
measurements every 5 minutes at 40°C.  
CD81 in the presence of glycerol has increased stability in comparison to without (see 
figure 5.14). CD81 in buffer without glycerol resulted in a mean unfolding half life of 
19.29 ± 0.39 minutes in comparison to 24.71 ± 1.66 minutes in the presence of 10% 
glycerol. This indicates that glycerol may increase the thermal stability of purified 
CD81, although the result did not reach statistical significance. Increasing the glycerol 
concentration to 20 and 30% did not make a significant difference when compared to 
10%, and so it can be concluded that 10% glycerol provides CD81 with sufficient 
stability. 
Although this experiment does not provide evidence as to why glycerol improves the 
stability of CD81, it has been previously found that glycerol reduces a protein’s ability 
to undergo conformational changes and therefore stabilises the native protein structure 
(Tsai et al., 2000). Therefore, glycerol may improve CD81 thermal stability as shown 
here by reducing conformational changes in the extracellular loop domains for example.  
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Figure 5.14: Effect of glycerol on CD81 thermal stability. 8µg of purified CD81 was 
incubated in buffer (20mM Tris, pH 7.5, 150mM NaCl, 0.26% DM) with or without glycerol (0, 
10, 20 and 30%) for 10 min at room temperature prior to adding CPM and incubating at 40°C 
for 180 min. Using a spectrofluoremeter, measurements were recorded every 5 min and the raw 
data for each condition were converted to a fraction of folded protein, using the highest 
fluorescence value reached for that condition as ‘maximal unfolded protein’. a) Representative 
exponential one phase decay curve. b) The mean unfolding half life in minutes for n=3 (using 2 
different protein preparations). ANOVA was performed followed by a Tukey’s multiple 
comparison test.  
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5.4.4 The influence of buffer composition and pH on CD81 thermal stability 
 
The buffer composition and pH can have a significant effect on protein stability as 
shown previously for the human apelin receptor, a GPCR family member (Alexandrov 
et al., 2008). We next investigated the stability of CD81 in different buffers in a range 
of pH values between 6.5- 8.3. Buffers at different pH values were incubated with 8µg 
total CD81 for ten minutes before exposure to CPM and fluorescence recorded over 
time at 40°C.  
The results demonstrated that CD81 has increased stability at lower pH (~6.5- 7) (see 
figure 5.15). This trend appeared in all three different buffers tested, which were Tris, 
HEPES and MOPS. In each buffer, when the pH was increased, the stability of CD81 
decreased as shown by the fraction of folded protein (figure 5.15 a-e). The least 
favourable combination for CD81 stability was MOPS at pH 8.3 which gave a mean 
unfolding half life of 13.86 ± 3.04 minutes (figure 5.15 e). In comparison, MOPS at pH 
6.5 provided the highest level of stability out of the conditions tested, since the mean 
unfolding half life for CD81 was 22.51 ±4.41 minutes, although this result was not 
shown to be statistically significant. These data may suggest that the pH rather than the 
buffer composition has more influence on CD81 stability.  
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Figure 5.15: The influence of buffer composition and pH on CD81 thermal stability. 8µg 
of purified CD81 was incubated in buffer (20mM buffer, pH 6.5-8.3, 150mM NaCl, 0.26% 
DM) for 10 min at room temperature prior to adding CPM and incubating at 40°C for 180 min. 
Using a spectrofluoremeter, measurements were recorded every 5 min and the raw data for each 
condition were converted to a fraction of folded protein, using the highest fluorescence value 
reached for that condition as ‘maximal unfolded protein’. a-d) Representative exponential one 
phase decay curves for a) Tris pH 7-8, b) HEPES pH 7-7.6, c) MOPS pH 6.5-8.3 and d) all 
three buffers tested at the lowest pH. e) The mean unfolding half life in minutes for n=2 (using 
2 different protein preparations). Dotted line indicates the decrease in unfolding half life of 
CD81 as the pH is increased. ANOVA was performed followed by a Tukey’s multiple 
comparison test.  
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5.4.5 Effect of cholesteryl hemisuccinate (CHS) on CD81 and Claudin-1 
thermal stability 
 
DM was used to extract CD81 from P. pastoris membranes, since it was found to 
extract more CD81 than β-OG. Since initial findings, using the CPM assay, suggested 
CHS increased the thermal stability of CD81 in β-OG (see figure5.9), we then 
investigated further to determine if the same applied to DM and CHS. Also, we 
investigated if the amount of CHS present (0.1% and 0.2% (v/v)) with DM or OG had 
any effect on protein stability using the CPM assay. CHS was previously found to 
stabilise the CD81-Claudin-1 complex (Bonander et al., 2013) as shown by dynamic 
light scattering. Therefore, we investigated using the CPM assay whether this previous 
finding was due to a CD81-specific CHS stabilising effect or whether CHS has a 
stabilising influence on Claudin-1 also. To test this, Claudin-1 was extracted and 
purified using Fos-10 and incubated with two different concentrations of CHS (0.1% 
and 0.2%).  
Results shown that CD81 stability is significantly increased when DM is used in 
combination with 0.2% CHS, as the mean unfolding half life for CD81 in DM alone is 
16.33± 1.13 minutes in comparison to 24.51 ± 1.25 minutes when DM and 0.2% CHS is 
added (see figure 5.16a). The same trend applied to the stability of CD81 when in β-OG 
with or without 0.2% CHS. The mean unfolding half life of CD81 in β-OG alone was 
18.68 ± 1.19 minutes, in contrast to a significant increase for β-OG with 0.2% CHS at 
24.26 ± 1.62 minutes (see figure 5.16a). The stability CHS provides CD81 appears to be 
concentration dependent since unfolding half life mean values slightly increase from 
0.1% to 0.2% CHS in both DM and β-OG. These data suggest that the stability 
improvement of CD81 is CHS dependent, but also with some contribution to which 
detergent is used, with β-OG providing more stability than DM (see figures 5.16).  
Results also demonstrated that CHS has a stabilising effect on Claudin-1 (figure 5.16b). 
When Claudin-1 is in Fos-10 alone the mean unfolding half life is 16.64 ± 0.23 minutes. 
Claudin-1 is further stabilised by the presence of CHS, with both concentrations 0.1% 
(21.16 ± 1.09 minutes) and 0.2% (22.2 ± 0.10 minutes) being a significant increase as 
compared to Fos-10 alone (see figure 5.16b). Although in this case, for Claudin-1, CHS 
does not appear to be providing protein stability in a concentration dependent manner, 
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as there is not a great difference between mean unfolding half life for 0.1% and 0.2% 
CHS (21.16 and 22.2 minutes, respectively).  
It seems apparent that both CD81 and Claudin-1 independently benefit, regarding 
protein structure stability, in the presence of CHS. These data may explain why 
cholesterol in mammalian membranes is crucial for the CD81-Claudin-1 complex to 
carry out HCV entry, since depletion of cholesterol inhibits HCV infection (Harris et 
al., 2010). Furthermore, it provides more evidence as to why CHS prolongs the stability 
of recombinant forms of the CD81-Claudin-1 complex seen previously (Bonander et al., 
2013) and that both membrane proteins benefit from CHS addition to reduce protein 
unfolding and increase stability.  
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Figure 5.16: Effect of CHS on CD81 and Claudin-1 thermal stability. a) CD81 
representative exponential one phase decay curve and the mean unfolding half life in minutes. 
6-8µg purified CD81 was incubated with DM or β-OG with/without 0.1% or 0.2% CHS in 
buffer (20mM Tris, pH 7.5, 150mM NaCl). b) 4 µg purified Claudin-1 incubated in Fos-10 
with/without 0.1 or 0.2% CHS in buffer. Solution conditions were incubated in a 96-well plate 
for 10 min at room temperature prior to adding CPM and incubating at 40°C for 180 min. Using 
a spectrofluoremeter, measurements were recorded every 5 min and raw data converted to a 
fraction of folded protein, using the highest fluorescence value reached for that condition as 
‘maximal unfolded protein’. ANOVA was performed followed by a Dunnett’s multiple 
comparison test, n=5 CD81, n=2 Claudin-1. One batch of CD81 was produced and purified for 
CPM analysis in collaboration with Dr Justin MacDonald (University of Calgary).  
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 5.4.6 Optimised conditions for CD81 stability 
 
The CPM thermal stability assay was able to predict which solution conditions may be 
suitable for CD81 and possibly other tetraspanin family members to remain stable and 
folded in solution. The optimised conditions that came out of the thermal stability 
assessments are summarised in table 5.1, along with those conditions that were initially 
used but were unsuccessful due to CD81 aggregation.  
The optimised conditions will now be used in purification buffers and tested in 
subsequent SEC-MALS analysis and crystallisation trials of CD81. The detergent DM 
could be used for the initial extraction of CD81 from yeast membranes (since it extracts 
a higher level than β-OG), but then CD81 would be exchanged into β-OG during 
purification procedures. Also, we have previously noted difficulty in concentrating 
CD81 in β-OG plus CHS using a 50 kDa cut off concentration device (Sartorius), 
therefore in future preparations the protein may be concentrated then subsequently 
mixed with CHS for stability purposes. 
 
Table 5.1: Optimised thermal stability conditions for CD81. The table shows buffer 
components that were tested in a CPM thermal stability assay. The initial conditions caused 
CD81 to aggregate in solution. The optimised conditions show solution components that result 
in the most thermally stable form of CD81 according to a CPM assay and will be tested in 
protein sample analytical methods such as SEC-MALS and used for CD81 crystallisation trials.  
 
 
 
 
 
 
 
 
 
 
 
Sample 
component 
Initial conditions Optimised condition 
Detergent DDM (3x CMC) OG (3x CMC) 
NaCl 150mM 100mM 
Glycerol 10% 10% 
Buffer and pH 1X PBS, pH 7.4 MOPS, pH 6.5- 7 
Lipid content None 0.2% CHS 
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6. Discussion 
 
The CD81-Claudin-1 receptor complex is necessary for HCV entry and infection of 
hepatocytes, but the normal biological function of such complexes remains to be 
determined. The hetero- and homo- interactions involving all four HCV receptors; 
CD81, Claudin-1, SR-B1 and Occludin and a high resolution structure of any full length 
HCV receptor component remain elusive. The focus of this thesis was to extend 
knowledge on how two of the HCV receptor components, CD81 and Claudin-1, interact 
via protein domains such as extracellular loops and TM domains using full-length 
membrane proteins. Yeast was used as the experimental host to characterise the role of 
specific amino acids in the interaction of hetero- and homo-oligomers and also to 
produce recombinant forms of CD81 and Claudin-1 to move towards understanding the 
3D structure of the HCV receptor complex, which may in turn help to direct future 
structure-aided anti-viral drug design.  
A yeast split-ubiquitin assay was optimised to quantify membrane protein-protein 
interactions of CD81 and Claudin-1 in the absence of other HCV receptor components 
present in higher eukaryotic cell models. This enabled analysis of the specific role of 
amino acid residues previously known and those predicted here in CD81 homo- and 
hetero-oligomerisation. CD81 LEL residues and TM1 residues have been shown in this 
thesis to play a part in both CD81-Claudin-1 interactions and also in CD81-CD81 
interactions, which contribute to an understanding of the complex association of the 
4TM membrane proteins with each other. Furthermore, this thesis explored CD81 
thermal stability under different solution conditions that may be used in crystallisation 
attempts, the optimised thermal stability conditions found here may also apply to other 
tetraspanin family members for which no full length member has had a high resolution 
structure solved to date. Thermal stability studies showed that cholesterol plays an 
important role in the structural integrity of both CD81 and Claudin-1 and may 
contribute in future to obtain the 3D structure of CD81 alone or in complex with 
Claudin-1. Table 6.1 presents the four main objectives of this thesis, what was achieved 
and in which direction future work may go from these findings. This chapter will 
discuss each of the four objectives in turn and draw general conclusions about the main 
findings of the thesis.  
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Thesis objectives Achievements Main outcomes Future work 
1) Optimisation of a 
yeast split-ubiquitin 
Dualmembrane system 
assay to detect CD81-
Claudin-1 
heterodimers and 
CD81 homodimers in 
yeast membranes. 
 
 Optimal vector selection (Table 
3.2/3.3) to determine CD81 
homo- and hetero- interactions 
with Claudin-1 (Figure 3.6), 
expressed in yeast membranes 
(Figures 3.9, 3.10).  
 High throughput measurement 
of protein interactions using 
growth reporter genes in a 96-
well plate format (Figure 3.12) 
 Capability to detect 
specific CD81-CD81 and 
CD81-Claudin-1 
interactions in the yeast 
membrane.  
 Potential to measure 
protein interactions in a 
high-throughput manner 
using yeast growth curve 
analysis.  
 
 Using a 96-well plate 
format to measure 
yeast growth reporter 
gene activation, the 
split-ubiquitin assay 
can be used in a high-
throughput manner, 
including the use of 
cDNA libraries to 
screen for novel 
interaction partners.  
2) Analysis of CD81 
LEL and TM1 amino 
acid residues in the 
full length interaction 
interface of the CD81-
Claudin-1 complex 
and a comparison of 
the binding interface 
of CD81 homo- and 
hetero-interactions. 
 
   CD81 LEL mutants T149A, 
E152A and T153A reduce 
Claudin-1-CD81 interactions as 
shown by yeast colony counts 
(figure 4.5) and growth curves 
(figure 4.6).  
 CD81 TM1 is involved in 
Claudin-1- CD81 interactions as 
residues L14A, F17A and C89A 
knock-down interactions (figure 
4.8).  
 CD81 homo-oligomerisation is 
reduced by E152A and T153A 
in the LEL. In TM1 residue 
L14A and L14A-F17A reduce 
CD81-CD81 interactions 
(Figure 4.10) 
 CD81 LEL mutants 
validate the yeast split-
ubiquitin assay, since 
shown to reduce CD81-
Claudin-1 interaction and 
HCV entry previously 
(Davis et al., 2012). 
 CD81 TM1 is involved in 
CD81-Claudin-1 
interactions. 
 Common residues reduce 
protein interactions for 
CD81-Claudin-1 and 
CD81-CD81 interactions; 
in CD81 LEL; E152 and 
T153 and in TM1; L14A 
(possibly F17A). 
 Investigation into 
CD81 TM1 residues, 
L14, F17 and C89 
regarding their 
functional 
involvement in HCV 
entry into hepatocytes.  
 
 Further repeated 
experiments for CD81-
CD81 interactions to 
determine if F17 and 
C89 are important in 
homo-oligomerisation.  
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Table 6.1: Thesis summary. An overview of thesis objectives; how each one was achieved by referring to specific figures, the main outcomes from the 
achievements and what future work will be done as a result of the findings. 
3) Prediction of CD81 
and Claudin-1 TM 
residues involved in 
the interaction as 
guided by molecular 
modelling and tested 
in a split-ubiquitin 
yeast assay. 
 
 Residues in CD81 TM1 
predicted to be on the CD81-
Claudin-1 interface are; F21, 
G25, I28 and L35 (figure 4.11) 
 CD81 mutants tested in the 
CD81-Claudin-1 interaction that 
result in reduced protein 
interactions are I28A and L35A 
(figure 4.12 and 4.13). 
 
 
 Experimental data 
demonstrate that the full 
length CD81-Claudin-1 
molecular model can be 
used to predict the TM 
binding interface. 
 The predicted CD81 
TM1 residues that 
knock-down CD81-
Claudin-1 could be 
investigated further 
regarding function in 
HCV entry. 
 Investigation of 
predicted TM1 
residues, found here 
using a molecular 
model, in CD81-CD81 
heterotypic 
interactions. 
4) Structural 
characterisation of full 
length recombinant 
CD81 by means of 
improvements to 
solubilisation, 
purification and 
stabilisation 
procedures. 
 
   Expression, solubilisation and 
purification of full length CD81 
using P. pastoris as a 
recombinant host (figures 5.2-
5.6).  
Thermal stability investigation 
of CD81 for optimisation of 
crystallisation trials (figure 5.9 
and 5.13- 5.16). 
 CD81 was produced to 
mg quantities in a 
functional and correctly 
folded state.  
 CD81 can be solubilised 
in many detergents but 
optimal detergent and 
buffer conditions were 
optimised using a thermal 
stability assay, which 
shows cholesterol 
stabilises the structure of 
CD81. Optimisation steps 
should lead to future 
crystallisation success.   
 Assessment of 
optimised CD81 
thermal stability 
conditions will be 
analysed using SEC-
MALS and other 
techniques to 
determine the 
homogeneity and the 
level of excess 
detergent compared to 
in protein-detergent 
complexes, this will 
lead to crystallisation 
trials of CD81. 
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6.1 The yeast split-ubiquitin Dualmembrane system assay can be optimised to 
detect CD81-Claudin-1 heterodimers and CD81 homodimers in the yeast 
membrane. 
 
Previous studies that monitored CD81-Claudin-1 interactions used mammalian cells 
(293-T cells) and FRET analysis (Davis et al., 2012). Yeast systems to study 4TM 
membrane protein interactions have been less commonly used with no other study 
assessing CD81-Claudin-1 interactions in vivo using yeast. Therefore, optimisation was 
required to ascertain if specific interactions could be measured and provide reliable 
data. The orientation of the split ubiquitin fusion partner with CD81 or Claudin-1 N- or 
C- terminus was important for protein interaction detection. For bait proteins a C- 
terminal fusion of Cub in combination with a prey protein N-terminal NubG fusion was 
optimal for both Claudin-1-CD81 interactions and CD81-CD81 interactions (see figure 
6.1 for a possible combination). This result may be due to the presence of a STE2 leader 
sequence at the 5’ end of bait vector CD81 and CLDN1 genes, which may have 
enhanced protein translation. In the absence of a STE2 leader sequence, other bait C-
terminal fusions were unsuccessful in showing a protein-protein interaction (refer to 
table 3.2/3.3). This was also the case for the prey protein fusion, it was required on the 
N-terminal end of CD81, if fused to the C-terminus, a protein-protein interaction was 
not detected (see table 3.2). This work was crucial for a successful assay, since once the 
correct protein fusions were chosen, the expressed proteins were characterised for 
specific expression in yeast membranes and showed evidence of specific CD81 homo- 
and hetero- interactions (see chapter 3).  
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Figure 6.1: Split ubiquitin fusion orientation using 4TM membrane proteins. Multiple 
combinations of Cub and NubG fusions were tested to determine the correct orientation to 
detect protein-protein interactions using the split-ubiquitin reporter gene system. Optimal 
vectors used expressed bait proteins with a 5’ end STE2 leader sequence and the Cub fusion on 
the C-terminus. Prey proteins (either CD81 or Claudin-1) were optimal when an N-terminal 
fusion was used for NubG. 
 
 
An informative feature of the split-ubiquitin assay was to show higher frequency of 
CD81 homo-oligomers than that of CD81 hetero-oligomers in vivo (see chapter 3, 
figure 3.7). This was demonstrated using a yeast spotting assay, where 10µl yeast 
culture is grown on an agar plate in serial dilutions. This approach showed that cells co-
transformed with CD81-CD81 would grow at higher dilutions than CD81-Claudin-1 
transformed cells on plates lacking histidine or adenine, suggesting higher frequency of 
homo-oligomer protein-protein interactions activated increased expression of HIS3 and 
ADE2 growth reporter genes. Previous studies have shown CD81 to associate with 
Claudin-1 at a ratio of 2:1 (Bonander et al., 2013) and so it may be that CD81 oligomers 
are predominant over CD81-Claudin-1 complexes as a minimum of a CD81 dimer is 
thought to be required for complex formation with Claudin-1 (Harris et al., 2010). This 
result may also demonstrate the function of tetraspanins as regulators at the membrane, 
binding to other interaction partners due to breaking away from higher order CD81 
oligomers (Hemler, 2005).  
 
Progress was made in chapter 3 regarding the way in which protein-protein interactions 
were quantitatively measured using reporter genes. Expression of the lacZ reporter gene 
was measured using a β-galactosidase substrate such as X-gal or FDG and both gave 
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signals for a specific protein-protein interaction by using positive and negative controls 
to interpret data (figure 3.8). Numerous studies in the literature have used the lacZ 
reporter for previous studies that monitor protein-protein interactions using similar 
assays as the split-ubiquitin approach shown here (Stagljar et al., 1998), (Hou et al., 
2010). Although the lacZ reporter is useful, it is advantageous to collect data from intact 
yeast cells in order to cut down on sample preparation time and on artefacts that may be 
introduced during cell lysis. The X-gal approach requires lysis of yeast cells for β-
galactosidase quantification but the FDG approach uses viable cells, although the 
substrate (FDG) is costly if used in large amounts. Due to these reasons, a growth curve 
assay approach was explored to measure OD546 yeast over time in a 96-well plate 
without using any substrates and using the activation of growth reporter genes HIS3 and 
ADE2 for the measurement of protein-protein interactions.  
 
This approach provided real-time protein interaction data over a 24-48 h period, which 
showed distinct differences between the positive control (using NubI), negative control 
(using NubG) and the CD81-Claudin-1 test condition (figure 3.10). It was appropriate 
to use this format to monitor homo- and hetero- interactions using WT and mutant 
proteins (chapter 4) as well as using the original approach of colony counts on selective 
agar plates. Previous studies including Toussaint et al., (2006) utilised yeast growth 
curves on a micro-scale (100µl volume) by assessing WT and DNA repair-deficient 
yeast strains to the treatment of DNA damaging agents such as ultraviolet light. The 
study found that generating data from yeast growth curves, in contrast to cell dilution 
spot test colony formation, was much more sensitive to phenotypic differences found 
with certain cytotoxic compounds and was more efficient for high-throughput screening 
(Toussaint et al., 2006). Other studies have used growth curves for real-time monitoring 
of peptide-protein interactions. For example, Rid et al., (2013) used the yeast two-
hybrid system with a peptide library to find novel interaction partners for a vitamin-D 
receptor.  
 
WT and mutant membrane protein interactions monitored in real-time using growth 
curves (as demonstrated in chapter 3 and 4 of this thesis) has not been performed in the 
same way previously in the literature, as far as we are aware. Therefore, this approach 
may be useful for defining the binding interface or finding novel interaction partners of 
other membrane proteins. It is important to note that using the DUALmembrane system 
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to define a protein binding interface may be possible, but a high number of biological 
replicates may be required to show a statistically significant result, as found in this 
study. This may be easier to achieve using yeast growth curves on a 96-well plate in 
contrast to counting yeast colonies on agar plates. 
 
Even though the yeast split ubiquitin method was used successfully here to study the 
CD81-Claudin-1 interaction, there are limitations to this method which must be 
considered. A well known limitation of this method includes the high frequency of false 
positive read-outs for a protein-protein interaction (Sjohamn and Hedfalk, 2014). For 
this reason, multiple controls must be included to ensure that a genuine interaction pair 
is being monitored. Alternative techniques that could be used to support data generated 
using this method include FRET in a mammalian cell system and DLS using 
recombinant CD81 and Claudin-1.  
 
6.2 CD81 LEL and TM1 amino acid residues are involved in the interaction with 
Claudin-1 and share common residues with CD81 homotypic interactions. 
 
Previous work by Davis and colleagues (2012) found that CD81 LEL residues T149, 
E152 and T153 when mutated to alanine reduced CD81 FRET with Claudin-1 and also 
impaired virus entry. The CD81 mutants had no effect on CD81 interaction with HCV 
E2 which suggested that the residues play a distinct part in Claudin-1 association and 
viral entry. The study predicted residues in CD81 LEL would associate with Claudin-1 
ECL1 in a region between 63-66 using a molecular model of the loop regions (Davis et 
al., 2012). Additionally it was apparent that the LEL of CD81 is required to bind HCV 
E2 and Claudin-1 to result in HCV entry, forming an HCV E2-CD81-Claudin-1 ternary 
complex. Residues outside T149, E152 and T153 are responsible in the binding of HCV 
E2; therefore there are distinct functional regions in CD81 LEL (Drummer et al., 2002). 
CD81 LEL loop residues (T149, E152 and T153) were investigated in this thesis 
(chapter 4) to determine CD81-Claudin-1 associations in the yeast split-ubiquitin assay. 
This was necessary to indicate if differences exist when CD81-Claudin-1 are expressed 
and associate in a yeast plasma membrane rather than a mammalian host. Furthermore, 
yeast is a lower eukaryote and does not express other HCV receptor components or 
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CD81/Claudin-1 homologues so it was interesting to see if this may have an effect on 
CD81-Claudin-1 associations.  
Growth on agar plates and subsequent colony counts revealed that CD81 mutant T149A 
showed a significant decrease in association with Claudin-1 as compared to WT (figure 
4.4), whilst residues E152A and T153A only showed a significant decrease when 
observed using yeast growth curves (figure 4.5). In both approaches (colony counts and 
growth curves) it was apparent by mean values that all three CD81 mutants show a 
knock-down in their interaction with Claudin-1 in comparison to WT CD81, which is in 
agreement with current literature that used FRET and mammalian cells to measure the 
heterotypic protein interaction (Davis et al., 2012). These data would suggest that the 
binding interface of CD81-Claudin-1 can be investigated reliably using a yeast split-
ubiquitin assay and site-directed mutagenesis. Furthermore, such findings suggest 
CD81-Claudin-1 is a highly specific and direct interaction likely to not require 
additional HCV receptor components or other proteins that are expressed in mammalian 
cells but are absent in yeast.  
Residues in the LEL E152A and T153A also reduced CD81-CD81 interactions, as they 
did for CD81-Claudin-1 interactions, with T153A showing a significant reduction as 
compared to WT (figure 4.14). Interestingly, residue T149A did not show the same 
effect, but was more similar to WT CD81, although the mean value of T149A when 
data were normalised to internal controls was lower than WT (24.2% and 30.6%, 
respectively) and so increasing the number of experimental repeats may have shown 
this mutant to also knock-down CD81-CD81 interactions. Previous studies have 
suggested that CD81 LEL residues T149 and T153 may be involved in interactions with 
CD81 SEL, therefore are possibly involved in both homo- and hetero-oligomerisation 
of CD81 (Yalaoui et al., 2008). It is known that the SEL stabilises the conformation of 
the LEL, and CD81 expressed without the SEL shows reduced expression levels at the 
cell surface (Masciopinto et al., 2001). Previous findings may suggest reasons as to why 
mutant T153A caused a significant reduction in CD81-CD81 interactions, such as a 
reduction in LEL stability or that it is directly involved in putative homotypic 
interactions. Previous studies that focused on determination of the CD81 dimerisation 
binding interface used LEL recombinant soluble forms and found that mutants that 
affected LEL dimers did not show the same effects in the full length protein, therefore 
the orientation of the loops is likely to be different in the full-length protein (Drummer 
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et al., 2005).  
Expression analysis of CD81 mutants was performed on yeast total membranes by 
performing western blot analysis and anti-CD81 ELISA. This data provided evidence of 
1) total expression of mutant compared to WT and 2) the folded nature of CD81 and if 
it could bind specific anti-CD81 antibodies. If a CD81 mutant could bind CD81 
antibodies it was likely to be folded and not retained in the ER or Golgi, although 
further evidence of specific plasma membrane expression would guide the 
interpretation of mutant CD81-Claudin-1 interaction data as compared to WT CD81. 
Although, for the CD81-Claudin-1 interaction to be measured successfully using the 
DUALmembrane system the Cub and Nub moieties must be located on the cytosolic 
side of the plasma membrane in order to be cleaved by UBPs and for LexA-VP16 to 
translocate to the nucleus, hence, this signal indicates the location of a given interacting 
protein pair at the plasma membrane.  
After investigating CD81 LEL residues, we then set out to explore the role of TM 
domains of CD81 and their involvement in the CD81-Claudin-1 and CD81-CD81 
interaction. Our initial focus was to look at TM1 and TM2 since various studies had 
shown specific residues in tetraspanins to either be involved in HCV entry (residues 
N18 TM1 and C80 TM2, (Bertaux and Dragic, 2006) or form the interface of 
tetraspanin dimerisation (on CD9, residues L14, F17 and G80, (Kovalenko et al., 
2005)). After performing an alignment between CD9 and CD81, residues L14, F17 and 
C89 were chosen to mutate to alanine and test in both homotypic and heterotypic 
CD81-Claudin-1 interactions (see section 4.4.1 for a more detailed rationale for picking 
CD81 TM1 residues).  
Results showed that residues L14, F17, C89 have a role in CD81-Claudin-1 complex 
association, as when mutated to alanine, all significantly reduced the interaction. F17A 
did not result in a significant reduction, but data showed that the mean was reduced 
compared to WT and the double mutant L14A-F17A caused a larger knock-down than 
L14A alone, suggesting that F17A contributed to the reduction (see figure 4.7). These 
data revealed that there may be a link between tetraspanin dimerisation and tetraspanin-
Claudin-1 dimerisation binding interfaces. Kovalenko and colleagues (2005) predicted 
L14, F17 and G80 to be on the CD9 dimerisation interface and results from this current 
study suggest the corresponding residues in CD81 are involved in CD81-Claudin-1 
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binding. This may not only apply to CD81, but also for other tetraspanins that bind 
Claudin-1, since Claudin-1 has also shown evidence of associating with CD9 
(Kovalenko et al., 2007). Further work would be required to show if CD81 and CD9 
have a common binding interface with Claudin-1.  
To look further into the residues picked from the CD9 dimerisation study, we then 
tested them in CD81-CD81 interactions. CD81 TM1 mutants L14A and L14A-F17A 
demonstrated a significant reduction in CD81-oligomerisation as compared to WT 
CD81. Such findings are therefore in agreement with what was suggested to be 
involved in a tetraspanin dimerisation interface (Kovalenko et al., 2005). Furthermore, 
common residues that reduce CD81-Claudin-1 found in this study are responsible for 
reducing CD81 homotypic interactions. Residues F17A and C89A did not show 
significantly different results to WT for the CD81-CD81 interaction, which for CD81-
Claudin-1 had a more pronounced effect on reducing the interaction. Further 
experiments would be required to determine the role of F17 and C89 in CD81 
dimerisation.  
Kovalenko and colleagues (2005) suggest that the tetraspanin dimerisation interface 
involves conserved TM1 and TM2 residues and evidence points to TM3 and TM4 being 
involved in a second dimeric interface, contributing to the oligomerisation of 
tetraspanin dimers. Also predicted from the study was that the TM3/TM4 interface may 
be involved in heterologous protein-protein interactions as this is where residues are 
more variable and less conserved throughout the family. Data found here for CD81-
Claudin-1 suggests otherwise, since TM1 has a role in the heterotypic interaction; 
although TM1 mutants either have a direct effect on CD81-Claudin-1 or indirect due to 
the disruption of CD81-CD81 interactions. The distinction between which mechanism 
is correct is difficult to conclude from the results shown in chapter 4. Potentially 
combining specific mutations that are suspected to be on the CD81-Claudin-1 interface 
then producing recombinant proteins to analyse in a biophysical manner may provide 
further information on the oligomeric status of the 4TM proteins. In this thesis, we set 
out to learn more about the mechanism of how the mutants are causing a reduction in 
CD81-Claudin-1 interactions by using predictions from a molecular model (figure 6.2). 
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Figure 6.2: CD81-Claudin-1 complex model showing CD81 TM1 residues involved in 
Claudin-1 interactions. A CD81-Claudin-1 homology based model using CD81 full length 
homology model (PDB: 2AVZ) by Seigneuret (2006) with a Claudin-1 threading-based model 
generated and docked using Hex 8.0 by Dr Jonathan Mullins (Swansea University). CD81 TM1 
(yellow) shows residues L14, F17, F21, G25, I28 and L35 pointing outwards as a possible 
interaction interface with Claudin-1 TM2 (residues predicted to be involved are G87 and G91 in 
orange).  
 
Working in collaboration with Dr Mullins (Swansea University) we mapped the 
residues L14 and F17 on to a full length CD81 molecular model (Seigneuret, 2006) 
docked with a Claudin-1 threading-based model (see figure 6.2). The model showed 
that residues L14 and F17 face the same side of the helix pointing away from the CD81 
core. Since L14 is a branched chain bulky hydrophobic residue and F17 an aromatic 
bulky residue, they form a hydrophobic ridge. This hydrophobic region appears to fit 
appropriately into a groove on Claudin-1 TM2 (residues G87 and G91) (figure 6.2). The 
model also suggests that a branched chain residue, L83, on Claudin-1 TM2 may 
associate with residue G25 on CD81 TM1. The CD81-Claudin-1 complex model (figure 
6.2) suggests that the experimental reduction observed using L14A, F17A and L14A-
F17A mutants in the split-ubiquitin yeast assay is due to the mutation of CD81 TM1 
residues that directly interact with Claudin-1 TM2 residues. Future work may involve 
testing CD81 TM1 mutants in a HCV entry assay to determine if they have a role in 
viral entry due to their involvement in CD81-Claudin-1 interactions.  
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6.2.1 Position of key residues that interact within the extracellular domains 
in relation to the predicted packing of TM domains of CD81 and Claudin-1. 
 
The recent mouse Claudin-15 crystal structure (Suzuki et al., 2014) revealed the first 
extracellular loop contained an antiparallel beta sheet comprising of β1-β4 that was able 
to further interact with β5 located on the second extracellular loop. The beta sheet is 
further stabilised by a disulphide bridge found between C52 and C62, located on β3 and 
β4. This disulphide bridge is believed to be conserved across the family as the cysteines 
in these positions are highly conserved. The crystal structure also reveals that a short 
extracellular helix (ECH) found on the first extracellular loop prior to TM2 is essential 
for Claudin-15 homodimerisation (see figure 6.3). The packing of Claudin-15 
monomers within the crystal lattice may resemble tight junction strands. M68 found in 
the ECH of mouse Claudin-15 fits into a hydrophobic pocket in the adjacent Claudin-15 
monomer associating with residues found in TM3 and the second extracellular loop 
(residues F146, F147 and L158). Freeze fracture electron microscopy results shown that 
upon mutation of M68, F146 and F147 caused a disruption in tight junction strand 
assembly when mutated to charged or small residues (figure 6.3) (Suzuki et al., 2014).  
 
 
 
Figure 6.3 Identification of key residues involved in Claudin-15 oligomerisation via 
extracellular domains.  A and  B) A ribbon representation of a single row of Claudin-15 
monomers. C) High resolution view of the extracellular domain interaction site. D and E) 
Electrostatic potential surface of the interface on each monomer. Taken from Suzuki et al., 
(2014). 
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Mouse Claudin-15 and human Claudin-1 have been aligned. There is high conservation 
between the two family members (95% homology). The alignment shows that M68 in 
mouse Claudin-15 analogous residue in Claudin-1 is L70.  
 
humanClaudin-1        1 MANAGLQLLGFILAFLGWIGAIVSTALPQWRIY   33  
mouseClaudin-15       1 MSVA-VETFGFFMSALGLLMLGLTLSNSYWRVS   32  
 
humanClaudin-1       34 SYAGDNIVTAQAMYEGLWMSCVSQSTGQIQCKV   66  
mouseClaudin-15      33 TVHG-NVITTNTIFENLWYSCATDSLGVSNCWD   64  
 
humanClaudin-1       67 FDSLLNLSSTLQATRALMVVGILLGVIAIFVAT   99  
mouseClaudin-15      65 FPSMLALSGYVQGCRALMITAILLGFLGLFLGM   97  
 
humanClaudin-1      100 VGMKCMKCLEDDEVQKMRMAVIGGAIFLLAGLA  132  
mouseClaudin-15      98 VGLRCTNVGNMDLSKKAKLLAIAGTLHILAGAC  130  
 
humanClaudin-1      133 ILVATAWYGNRIVQEFYDPMTPVNARYEFGQAL  165  
mouseClaudin-15     131 GMVAISWYAVNITTDFFNPLY-AGTKYELGPAL  162  
 
humanClaudin-1      166 FTGWAAASLCLLGGALLCCSCPRKTTSYPTPRP  198  
mouseClaudin-15     163 YLGWSASLLSILGGICVFSTCCCSSKEEPATRA  195  
 
humanClaudin-1      199 YPKPAPS------------------SG-KDYV  211  
mouseClaudin-15     196 GLPYKPSTVVIPRATSDESDISFGKYGKNAYV  227  
 
 
Figure 6.4: Alignment between mouse Claudin-15 and human Claudin-1. Red residues 
show high conservation within alignment based on physicochemical properties of the amino 
acid, whereas orange residues show less conservation as assigned by T-Coffee. M68 and L70 
have been highlighted in white font on the appropriate protein. 
 
The alignment in figure 6.4 showed L70 in Claudin-1 to be homologous to M68 in 
Claudin-15. Given their similar hydrophobic nature the residues may perform the same 
functional role in Claudin homodimerisation. 
The role of L70 in Claudin-1 with CD81 interactions has not yet been investigated. 
However, highlighting this residue in our CD81-Claudin-1 full length model poses 
novel insight in how Claudin-1 and CD81 extracellular domains may interact.  L70 on 
the ECH of Claudin-1 is predicted to be in close proximity to the helix domain found in 
the LEL of CD81. In particular L70 is interacting with T153 and close to T149 and 
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E152 (see Fig.6.5 for relative positions). These residues have been highlighted as 
important for heterodimerisation by Davis et al., (2012) and in this thesis. This 
mechanism of interaction between the extracellular domains requires further 
investigation. Initial experiments may focus on L70 mutations to knock out the 
interaction. It is clear that this interface between CD81-Claudin-1 would competitively 
compete with Claudin-1-Claudin-1 interactions. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: Relative position of L70 of Claudin-1 to LEL of CD81. L70 on ECH of Claudin-
1 is highlighted as light blue. E152 (magenta), T149 (yellow) and T153 (green) located on the 
helix of LEL of CD81.  
 
Data presented in this thesis and the information provided by the Claudin-15 structure 
may suggest that CD81 has two available binding interfaces for CD81 monomers 
involving TM1 and TM2 in one interface and TM3 and TM4 in the second, as also 
suggested by Kovalenko and colleagues (2005). Potentially a Claudin-1 monomer may 
bind an available TM1/TM2 site or displace a bound CD81 monomer for its interaction. 
This would leave dimeric CD81 bound via TM3/TM4. Evidence that supports this 
theory was found when recombinant forms of the proteins existed in a 2:1 ratio (CD81: 
Claudin-1) (Bonander et al., 2013). Further experiments are required to provide 
evidence of the involvement of two CD81 interaction interfaces in the complex.  
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6.3 Molecular modelling can predict TM residues involved in CD81-Claudin-1 
interaction. 
 
Using the CD81-Claudin-1 full length model (figure 6.2), residues F21, G25, I28 and 
L35 were picked based on facing in the same direction as L14 and F17 on CD81 TM1 
and also based on α-helix periodicity. The selected residues were mutated to alanine 
and investigated using the yeast split-ubiquitin assay in CD81-Claudin-1 interactions. 
The results suggested I28A and L35A caused a reduction in CD81-Claudin-1 
interactions as compared to WT CD81 with L35A but not I28A showing a significant 
decrease from WT, although mean growth was reduced for I28A compared to WT 
CD81. Yeast growth curve analysis in comparison to yeast agar colony counts were 
able to distinguish knock-down mutants in a more sensitive manner, since the growth 
curve would shift to the right compared to WT if a mutant had a diminishing effect on 
the protein interaction. Previous studies that also use yeast growth curves but to monitor 
the effects of cytotoxic compounds suggested that phenotypes were discovered using 
growth curves that may not have been using yeast spot tests using colony growth 
(Toussaint et al., 2006), which is in agreement to that found in this study. 
Since the CD81-Claudin-1 model (figure 6.2) predicted residues I28 and L35 to be on 
the TM interface of the complex, the results described here would suggest that the 
model can predict TM residues that are important in structural heterotypic interactions 
(figure 6.2). Taking together, these data suggest that CD81 TM1 has cap regions either 
end of the helix, L14-F17 at one end and I28 and L35 at the other. Typically, TM cap 
regions are where specific structural interactions are found. Residues found in the 
middle of TM1 (F21 and G25) which did not display a knock-down in CD81-Claudin-1 
interactions, may be due to non-specific hydrophobic interactions.  
CD81 TM1 appears to play a role in CD81-Claudin-1 interactions, but there is also 
evidence to suggest it plays a role in CD81-CD81 interactions. Future work may 
investigate the role of TM1 in CD81-CD81 interactions by extending the number of 
mutant residues tested in the interaction, since only L14A-F17A were investigated here 
but found to reduce homotypic interactions. Results from analysing CD81 TM1 mutants 
imply that CD81-Claudin-1 and CD81-CD81 either share common features of their full 
length interaction interface, including LEL and TM residues or one interaction has a 
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direct result of the other. According to structural modelling of full length CD81-
Claudin-1, using Claudin-15 as template for Claudin-1 (in collaboration with Dr 
Jonathan Mullins), it was observed that stable arrangements of CD81-Claudin-1 
heterodimers were observed when Claudin-1 was superimposed upon either of the 
CD81 monomers in the CD81 homodimer, suggesting that a common face in CD81 
(possibly including some of the residues mutated in this work) may be implicated in 
homo- and hetero interactions. 
 
6.3.1 CD81-Claudin-1 homology based modelling 
 
Recent availability of a Claudin-15 structure in the Protein Data Bank meant that it was 
used to produce a more reliable full length homology model for Claudin-1 (rather than 
using a threading based approach seen in figure 6.2) and subsequent modelling of 
CD81-Claudin-1 (produced by Dr Jonathan Mullins).Using the evolved homology 
model, FoldX (a computer algorithm that can predict the effect of an amino acid 
mutation on the stability of proteins and protein complexes) was used to predict the 
effect of CD81 TM1 mutations on protein stability and on CD81-Claudin-1 complexes. 
Each of the CD81 TM1 residues mutated to alanine in this thesis was analysed: 
L14A- On the CD81-Claudin-1 homology model L14A was found on the first turn of 
TM1 facing into the CD81 TM bundle (see figure 6.6). FoldX showed that the mutation 
has an effect on CD81 monomeric stability because it is involved in a hydrophobic 
cluster that includes Val 225 (TM4) and L222 (TM4). The mutation of L14 has a minor 
indirect effect on CD81-Claudin-1 interaction energy because it supports F17, which is 
capable of forming a direct interaction with Claudin-1. Mutation of L14 may cause a 
rotamer shift in F17 that could impair the CD81-Claudin-1 interaction interface, which 
supports findings in chapter 4.  
F17A- F17 is found on the second turn of CD81 TM1 facing towards Claudin-1 
intracellular loop (figure 6.6). Mutation to alanine has a minor effect on CD81 stability 
because it supports Val 20 (TM1) and Phe 21 (TM1). F17 has a major effect in CD81-
Claudin-1 interaction as its aromatic ring produces a hydrophobic interaction with 
Claudin-1 intracellular loop M105. Predictions of the role of L14 and F17 support 
184 
 
results found in this study and suggest why a double mutant of L14A-F17A causes a 
significant effect on the CD81-Claudin-1 interaction.  
 
 
 
 
 
 
 
 
 
Figure 6.6: CD81 TM1 L14 and F17 in the CD81-Claudin-1 interaction. A homology based 
CD81-Claudin-1 model labelled with CD81 TM1 residues L14 (green) and F17 (light blue) and 
Claudin-1 intracellular loop residue M105 (yellow). Image created using Accelrys, Discovery 
studio 4.0. Docked homology model produced by Dr Jonathan Mullins. 
 
C89A- Located at the cytosolic region just before CD81 TM3. It is found on the 
opposite side of CD81 away from the Claudin-1 predicted interface. This could be a 
second protein binding face for tetraspanins or other partner proteins as suggested 
previously by Kovalenko et al (2005). This could also be a potential palmitoylation site.  
F21A- F21 is located on the third helix turn of CD81 TM1 and faces towards the 
Claudin-1 TM2 interface (figure 6.7). This residue is predicted to interact directly with 
F96 on Claudin-1 TM2. However, a large effect was not found experimentally in this 
study. This may be due to the fact that directly behind F21 is F218 (CD81 TM4) which 
may compensate for the hydrophobic interaction (e.g. redundancy in the receptor 
mechanism), as discussed earlier regarding non-specific mid-TM hydrophobic 
interactions. A future experiment could analyse a double mutation of F21A and F218A 
to evaluate if there was an effect on the CD81-Claudin-1 interaction.  
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Figure 6.7: CD81 TM1 F21 and I28 in the CD81-Claudin-1 interaction. A homology based 
CD81-Claudin-1 model labelled with a) CD81 TM1 residue F21 (green) and Claudin-1 TM2 
residue F96 (pink). b) CD81 TM1 I28 and Claudin-1 TM2 V92. Image created using Accelrys, 
Discovery studio 4.0. Homology model made by Dr Jonathan Mullins. 
 
G25A- This residue is located on CD81 TM1 fourth helix turn and faces towards the 
CD81 bundle (predicted originally using the threading based Claudin-1 –CD81 model). 
It has a predicted effect on protein stability because ILE215 (TM4 fourth turn) makes a 
hydrophobic interaction with G25 backbone. Also M73 located on CD81 TM2 packs 
against G25 side-chain. This mutation had no effect on CD81-Claudin-1 interactions, 
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which show the importance of Claudin-1 facing cap residues of CD81 TM1 in our 
experiments.  
I28A- I28 is located on CD81 helix turn five on TM1 and is found in the CD81-
Claudin-1 interface (figure 6.7). It is predicted to interact directly to Claudin-1 residue 
V92. I28A is predicted to impair CD81 stability by the deletion of essential 
hydrophobic interactions with V31 located on CD81. 
L29A- L29 faces into CD81 TM bundle and is essential for stability as it predominately 
packs against M73. This residue was investigated as it was unclear whether the double 
glycine motif G25 and G26 could alter the periodicity of the alpha helix TM domain. 
L35A- L35 was predicted by FoldX software to have an effect on protein stability. The 
residue is predicted to make a direct hydrophobic interaction with V85 on Claudin-1 
TM2 (see figure 6.8), which supports experimental findings shown in this thesis 
(chapter 4). 
 
 
 
 
 
 
 
 
 
Figure 6.8: CD81 TM1 L35 in the CD81-Claudin-1 interaction. A homology based CD81-
Claudin-1 model labelled with CD81 TM1 L35 and Claudin-1 TM2 V85. Image created using 
Accelrys, Discovery studio 4.0. Homology model made by Dr Jonathan Mullins. 
 
Analysis performed using FoldX has given a certain degree of insight. The CD81-
Claudin-1 homology model used for analysis shows that the orientation of the loop 
domains in regard to TM bundles may differ in reality and when complexed as CD81-
Claudin-1. The homology model of Claudin-1 based on the crystal structure of Claudin 
-15 suggests the loop sits on top of the bundle. CD81 LEL, in the full length homology 
model, is based on the crystal structure of a soluble dimer which has been critised for 
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not showing feasibly where the TM domains would be incorporated in reality. 
However, given that the loops (Claudin-1 ECL1 and CD81 LEL) have previously 
shown to interact with (Davis et al., 2012) and the results of which have been validated 
in this thesis, the ECL1 of Claudin-1 must extend for this interaction to take place or 
CD81 LEL would be in a different orientation in relation to its TM bundle.  
The working full length molecular model (figure 6.5) has provided a useful tool to 
predict the CD81 TM1-Claudin-1 TM2 interface between the two proteins via their TM 
bundles. The empirical data collected shows excellent agreement between residues that 
face towards the CD81-Claudin-1 heterodimer interface compared to residues that face 
towards their own TM bundle. For example, the model and FoldX analysis predicted 
residues L14, F17, F21 and I28 to have an effect (once mutated to alanine) on the 
CD81-Claudin-1 interaction. Experimental findings agree with L14A, F17A and I28A 
and show a reduction on the heterotypic interaction. G25 and L29, according to the 
CD81-Claudin-1 homology model face towards the CD81 TM bundle, this is predicted 
in FoldX analysis not to have any involvement in the interaction and also experiments 
in yeast agree. L35A was found experimentally to be important for the heterotypic 
interaction, but FoldX analysis of the CD81-Claudin-1 homology model did not suggest 
the same, although when observing the model, L35 looks in very close proximity to 
V85 on Claudin-1 suggesting limitations with the structural model as it currently stands.  
In summary, throughout the duration of this study, much progress has been made. At 
the beginning, CD81 LEL crystallised dimer provided more structural information than 
what was available for any Claudin family member. In contrast, at the end of this study, 
Claudin-1 has a very strong template for molecular modelling since full length Claudin-
15 (a close homologue) was determined. Future work in this field will hopefully move 
towards the structural determination of a full length tetraspanin, be it CD81 or another 
family member, which is required for more accurate CD81-Claudin-1 modelling and 
knowledge of how these molecules interact.  
6.4 Optimisation of full length recombinant CD81 for future structural studies.  
 
As one of the major HCV receptor components for virus internalisation, CD81 is a key 
drug target and so knowledge of the full length structure would contribute to the design 
of antiviral therapy. Furthermore, tetraspanins are involved in a wide range of cellular 
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processes including their role in human cancer such as metastasis (Hemler, 2014) and 
so the advantages of solving the structure of a full length tetraspanin to aid its use as a 
therapeutic target are continually growing in number. To date, there is high resolution 
structural information available for a CD81 LEL soluble dimer (Kitadokoro et al., 2001) 
and also low resolution data for the tetraspanin Uroplakin complexes (Min et al., 2006), 
but thus far the hydrophobic nature of membrane proteins has limited the success of 
tetraspanin crystallisation to provide high resolution information. Previous studies have 
shown the production of full length functional and correctly folded CD81 using 
recombinant host P. pastoris, which was solubilised using detergent (Jamshad et al., 
2008) and shown to complex with Claudin-1 (Bonander et al., 2013).  
This thesis has taken steps used previously to produce, solubilise and purify CD81 but 
then focused on determination of optimal thermal stability conditions, an approach that 
has shown to be a pre-requisite for successful crystallisation efforts previously 
(Alexandrov et al., 2008). Results show that CD81 is amenable to thermal stability 
assessment using a CPM assay and various conditions such as detergent choice, buffer 
conditions and lipid addition contribute to the maintenance of a stable purified CD81 
sample.  
P. pastoris expression of CD81 was performed under tight regulation of the AOX1 
promoter (as shown in figure 5.2), which is consistent with what is known about the 
promoter controlling the expression of other recombinant protein targets (Cregg et al., 
2000). Reproducible solubilisation of functional CD81 (as shown by HCV E2 binding) 
was then performed using β-OG (figure 5.3) consistent with that shown by a previous 
study (Jamshad et al., 2008). Scaling up production of CD81 was performed using 2L 
baffled shake flasks as growth in bioreactors using a minimal medium (BSM) was 
unsuccessful for unknown reasons. Typically, P. pastoris can be grown to high cell 
densities using a minimal medium (Macauley‐Patrick et al., 2005). Even so, the P. 
pastoris X33 strain producing CD81 would only demonstrate growth in a complex 
medium such as YPG in a bioreactor and so the advantages of using a bioreactor to 
control elements such as medium composition, pH, dissolved oxygen etc were 
unsuitable for this particular P. pastoris clone, therefore further investigation would be 
required to determine the reasons for particularly slow growth shown here in minimal 
media.  
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Subsequent to large scale production of CD81 in yeast membranes, the material was 
taken to the MPL at the Diamond Light Source to gain expert advice in attempts to try 
and crystallise the full length membrane protein. Since using the detergent DDM to 
extract membrane proteins is relatively common and successful with other membrane 
proteins, we applied this standard approach to CD81, but CD81 in DDM detergent 
micelles aggregated upon a concentration procedure, therefore a CPM thermal stability 
assay was used to determine the optimal detergent for CD81 stability. The results 
suggested that CD81 had increased stability in shorter chain detergents such as β-OG (8 
carbon chain length) in contrast to instability in longer chain detergents (figure 5.9), 
which explains why DDM (12 carbon chain length) caused CD81 aggregation. DM (10 
carbon chain length) was found to provide intermediate CD81 stability using the CPM 
assay compared to DDM and OG, which suggests a correlation between acyl chain 
length and protein stability. Interactions of detergents with membrane proteins is 
protein dependent and factors such as detergent concentration, detergent properties, 
such as headgroup, length of acyl chain and micelle structure, all contribute to the 
stability of a given protein used with a particular detergent (Stangl et al., 2012). It is 
suggested in a previous study that detergents with increasing acyl-chain lengths are 
usually considered mild, but this is not always the case, as some transmembrane helix 
oligomers (such as Human glycophorin A) are destabilised in longer chain detergents 
(Stangl et al., 2012), as was true here regarding CD81. Therefore, this suggests 
optimisation of detergent conditions is crucial to obtain functional and correctly folded 
membrane protein for downstream analysis.   
Determination of optimal CD81 detergents resulted in purification and concentration of 
CD81 in DM and OG +CHS at 13 mg/ml and 9 mg/ml, respectively. The ability to 
concentrate to such high concentrations (for a membrane protein) was further evidence 
to suggest that both detergents provided suitable stability for CD81 in protein-detergent 
complexes. Purification of CD81 in DM or OG+CHS showed that monomers and 
dimers were the predominant species in the samples (figure 5.10). Despite a lack of 
homogeneity, CD81 was set up for crystallisation trials using a lipid cubic phase 
approach, but was unsuccessful due to the presence of detergent crystals. Further 
analysis using SEC-MALS showed that in two different samples analysed (in two 
different buffers), there was excess detergent in samples, much higher than the level of 
detergent present in protein-detergent complexes (figure 5.11 and 5.12). Excess 
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detergent is unsuitable for crystallisation attempts as we had demonstrated with the trial 
we performed.  
Two SEC-MALS analyses were performed on the same protein sample purified in DM. 
The only difference between the two attempts was the buffer in which CD81 was 
exchanged to in the analytical column. In a PBS buffer, the predominant peak was a 
CD81 dimer, which may be due to the high salt concentration pushing the equilibrium 
to a dimer. Furthermore, a higher order CD81 oligomer was also observed minus 
detergent, suggesting that the protein was moving towards aggregation on the column. 
Using a Tris buffer, predominantly monomer and dimers were observed with negligible 
protein aggregates. This suggests that the buffer conditions are fundamental to the 
protein state and stability in solution, this prompted further investigation using the CPM 
assay. Additionally, future work would focus on reducing the level of excess detergent 
in a CD81 sample but sufficient to maintain the formation of protein-detergent 
complexes to improve future crystallisation attempts. 
6.4.1 CD81 thermal stability studies 
 
A thermal stability CPM assay measures the fraction of folded protein over time at a 
given temperature. The method has been used previously to optimise conditions to 
improve membrane protein stability to guide purification and crystallisation efforts 
(Alexandrov et al., 2008). The assay was used in this thesis to assess the unfolding 
nature of CD81 over time at 40C in given buffer conditions. Results suggested that 
CD81 is most stable (in the conditions tested in this work) in β-OG, 100mM NaCl, 10% 
glycerol, MOPS pH 6.5-7 and 0.2% CHS. CD81 did not show differences in stability 
when exposed to different levels of ionic strength (using NaCl); therefore the lowest 
concentration (100mM) used in the experiments was taken for future experiments. This 
data is in contrast to what has been found for other membrane proteins such as the 
human apelin receptor (a GPCR), which was found to be influenced with increasing 
ionic strength by an increase in protein stability (Alexandrov et al., 2008), suggested to 
be due to increased surface tension and exclusion of water from the protein interior. 
Even so, lower NaCl concentrations may be beneficial for downstream CD81 
applications as, for example, high salt concentrations may interfere with crystallisation 
by forming salt crystals.  
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Glycerol has previously been shown to stabilise protein conformation by shifting the 
native structure to a more compact state and reduce conformational changes (Tsai et al., 
2000), (Vagenende et al., 2009). CD81 was shown here to display increased stability in 
the presence of 10% glycerol in contrast to 0% glycerol (figure 5.14). Previous studies 
have explored the mechanism behind glycerol-dependent protein stability and suggest 
that it interacts with large protein hydrophobic surface regions, thus preventing protein 
unfolding and aggregation. This mechanism may apply to the effect glycerol has on 
CD81 and indeed other tetraspanin family members.  
We had observed, using SEC-MALS, the buffer used for CD81 can affect the 
oligomeric state (figures 5.11 and 5.12), but also pH and the buffer composition can 
have great effects on protein stability. Using the thermal stability assay, we found for 
CD81, a MOPS buffer at pH 6.5-7 results in the greatest level of protein stability out of 
those conditions tested (figure 5.15). The theoretical pI value for CD81 is 5.94 and so 
using buffers between 6.5 -7 would seem appropriate. Careful interpretation of data 
must be done when pH values lower than 6.0 are tested, since the CPM dye shows 
decreased reactivity at pH >6 (Alexandrov et al., 2008).   
Enhanced stability was also observed in this study when recombinant CD81 was 
combined with 0.2% CHS (see figure 5.16). This was also the case when Claudin-1 and 
0.2% CHS was tested in a CPM thermal stability assay. Cholesterol has shown both 
functional and structural dependent effects for CD81 and Claudin-1 elsewhere in the 
literature; therefore data presented in this thesis provides supporting evidence that 
cholesterol may exert its effect by stabilising the structural integrity of the 4TM 
proteins. It was previously found that cholesterol is important for HCV entry since 
depletion of cholesterol at the plasma membrane caused a reduction in CD81-Claudin-1 
complexes (Harris et al., 2010). In a different study, on a molecular level, recombinant 
CD81 and Claudin-1 formed specific complexes that were stabilised in cholesteryl 
supplemented environments (Bonander et al., 2013). A full length model of CD81 
(Seigneuret, 2006) reveals that CD81 may have one or several cholesterol binding sites, 
due to aromatic residues that that are clustered on one side of the TM domain. Charrin 
and colleagues (2006) support this further by demonstrating a physical interaction exists 
between cholesterol and tetraspanins. Taken together, the data presented in this thesis 
contribute to what is already known by suggesting cholesterol supports the folded 
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nature of both CD81 and Claudin-1 and this will guide future structural and functional 
studies of the HCV receptor complex.  
This thesis shows the first thermal stability assessment of recombinant full length CD81 
and the results suggested may be applicable to other tetraspanin family members. 
Future work will determine if optimal thermal stability conditions shown here (β-OG 
(3CMC), 100mM NaCl, 10% Glycerol, MOPS, pH6.5-7 and 0.2% CHS) will benefit 
other aspects deemed suitable for crystallisation trials such as homogeneity and the 
level of excess detergent in the protein-detergent complex sample. Currently, the 
optimised sample conditions shown here are being analysed for CD81 using SEC-
MALS at the MPL. Predicted improvements to follow may include producing a more 
homogeneous protein sample using SEC, adjustments to the concentration of detergent 
used to maintain protein solubility or alternatively using a different solubilising agent 
such as a polymer.   
 
6.5 Overall conclusions 
 
This thesis has demonstrated both technical and molecular advancements in the 
tetraspanin and Claudin field. Technically, we have the ability to study CD81 
homotypic and heterotypic interactions with Claudin-1 in yeast both in vivo using 
S.cerevisiae using a split-ubiquitin assay and in vitro using recombinant protein 
produced in P. pastoris. The ability to measure membrane protein-protein interactions 
in the split-ubiquitin assay in real-time to produce yeast growth curves provided a 
useful tool, which could be used in a high-throughput manner, to explore the role of 
specific amino acids in soluble and membrane associated domains of CD81. We now 
have a better understanding of the full length binding interface of CD81-Claudin-1 
(involving CD81 LEL and TM1 and predicted Claudin-1 TM2) and CD81-CD81 
(involving residues in LEL and TM1). These results have revealed that CD81-Claudin-1 
interactions are likely dependent on the CD81 oligomerisation status in the plasma 
membrane and so using CD81-Claudin-1 as an anti-HCV target has associated 
complexities since inhibiting CD81-Claudin-1 may have a phenotypic effect due to 
reducing CD81-CD81 associations.  
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Since working on full length membrane proteins in this study, through collaboration we 
have developed a full length molecular model of the interaction to guide mutagenesis 
and define the protein binding interface via TM domains. Towards the end of 
completing this thesis, the Claudin-15 crystal structure was determined and so enabled 
us to generate a more reliable model that will guide future structural analysis of the 
CD81-Claudin-1 co-receptor complex.  
To date, a full length tetraspanin structure solved to high resolution does not exist but 
we are now further towards a novel CD81 structure. Tetraspanin thermal stability has 
not been demonstrated previously in the literature and so conditions found here that 
provide increased CD81 stability will contribute towards CD81 crystallisation trials in 
the future. As a HCV receptor, solving the structure of CD81 will not only benefit anti-
viral therapy design but will also advance treatment of other pathologies where CD81 
has a role, such as in cancer progression. 
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